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Resolvin E1 is a potent anti-inflammatory lipid mediator. At nanomolar levels, it is 
able to attenuate inflammatory responses such as leukocyte infiltration and pain. It is 
also chemically unstable and readily isomerises at the C6−C7 position. This gives the 
6E-isomer which is no longer anti-inflammatory in action. The research described in 
this thesis outlines the synthesis of a benzene annulated analogue of resolvin E1, 
named benzoresolvin E1. The inclusion of the benzene ring would improve the 
chemical stability of resolvin E1 by inhibiting the isomerisation pathway. 
 
 
The first approach details the synthesis of the bromide 122 (Chapter 2). This 
compound was prepared in 4% yield in 8 steps. It could be converted into the 
Grignard 123 to give the C13−C20 portion of benzoresolvin E1. Unfortunately, 
treatment of compound 122 with magnesium turnings led to degradation. It was 
postulated that upon formation, the Grignard reagent 123 eliminates TBDPSOMgBr 




In view of this, compound 122 was segmented into two smaller compounds, 
propargylmagnesium bromide and the iodide 28. The latter compound was 
synthesised in 20% yield and 96% ee in 7 steps from 1-pentyn-3-ol (Chapter 3). The 
iodide 28 was a key fragment in the synthesis of benzoresolvin E1, along with the 
stannane 209 and the iodide 197. From these compounds, the lithium carboxylate 
salt of benzoresolvin E1 was prepared in 6 steps (Chapter 4). The key step in the 




Having synthesised the lithium carboxylate salt of benzoresolvin E1, the chemical 
stability of this compound was investigated. A 1H NMR study conducted at room 
temperature showed no change to the target compound over 4 days. In comparison, 
resolvin E1 is known to degrade over the same period of time. This suggests that the 
benzene ring was significant in improving the stability of resolvin E1 (Chapter 4). In 
vitro studies also showed benzoresolvin E1 binds to the BLT-1 receptor with an 
inhibitory constant of 1.05 µM. This is comparable to the BLT-1 antagonist SC-
41930 that has a Ki of 1.00 µM but is higher than the inhibitory constant of 
resolvin E1 (Ki = 70 nM). Thus, the fusion of the benzene ring weakens but retains 
the binding towards the BLT-1 receptor. 
Using the same convergent strategy, the formal total synthesis of rac-12 resolvin E1 
was completed (Chapter 5). A Stille reaction between compounds 236 and 230 
afforded compound 243 in 65% yield. The product intersects the total synthesis of 




A C18-phenyl analogue of benzoresolvin E1 was also prepared (Chapter 6). 
Replacing the (18R)-alcohol with a phenyl ring would simplify the synthesis of the 
target compound. Using the same convergent approach, the phenyl analogue 244 was 
synthesised in 5 steps from the key intermediates 197, 209 and 248. In vitro studies 
showed that the phenyl analogue 244 binds to the BLT-1 receptor with 68% activity 
at 10 µM. This is only slightly lower than the activity of benzoresolvin E1 (76%), 
suggesting that the C18-phenyl substituent does not significantly reduce the binding 
affinity of the molecule. 
          
The final chapter details investigations towards a benzene annulated analogue of 
leukotriene B4, named benzoleukotriene B4. Using the cross-coupling approach 
developed for benzoresolvin E1, the key fragment 275 was prepared in 3 steps as an 
inseparable mixture with the allene 279 (Chapter 7). Alternate methods to synthesis 
compound 275 using an organolithium and epoxide strategy were investigated, 
however these were unsuccessful.  
vii 
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Inflammation is ubiquitous in society. It is the body’s response to tissue injury or 
infection and serves to provide a suitable environment to repair the damaged site. 
This often results in redness, swelling, pain and loss of mobility of the infected area.
1
 












 and Crohn’s disease
9





 and Parkinson’s disease
12
 have been strongly linked 
to chronic inflammation.  
Inflammation can be divided into two distinct categories; initiation and resolution 
(Figure 1.01). The onset of inflammation is typically caused by tissue trauma or 
microbial invasion of host cells. Pattern recognition receptors present in the cell 
identify these inflammatory stimuli, producing a cascade of biological signals that 
trigger the release of pro-inflammatory messenger molecules.
13
 These molecules 
establish a protective environment for the inflamed tissue and help extradite foreign 
microbes. Once this process is complete, pro-resolving lipid mediators are 




         Figure 1.01: Inflammation overview. 
It has been known for some time that prostanoids play a pivotal role in the initial 
stages of inflammation.
14-17
 Prostanoids aid in accelerating the inflammatory process 
by increasing pain sensitivity and blood flow to an inflamed tissue.
18-19
 Prostanoids 
are derived from arachidonic acid, which is a constituent of the cellular membrane. 
Hydrolysis of arachidonic acid from the cellular membrane, by a class of enzymes 





Once released from the phospholipid membrane, arachidonic acid is rapidly 
converted into an assortment of cell-specific lipid mediators by cyclooxygenase 
(COX), lipoxygenase (LOX) and epoxygenase (cytochrome P450) enzymes.
21-22
 
COX enzymes are responsible for the formation of prostanoids (prostaglandins, 
prostacyclin and thromboxanes), LOX enzymes convert arachidonic acid into 
leukotrienes and lipoxins while the P450 pathway leads to the synthesis of 




Figure 1.02: Overview of the biosynthetic pathways of arachidonic acid. 
 
1.1.1 Pro-inflammatory lipid mediators 
 
Of the lipid mediators derived from arachidonic acid, the role prostanoids play in 
inflammation has been extensively documented.
23
 Prostanoids encompass a large 
class of structurally similar compounds that include prostaglandins, prostacyclin and 
thromboxanes.
24
 Prostaglandins and prostacyclin contain a cyclopentane ring (red) 
while thromboxanes can be distinguished by their dioxane moiety (blue).
25
 The 
hydroxyl group (purple) at the C12 position is a common feature of all three lipid 
mediators (Figure 1.03).
25
 Interestingly, prostanoids were given their name in 1935 
after they were isolated from the prostates of male sheep.
26-27
 
           





Prostanoids are biosynthesised by membrane-bound cyclooxygenase (COX) 
enzymes.
23-28 
These heme-containing enzymes catalyse the oxygen dependent 
cyclisation of free archidonic acid into prostaglandin G2 (PGG2) and the peroxidase 
reduction of PGG2 into prostaglandin H2 (PGH2), as shown in Figure 1.04.
23-28
 
Studies on human tissue isolated from the brain showed two distinct COX isoforms 
partaking in prostanoid synthesis.
29
 These were named COX−1 and COX−2. Crystal 
structures obtained by the Garavito, Browner and Pak groups confirmed the 
morphology of these enzymes.
30-32
 COX−1 is primarily responsible for the formation 
of prostanoids during the initial stages of inflammation, with COX−2 up-regulation 
following several hours later.
33
 COX−2 is the major source of prostanoids in 
inflammation, accounting for over 85% of the prostanoids formed in humans.
34-35
               
        
1.1.2 Biosynthesis of prostanoids 
 
Once PGG2 is formed, it is converted into a range of prostaglandins that include 
PGD2, PGE2, PGF2, TxA2 and PGI2 (Figure 1.04).
23
 The distribution of these 
prostanoids in the body is dictated by prostanoid synthase enzymes present in 
different cells and tissues. For example, PGD2 is predominately expressed in mast 
cells containing PGD2 synthase and PGD2 hematopoietic synthase while PGF2is 









Figure 1.04: Biosynthetic pathway of the prostanoids.3 
 
Upon cellular release, prostanoids interact with G protein-coupled receptors to 
produce a range of inflammatory responses.
36-38
 The first prostanoid receptor 
structurally identified was the thromboxane receptor.
39
 Using the radiolabelled 
ligand S-145, Ushikubi and co-workers purified the thromboxane receptor from 
human blood platelets in 1989.
39
 Two years later, Hirata and co-workers successfully 
sequenced and cloned this receptor.
40
 This paved the way for the isolation of other 
prostanoid receptors. By 1995, the receptor for prostacyclin (IP),
41-43
 two receptors 
for PGF2FPA and FPB),
44-45
 four receptors for PGE2 (EP1-4)
46-49
 and two receptors 
for PGD2 (DP1 and DP2)
50-51
 had been cloned.  
 
1.1.3 Prostanoid actions 
 
PGE2 and PGI2 are the main prostanoids involved in inflammation.
34,38 
Both 
prostanoids contribute to edema formation and leukocyte infiltration.
52-54
 This helps 
maintain a protective environment for the damaged area. PGE2 and PGI2 also play a 
pivotal role in potentiating the pain-producing activity of the nonapeptide 
5 
 
bradykinin, resulting in peripheral sensitisation.
55-57
 PGD2 also contributes to 
inflammation, specifically regulating allergic responses in the lungs.
27,58
 Activation 
of the DP1 receptor increases blood flow and vascular permeability while activation 
of the DP2 receptor promotes T-cell polarisation.
59-60
 The latter is essential for 
triggering the synthesis of a range of cytokines that attract neutrophils to remove 
pathogens.
60
 Eosinophils are also released during DP2 stimulation, providing yet 
another alternative for pathogen extermination.
37-38
 Finally, thromboxanes play a role 




Since the discovery of prostanoids and their target receptors, three main classes of 
drugs have been developed to treat the initial stages of inflammation. These include 
selective prostanoid (PG) antagonists, non-steroidal anti-inflammatory drugs 
(NSAIDs) and corticosteroids.
64-67
 Each class attenuates inflammation at different 
stages of the inflammatory pathway (Figure 1.05). PG antagonists function by 
inhibiting prostanoid specific receptors while cyclooxygenase (COX) inhibitors and 
corticosteroids prevent the synthesis of prostanoids altogether. The most common 




















1.2 Treatment methods for the onset of inflammation 
 
1.2.1  Prostanoid receptor antagonists  
 
Prostanoid receptor antagonists provide targeted treatment for the onset of 
inflammation.
68-70
 Unlike COX inhibitors that broadly suppress all prostanoid 
pathways, prostanoid antagonists selectively inhibit individual receptors.
71
 In this 
way, specific inflammatory responses can be suppressed. Substantial progress in the 
development of prostanoid antagonists was made following the cloning of several 
prostanoid receptors in the early 1990s. Through the use of radio-ligand binding 




















 receptors were slower to emerge. A perceived lack of 
therapeutic utility and minimal commercial support are reasons for the under-
development of the latter class of antagonists.
61
   
Commercial prostanoid antagonists are typically acyl-sulfonamides. These 
compounds offer a number of advantages including excellent bioavailability, 
improved metabolic stability and cheap syntheses.
61
 One of the most widely 





Developed by the German company Bayer, Ramatroban
®
 is a potent dual acting 
thromboxane and PGD2 antagonist.
92
 It is used in the treatment of cardiovascular 
diseases and allergic rhinitis.
93-95
 By targeting the thromboxane receptor, key 





 also inhibits the PGD2 receptor expressed 
in pro-inflammatory mast cells.
92
 This attenuates leukocyte infiltration and 
degranulation of granulocytes by suppressing the monocyte chemoattractant protein 
MCP-1, preventing exacerbation of late-phase inflammation.
92
 Studies by Ishizuka 
and co-workers also showed that Ramatroban
®
 can prevent the build up of scar tissue 






Figure 1.06: Mechanism of action of Ramatroban® 
 
Despite the availability of potent and selective antagonist for most of the prostanoid 
receptors, their future as a treatment for inflammation is not encouraging. Although 









 have received regulatory approval to be marketed, these cases are 
limited and are confined to a select number of countries.
92
 In the last decade, an 
increasing number of these antagonists have been discontinued by pharmaceutical 
companies. Prostanoid antagonists appear to be superseded by more effective 
treatments such as NSAIDs, corticosteroids and resolution phase drugs. Expectations 
that one prostanoid and one receptor play a dominant role in diseases induced by 
inflammation are extremely lofty. Instead, it is believed that a number of prostanoids 
act together to initiate and sustain diseases.
1
 With the exception of several dual 
acting compounds, it appears that the majority of prostanoid antagonists on the 




1.2.2 Non-steroidal anti-inflammatory drugs 
 
In recent times, NSAIDs have become the main treatment for inflammation.
99
 Since 
the turn of the twentieth century, the number of NSAIDs available to patients has 
grown significantly, with over fifty different NSAIDs currently on the global 
market.
1
 Unlike prostanoid antagonists that inhibit prostanoid receptors, the majority 
of NSAIDs target a different class of enzymes known as cyclo-oxygenases (COX). 
By inhibiting the COX enzymes, free arachidonic acid is unable to be converted into 
8 
 
prostanoids, thus terminating inflammation in the initial stages.
100
 In the early 1970s, 
Vane was the first to elucidate the anti-inflammatory properties of several commonly 
used NSAIDs including indomethacin and aspirin (Figure 1.07).
101
 Using assays 
containing Krebs solution, Vane observed a 47% reduction in PGF2activity when 
rabbits were administered with indomethacin at a concentration of 0.75 M while a 
24% reduction with aspirin was observed at 35 M.
100
 Since this research, many 
studies have investigated the anti-inflammatory properties of a range of other 
NSAIDs.
102-105
                                                      
 
Figure 1.07: Commonly marketed NSAIDs for the treatment of inflammation. 
 
Traditional NSAIDs such as fenoprofen and zomepirac inhibit both the COX−1 and 
COX−2 enzymes (Figure 1.07).
106
 Although effective towards treating symptoms of 
inflammation, these compounds can cause a wide range of side effects that include 
diarrhoea, abdominal pain, nausea, gastric ulcers, bone marrow disturbances, liver 
disorders and renal impairment.
107-110
 It is estimated that 34−46% of traditional 
NSAID users sustain gastrointestinal (GI) damage, with up to 4,500 hospital 
admissions and 400 deaths recorded each year in Australia.
111
 A range of histological 
studies have linked these side effects to the COX−1 enzyme.
112-114
 COX−1 is 
responsible for regulating the GI tract by stimulating bicarbonate secretion and 
reducing acid excretion.
115
 Disruptions to these functions arise upon NSAID binding, 
causing GI related side effects.
105
 These studies have paved the way for the 
development of NSAIDs selective for the COX−2 enzyme. It was anticipated that 
COX−2 selective inhibitors would be superior to traditional nonselective NSAIDs as 




Early attempts to develop selective COX−2 inhibitors led to the synthesis of NS-398 
and DuP-697 (Figure 1.08).
116-117
 These drugs have served as the platform for the 


















   
 




A comparative study by Warner et al. showed sulides and coxibs to be up to fifty-
times more selective for COX−2 than non-selective NSAIDs such as fenoprofen and 
zomepirac (Figure 1.09).
120
 Unlike traditional NSAIDs, these drugs are bulkier and 
cannot fit into the COX−1 receptor. This is attributed to the bulky amino acid 
isoleucine present at the active site of COX−1 which restricts the access of large, 
rigid compounds.
1
 On the contrary, the COX−2 enzyme has a valine amino acid. 
This is smaller than isoleucine, providing a larger pocket for molecules to fit in the 



















      COX−2                        COX−1  
 
 
Figure 1.09: Selectivity of NSAIDs given as log inhibitory concentrations (IC80).
120 
 
Despite their effectiveness as potent anti-inflammatory drugs, chronic use of 
selective COX−2 inhibitors can lead to cardiovascular problems.
121
 A study 
conducted by Bombardier and co-workers in 2000 showed an increased risk of 
myocardial infarction in elderly patients consuming rofecoxib (Vioxx
®
) over an 
eleven month period.
99
 This was a four-fold increase compared to individuals who 
were given the non-selective NSAID naproxen.
99
 Further studies by Aw and co-
workers showed a 61% risk of developing hypertension and elevated blood pressure 
in patients administered with celecoxib, rofecoxib or etoricoxib.
122
 Coxib induced 
suppression of PGI2 followed by accelerated atherosclerosis have been linked to 
these cardiovascular effects.
123
 In light of these findings, Vioxx
®
 was voluntarily 
withdrawn from the market by Merck in 2004, followed by the withdrawal of 
Bextra
®
 (valdecoxib) by Pfizer in 2005.
123
 Consequently, the future of selective 




Corticosteroids have been known since the early 1950s to exhibit anti-inflammatory 
properties.
124
 Along with NSAIDs, they are among the most widely used anti-
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treated using corticosteroid therapy. Corticosteroids are divided into two distinct 
groups; mineralocorticoids and glucocorticoids (Figure 1.10).
129-130
  
Mineralocorticoids regulate the body’s blood pressure by increasing sodium and 
water retention in the kidneys while glucocorticoids mitigate inflammation by 
regulating pro-inflammatory transduction pathways.
129
 Both classes are 
endogenously produced in the adrenal cortex from cholesterol. Extensive efforts 
have been made over the last three decades to design drugs that mimic 
glucocorticoids synthesised in the body.
129,131
 More than 300 glucocorticoids are 











      
 
 
Figure 1.10: Top three marketed glucocorticoids in 2011.134 
 
Glucocorticoids function by regulating multiple inflammatory genes that are 
activated during inflammation.
132
 As much as 1% of a cells total genome is altered in 
this way.
133
 Glucocorticoids exert anti-inflammatory action through a series of 
complex biological pathways. They firstly diffuse across a cell membrane and bind 
to glucocorticoid receptors (GR) located in the cytoplasm. These receptors are 
typically bound to molecular chaperones such as heat shock protein-90 or FK-
binding protein.
132
 Molecular chaperones serve as GR protection, preventing 
unwanted nuclear localisation from occurring.
134-135
 Once the glucocorticoid has 
12 
 
bound to the GR, conformational changes are induced in the complex. This causes 




The glucocorticoid-GR complex then binds to specific glucocorticoid-responsive 
genes located in the promoter region of DNA. With the assistance of co-activator 
molecules such as CBP, pCAF or GRIP−1, acetylation of histone lysine groups 
trigger the unravelling of chromatin.
136-137
 This open chromatin structure facilitates 
RNA polymerase II binding which initiates the transcription of genes encoded for 
anti-inflammatory inhibitor proteins. These include lipocortins, SLPI, IL-10 and the 
inhibitor of NF-B, IB-.
132
 In this way, corticosteroids are different from NSAIDs 
and prostanoid antagonist as they reduce inflammation through a multitude of 
transduction pathways. 
One of the most widely documented class of glucocorticoid induced proteins are 
lipocortins.
133
 Lipocortins are localised cellular proteins that prevent the formation of 
free arachidonic acid.
64
 Originally isolated from guinea pig macrophages by 
Blackwell and co-workers in 1980, over fifteen different lipocortin proteins have 
been discovered in humans.
138-140
 These variants are the consequence of cellular 
proteolysis and are shown in several studies to exhibit similar functional 
activities.
141-143
 Lipocortins reduce inflammation by mitigating the activity of the 
phospholipase A2 enzyme (PA2).
133,144
 Key studies conducted by Hirata and 
Schlaepfer suggest that lipocortins reduce phospholipase activity through calcium 
sequestration.
144-145
  By forming a ternary complex with Ca
2+
 and the phospholipid 




Despite the treatment of many diseases and disorders, corticosteroids are known to 












 and growth retardation.
132
 Although little is known about the cause of 
these side effects, it is speculated that corticosteroid induced suppression of genes 
coding for bone metabolism, skin structure and the hypothalamo-pituitary axis are 






1.3 Treatment methods for the resolution of inflammation 
. 
An alternative approach to reduce inflammation in the body is to mimic the protectin 
and resolvin messenger molecules. These messenger molecules are endogenously 
synthesised during the resolution phase of inflammation. They are derived from 
omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA), 
docosahexaenoic acid (DHA) and α-linoleic acid and are ultimately introduced in our 




1.3.1 Omega-3 polyunsaturated fatty acids 
 
The benefits of omega-3 fatty acids in human health have been known for nearly a 
century. George and Mildred Bur were the first to demonstrate the importance of 
PUFA enriched diets.
159-160
 They showed a compelling link between the health of 
laboratory rats and the exclusion of fat-free diets. In most cases, failure to the 
kidneys, bladder and physiological deterioration were noted, with premature death a 
definite outcome.
156-157
 Despite these findings, the importance of PUFAs went 
largely unnoticed until research conducted by Bang et al. in the early 1970s.
158
 By 
comparing the dietary intake of Greenland Eskimos and Caucasian Danes, they were 
able to show the benefits of omega-3 rich diets towards minimising chronic 
inflammatory diseases. Greenland Eskimos who consumed large amounts of whale, 
seal and fish, had lower incidences of cardio-vascular disease and arthritis.
159-160
  
Since this research, numerous studies have uncovered an assortment of other benefits 
of omega-3 rich diets including a lower risk of developing cancer, type-2 diabetes, 
autoimmune diseases, rheumatoid arthritis, cardiovascular diseases, 
immunomodulation and Alzheimer’s disease.
161-166
 Recent findings by Mozaffarlan 
have also shown a remarkable 27% reduction in the mortality of individuals who 
have PUFA rich diets compared to those with a low omega-3 fatty acid intake. This 
equates to an extended life expectancy of up to 2.2 years.
167
 The Australian 
government has also recognised the unique array of benefits provided by PUFAs and 








1.3.2 Biosynthesis of resolution phase lipid mediators  
 
Although EPA and DHA were known to be beneficial for human health, the 
biosynthetic pathways for these properties remained a mystery for many years. 
Recent research conducted by Serhan and co-workers have discovered the first 
molecular level evidence for the health promoting contributions of EPA and DHA.
169
 
By treating mice with PUFAs and aspirin, then subjecting the inflammatory exudates 
to liquid chromatography-tandem mass spectrometry, they were able to profile the 
loss or gain of lipid mediators. This study uncovered a new class of bioactive 
messenger molecules, named the resolvins and protectins, that are responsible for the 
resolution of inflammation.
169
 It was later discovered that E-series resolvins are 
derived from EPA while DHA is the precursor for the D-series resolvins and 
protectins (Figure 1.11).
170
 The key difference between the two series is the number 
of carbons and double bonds in the skeletal backbone. E-series resolvins are twenty 
carbon molecules with five double bonds while D-series resolvins have twenty two 
carbons and six double bonds.  
 
Figure 1.11: EPA and DHA omega-3 fatty acids. 
 
EPA is converted into the pro-resolving messenger molecules resolvin E1 and 
resolvin E2 via the biosynthetic pathway shown in Scheme 1.01.
151
 Acetylated 
COX−2 or cytochrome P450 catalyses the oxygenation of EPA 15, forming the 
(18R)-peroxide 17 which is reduced to (18R)-HEPE 18 via a peroxidase enzyme.
169
 
A lipoxygenation reaction that is catalysed by the 5−LOX enzyme then forms the 
peroxide 19 from (18R)-HEPE 18. This intermediate is converted into the epoxide 21 
which undergoes enzymatic hydrolysis via a hydrolase enzyme to produce (18R)-
resolvin E1 22. Alternatively, the peroxide 19 can be reduced via a peroxidase 
enzyme to afford resolvin E2 20.
171
 Recent studies have shown that the (18S)-














One of the most potent anti-inflammatory metabolites derived from EPA is (18R)-
resolvin E1 22. A range of pro-resolving actions have been reported for this 
messenger molecule. These include initiation of macrophage ingestion of apoptotic 
neutrophils,
173
 an increase in IL-12 production,
174
 protection against bone destruction 
and periodontitis,
175
 protection against colitis,
176
 regulation of platelet formation
177
 
and attenuation of inflammatory pain.
178
 Through these actions, resolvin E1 helps 
reduce the severity and duration of inflammation. Resolvin E1 also regulates 
leukocyte infiltration, with nanomolar concentrations (100 nM) resulting in a 
50−70% reduction in the recruitment of white blood cells to an inflamed site. This is 
remarkably potent, with the commercially available glucocorticoid dexamethasone 




1.4 Total synthesis of resolvin E1  
 
There are currently three total syntheses for (18R)-resolvin E1. These were 




1.4.1  Total synthesis of resolvin E1 developed by Petasis 
 
The first total synthesis of resolvin E1 was reported by Petasis in 2003.
183
 This was 
republished by Arita, Petasis and co-workers in 2005 and Uddin and Petasis in 
2008.
171,180
 The synthesis focused on a series of Sonogashira reactions between 
compounds 26, 27 and 28 to give the methyl ester of resolvin E1. The key 
disconnections in the retrosynthesis are shown in Scheme 1.02.  
 





The key intermediate 26 was used to form the C1−C7 portion of resolvin E1 methyl 
ester 25. This compound was synthesised in 4 steps starting from methyl 4-
chloroformylbutanoate 29 (Scheme 1.03). The starting material was treated with 
aluminum chloride and bis(trimethylsilyl)acetylene 30 to afford the ketone 31. This 
compound was asymmetrically reduced using S-Alpine-Borane
® 
to furnish the (S)-
enantiomer of alcohol 32 in 73% yield and 90% ee. The TMS group was removed 
using potassium carbonate in methanol followed by protection of the alcohol with a 
TBS group to afford the intermediate 26.  
 
Scheme 1.03: Preparation of the ester 26.180 
 
The starting point for the synthesis of the intermediate 27 was the TBS protected 
chiral glycidol 33 (Scheme 1.04). The addition of the organolithium reagent 34 to 
this compound gave the alkylated product 35. Compound 35 was protected with a 
TBS group, giving the disilylated compound 36 in 99% yield. Selective deprotection 
of the primary alcohol using CSA followed by a Swern oxidation afforded the 
aldehyde 38 in 60% yield in 2 steps. A Horner-Wadsworth-Emmons olefination 





Scheme 1.04: Preparation of the bromide 27.180  
 
The intermediate 28 was used to form the C16−C20 portion of resolvin E1 methyl 
ester 25. Using the same starting material as in Scheme 1.04, the iodide 28 was 
synthesised in 7 steps (Scheme 1.05). Alkylation of glycidol 33 using methyllithium 
followed by protection of the secondary alcohol with a TBDPS group afforded 
compound 41. Selective deprotection of the primary alcohol using CSA followed by 
oxidation of this functional group gave the aldehyde 43. This compound was then 
converted into the iodide 28 in 53% yield over 3 steps. These steps included a Takai 
olefination using CrCl2 and iodoform, removal of the TBDPS group and protection 





Scheme 1.05: Preparation of the iodide 28.180  
 
Having synthesised the key fragments, compounds 26 and 27 were coupled together 
to afford the Sonogashira product 44 as a mixture of stereoisomers at the C8 position 
(Scheme 1.06). Treatment of this compound with a catalytic amount of iodine in 
dichloromethane gave the desired 8E-isomer while the TMS group of compound 44 
was removed using Na2CO3 to give compound 45.    
 





The final steps of the synthesis involved a Sonogashira reaction between the alkyne 
45 and the iodide 28 (Scheme 1.07). This gave compound 46 in 80% yield as the 
16E-isomer. The target compound 25 was then prepared in 2 steps from compound 
46 by global deprotection of the silyl groups and reduction of the C6−C7 and C14−C15 
alkynes using a Zn(Cu/Ag) amalgam. The longest linear sequence of compound 25 
was 11 steps from glycidol 33 and had an overall yield of 13%. 
 
Scheme 1.07: Final steps in the synthesis of resolvin E1 methyl ester 25.180  
 
Despite developing the first total synthesis of resolvin E1, Petasis recognised that the 
enantiomerically pure glycidol 33 was an expensive starting material for compounds 
27 and 28 ($47.50/g, Sigma-Aldrich).
184
 Subsequently, the preparation of analogues 
of resolvin E1 would be costly. Kobayashi and Ogawa addressed this issue in their 
total synthesis of resolvin E1 by using cheaper starting materials such as 








1.4.2 Total synthesis of resolvin E1 developed by Kobayashi  
 
The second total synthesis of resolvin E1 was released by Kobayashi and Ogawa 
in 2009.
181
 The linchpin for this synthesis was a Suzuki reaction at the C9−C10 
position and a Wittig olefination at the C14−C15 position (Scheme 1.08). The key 
intermediates for this synthesis were compounds 47, 48 and 49. 
 
                     
Scheme 1.08: Retrosynthesis of resolvin E1 22 developed by Kobayashi.181 
 
The intermediate 47 provided access to the C1−C9 portion of resolvin E1 22. The 
starting point for this compound was methyl 5-oxopentanoate 51 (Scheme 1.09). 
Addition of compound 50 to 51 afforded a racemic mixture of the alcohol 52. 
Kinetic resolution of the racemic alcohol using Ti(i-OPr)4 and D-(-)-DIPT provided 
the (S)-enantiomer in 43% yield and 99% ee. This compound was converted into the 
bromide 53 in 2 steps followed by protection of the secondary alcohol with a TBS 
group to afford compound 54 in 74% yield over 3 steps. A Sonogashira reaction 
between compound 54 and the alkyne 55 followed by removal of the TMS group and 
reduction of the alkyne with disiamylborane gave the key intermediate 47 in 95% 





Scheme 1.09: Preparation of the intermediate 47.181 
 
The intermediate 48 was synthesised in 10 steps starting from compound 56 
(Scheme 1.10). The starting material for this synthesis was inturn prepared from 1,3-
propanediol in 4 steps and 58% yield.
181
 A Parikh-Doering oxidation of the alcohol 
56 afforded the ketone 57. The ketone was reduced to the (R)-alcohol using Noyori’s 
catalyst, giving compound 56 in 89% yield and 98% ee. Subsequent protection of the 
secondary alcohol with a TBDPS group followed by removal of the TMS group 
using K2CO3 in methanol furnished the alkyne 58. Hydrostannation of the alkyne 
and treatment with iodine then afforded compound 59. Functional group 





Scheme 1.10: Preparation of the iodide 48.181 
 
The final intermediate 49 was synthesised via a kinetic resolution strategy starting 
from propionaldehyde 60 (Scheme 1.11). Treatment of 60 with the lithium 
acetylide 34 afforded rac-alcohol 61. The alkyne was reduced to an E-alkene using 
Red-Al
®
, followed by kinetic resolution of the rac-alcohol using D-(-)-DIPT and 
Ti(i-OPr)4 to give the epoxide 63 in 45% yield and 99% ee. Epoxide ring opening 
was then achieved with diethylaluminium cyanide, affording compound 64 after 
elimination of the alcohol and TMS group. The secondary alcohol was protected 
with a TBDPS group and the nitrile moiety was reduced to an aldehyde using 





Scheme 1.11: Synthesis of the aldehyde 49.181 
 
The final steps of the synthesis involved a Wittig olefination between the 
phosphonium salt 48 and the aldehyde 49 (Scheme 1.12). This gave the Z-alkene at 
the C14−C15 position. The product was then treated with TBAF to remove the TBDPS 
groups, affording the iodide 65 in 82% yield over 2 steps. A Suzuki reaction between 
the iodide 65 and the borane 47, followed by silyl group deprotection, gave the target 
compound 22 in 55% yield in 2 steps. 
The main advantage of this synthesis was the cheap starting materials used to 
prepare the key fragments 47 and 49. The drawback however, was the number of 
steps required to synthesis the target compound. The longest linear sequence of 
resolvin E1 was 18 steps from 1,3-propanediol. This was 6 steps more than the 
synthesis reported by Petasis.
180
 Thus, this pathway was not ideal for large scale 





Scheme 1.12: Final steps in the synthesis of resolvin E1.181 
 
1.4.3 Total synthesis of resolvin E1 developed by Allard  
 
The most recent total synthesis of resolvin E1 was reported by Allard et al. in 
2011.
182
 The key intermediates in the synthesis were compounds 66, 67 and 68 
(Scheme 1.13). Following a similar approach to Petasis,
180
 these compounds were 






Scheme 1.13: Retrosynthesis of resolvin E1 developed by Allard.182 
 
Compound 66 was synthesised in 4 steps from glutaric anhydride 69 (Scheme 1.14). 
Treatment of 66 with compound 30 and aluminium chloride followed by the addition 
of p-toulenesulfonic acid and isopropyl alcohol gave the ketoester 70 in 70% yield 
over 2 steps. The ketone was asymmetrically reduced using Noyori’s catalyst, giving 
the (S)-alcohol of compound 71 in 98% ee. Subsequent removal of the TMS group 
with TBAF furnished the ester 66 in 86% yield from compound 70.  
 
Scheme 1.14: Preparation of compound 66.182 
 
Following the synthetic route described by Petasis
180
 (Scheme 1.04), the aldehyde 72 
was prepared in 4 steps from glycidol 33 (Scheme 1.15). This compound was then 




                    
Scheme 1.15: Preparation of the iodide 67.182 
 
The final intermediate 68 was synthesised using the pathway developed by Petasis 
(Scheme 1.05).
180
 Starting from glycidol 33, the iodide 74 was prepared in 47% yield 
in 5 steps (Scheme 1.16). The product was then treated with TBAF to afford 
compound 68 in 72% yield. 
 
Scheme 1.16: Preparation of the iodide 68.182 
 
Following the same strategy as Petasis,
180
 the alkyne 66 and the iodide 67 were 
coupled together (Scheme 1.17). The product was treated with TBAF to remove the 





Scheme 1.17: Synthesis of compound 75.182 
 
The antepenultimate step in the synthesis involved a second Sonogashira reaction 
between the alkyne 75 and the iodide 68 (Scheme 1.18). This furnished the product 
76 as the isometrically pure 8E-alkene in 48% yield from compounds 66 and 67. The 
two alkynes of compound 76 were reduced using a Zn(Cu/Ag) amalgam and the 
isopropyl ester was hydrolysed with NaOH to afford resolvin E1 22 in 45% yield 





Scheme 1.18: Final steps in the synthesis of resolvin E1.182 
 
Following a similar pathway to Petasis,
180
 Allard was able to optimise several 
reactions from this synthesis. One example was the asymmetric reduction of 
compound 70 using Noyori’s catalyst. This gave the (S)-alcohol 71 in 98% ee. In 
contrast, Petasis reduced the ketone using S-Alpine-Borane
®
 to give the (S)-
enantiomer of alcohol 32 in only 90% ee.
180
 By changing several reactions from the 
original synthesis,
180
 the yield for the longest linear sequence of resolvin E1 was 




1.4.4  A scalable synthesis of compound 28 
 
An alternate synthesis that targeted the C16−C20 segment of resolvin E1 was 
developed by Amin and co-workers in 2013 (Scheme 1.19).
185
 The starting material 
for this pathway was the commercially available propionyl chloride 77. This 
compound was cheaper than the starting material used by Petasis and Allard.
180-182
 




on a multikilogram scale. This was important for the large scale production of 
resolvin E1 which was required for early-phase clinical testing.
185
 
Starting from propionyl chloride, the iodide 28 was synthesised in 16% yield in 
4 steps (Scheme 1.19). The addition of acetylene to propionyl chloride afforded the 
chloride 78. This compound was treated with sodium iodide and aluminium chloride 
to give compound 79. The key step in the synthesis was the asymmetric reduction of 
the ketone. After testing a number of chiral reagents and reducing reagents, the (S)- 
(-)-2-methyl-CBS-oxazaborolidine catalyst and BH3•DMS gave the (R)-alcohol in 
the highest enantiomeric purity. Using these reagents, the (R)-alcohol 68 was 
afforded in 87% yield and 96% ee. The alcohol 68 was then protected with a TBS 
group to afford the target compound 28 in 85% yield.  
 
        
Scheme 1.19: Amin’s scalable synthesis of the iodide 28.185 
 
1.5 Resolvin E1 target receptors 
 
1.5.1 ChemR23 and BLT-1  
 
Resolvin E1 is able to regulate pro-inflammatory pathways by acting on the 
G protein-coupled receptors ChemR23 and BLT-1.
171,186
 Radio-ligand binding 
assays carried out by Arita et al. in 2005 showed resolvin E1 binds to a single site on 
the ChemR23 receptor with a high affinity (Ki  = 300 nM).
171
 Other receptors such as 
ALX, FPR and GPR1 that are known to regulate inflammation were screened. 
Resolvin E1 had no affinity for these receptors. Using dot blots containing mRNA 
from human tissues, Arita and co-workers showed that ChemR23 is expressed in a 






 ChemR23 was also abundantly expressed in 
monocytes, macrophages and dentric cells.
171
 Additional tests indicated that 
resolvin E1 inhibited pro-inflammatory TNF-induced NFB activation in a 
concentration-dependent manner upon binding to ChemR23.
171
 This was supported 
by functional interaction studies that suggested resolvin E1 acts as a selective agonist 
for the ChemR23 receptor.
171
 
Further studies by Arita and co-workers in 2007 also showed resolvin E1 binds to 
the leukotriene B4 receptor BLT-1 with a high affinity (Ki  = 70 nM).
186
 Similar to 
the ChemR23 receptor, BLT-1 is expressed in neutrophils, monocytes and 
eosinophils.
187
 Upon activation of the BLT-1 receptor by leukotriene B4, these cells 
are recruited to the site of inflammation.
187
 In vitro studies showed resolvin E1 
mitigates this process by inhibiting the stimulation of leukotriene B4 through calcium 
mobilisation. Resolvin E1 also attenuated leukotriene B4 induced NFB activation in 
BLT-1 transfected cells.
186
 These results suggest that resolvin E1 dampens BLT-1 




Despite the discovery that resolvin E1 acts on the ChemR23 and BLT-1 receptors, 
the exact binding site of this molecule is yet to be established. Chemerin, the natural 
agonist of the ChemR23 receptor, could hold the key to solving this problem. 
Chemerin belongs to the polypeptide family of cathelicidin and cystatin proteins 
which eradicate microbes and pathogens.
188-190
 Chemerin is known to exhibit anti-
inflammatory properties similar to resolvin E1, promoting chemotaxis and calcium 
release in immature macrophages and dendritic cells.
191-192
    
Through a series of structure-function relationship studies conducted in 2004, 
Wittamer and co-workers identified a nine amino acid sequence derived from the 
chemerin C-terminus responsible for ChemR23 agonism.
193



























Several nonapeptide analogues were synthesised by Wittamer and co-workers to 
determine the key amino acids that activate the ChemR23 receptor. Compared to the 
unsubstituted nonapeptide (EC50 = 7.1 nM), moderate decreases in the bioactivity of 






 were exchanged with 







 residues were altered, the peptide potency was dramatically 
reduced by more than two orders of magnitude (EC50 = 496 nM, 155 nM and 6.7 µM 
respectively).
193
 On the basis of unpublished studies
194
 and molecular modelling, the 









 at the N-terminus of the nonapeptide form a 
loop at the active site of the receptor. Substituting these amino acids with alanine 
would change the size of the loop, thus reducing the binding affinity and the potency 





Figure 1.12: Chemerin-9 bound to the ChemR23 receptor. 
 
Although the exact site on the ChemR23 receptor to which resolvin E1 binds is yet 
to be determined, it has been postulated that it could bind to the same site as the 
chemerin-9 peptide.
1,194
 This is based on the structural similarities between the two 




is shown in Figure 1.13. When bound to ChemR23, the chemerin-9 peptide adopts a 
loop-like geometry. This allows the peptide to bind tightly to the receptor. 
Resolvin E1 also has a loop that is formed by the 6Z-alkene (Figure 1.13). This 
provides the molecule with a conformational rigidity similar to chemerin-9. 
Resolvin E1 modelled into the ChemR23 receptor showed this loop fits in the same 
pocket as the loop of chemerin-9. Thus, it is speculated that the two compounds 
could bind to the ChemR23 receptor at the same site.  
 
Figure 1.13: 3D molecular structures of resolvin E1 and chemerin-9. 
 
1.6 Chemical stability of resolvin E1  
 
Although resolvin E1 is a potent pro-resolving lipid mediator, it is also highly 
unstable. This was confirmed by in vitro stability studies conducted by Maddipati 
and Zhou in 2011.
195
 The studies showed that when incubated with a phosphate 




C, and 37 
o
C, the concentration of resolvin E1 reduced 
significantly over 48 hours, as judged by HPLC-MS. It was estimated that the half-
life of resolvin E1 at 25 
o
C in this buffered system was 18 hours (Figure 1.14). Rapid 
degradation of resolvin E1 was also observed when incubated with a complex 
mineral medium such as Roswell Park Memorial Medium 1640.
195
  
The decomposition of resolvin E1 could be attributed to the chemical instability of 
the triene system which is highlighted in red (Figure 1.14).
181
 The Z-alkene at the 
C6−C7 position can readily isomerise to the more thermodynamically stable E-
alkene, giving compound 80.
172
 This isomer has a significantly reduced anti-
inflammatory activity.
177
 Biological tests conducted by Serhan and co-workers have 






 This decrease in anti-inflammatory activity could be attributed to a 
change in the confirmation of the two isomers. Upon isomerisation, resolvin E1 
adopts a linear structure rather than a loop-like geometry (Figure 1.14). The loss of 
chemical rigidity prevents compound 80 from binding tightly to the ChemR23 
receptor as it can no longer fit in the proposed pocket. Subsequently, the anti-
inflammatory potency of the 6E-isomer is diminished. 
 
                                            
Figure 1.14: Resolvin E1 stability plot and isomerisation of the triene unit.195 
 
1.7 Project aims 
 
 
The aims of this project were to synthesise an analogue of resolvin E1, investigate its 
chemical stability and determine its affinity for the BLT-1 receptor using a radio-
ligand binding assay. The target compound chosen for this study was a benzene 
annulated analogue of resolvin E1, herein referred to as benzoresolvin E1 81 
(Scheme 1.20). As previously mentioned,
172,181
 the 6Z-alkene of resolvin E1 readily 
isomerises at room temperature to the more thermodynamically stable 6E-alkene. 
This results in a loss of anti-inflammatory potency.
177
 By adding a benzene ring, 
isomerisation could no longer take place at this position (Scheme 1.20). With this 
decomposition pathway suppressed, it is envisaged that benzoresolvin E1 would be 



























Stability of resolvin E1  





Scheme 1.20: The benzene ring of compound 81 inhibits isomerisation at the C6−C7 position. 
 
Based on molecular modelling studies with resolvin E1 and the ChemR23 
receptor,
194
 the benzene ring could also utilise an extra hydrophobic pocket at the 
proposed binding site (Figure 1.15). The benzene ring would be in proximity to the 
phenyl alanine residue of the ChemR23 receptor and could undergo - stacking. 
Subsequently, the benzene annulated analogue of resolvin E1 should have a greater 




Figure 1.15: Proposed binding site for resolvin E1. 
 
1.7.1 Synthesis of benzoresolvin E1 
The target compound 81 could be synthesised from the intermediates 82, 83 and 84, 
with the key disconnections located at the C4−C5 and the C12−C13 positions (Scheme 
1.21). Unlike the pathways developed by Petasis, Kobayashi and Allard,
180-182
 cross-




strategy was planned for benzoresolvin E1. This offered an alternate pathway to 
prepare the C6−C11 benzodiene and the C14−C17 diene of the target compound. The 





Scheme 1.21: Proposed retrosynthesis of benzoresolvin E1 81. 
 
1.7.2 Stability study 
 
Once benzoresolvin E1 is synthesised, the stability of this compound in a phosphate 
buffered solution will be investigated and compared to resolvin E1. This study will 
determine the importance of the benzene ring towards improving the stability of this 
messenger molecule by blocking isomerisation at the C6−C7 position. 
 
1.7.3  Inhibition of BLT-1 and preparation of analogues 
To determine the affinity of benzoresolvin E1 81 for the BLT-1 receptor, radio-
ligand assays will be conducted by Eurofins Panlabs in Taiwan. BLT-1 will be used 
instead of ChemR23 since it is available for testing. The target compound will be 
initially screened with the BLT-1 receptor at 10
-5 
M. This will be followed by a 
semi-quantitative analysis to determine the IC50 and inhibitory constant of 81. If 
these results are positive, analogues of benzoresolvin E1 will be synthesised to 






Synthesis of Benzoresolvin E1: A Grignard Strategy 
 
2.1  Proposed synthetic pathway 
 
Benzoresolvin E1 81 could be synthesised from the pathway shown in Scheme 2.01. 
The target compound could be prepared from the triol 85 in 3 steps. These steps 
include the reduction of the alkyne, removal of the acetal group and oxidation of the 
aldehyde to give the carboxylic acid of benzoresolvin E1 81. Compound 85 could be 
prepared by an addition reaction between the aldehyde 86 and the propargylic 
Grignard 84. Examples of propargylic Grignards similar to 84 are known, although 
they are limited in the literature.
196,197
 Finally, the aldehyde 83 could be prepared by 
a second Grignard reaction between the aldehyde 83 and the Grignard reagent 82 
followed by reduction of the methyl ester. 
     





2.2  Preparation of fragment 83 
 
Focusing on the synthesis of the aldehyde 83, this compound could be prepared in 
2 steps. A Wittig olefination between the lactol 87 and the phosphonium salt 88 
could give the alcohol 89. The benzyl alcohol could then be oxidised to afford the 
aldehyde 83 (Scheme 2.02). 
          
Scheme 2.02: Proposed synthesis of the aldehyde 83. 
 
The lactol 87 was synthesised in 34% yield along with the diol 91 in 40% yield by 




 Under normal 





NMR spectrum of the product showed a 34:16 mixture of the lactol 87 and the 
aldehyde 92, with the signal at 10.09 ppm ascribed to the aldehyde hydrogen of 92 
and the resonance at 5.28 ppm attributed to the methine hydrogen of the lactol 87. 
These signals are consistent with the resonances observed in the 
1
H NMR spectrum 
provided in the literature.
199
 Alternatively, phthalide 90 was completely reduced to 
the diol 91 in 90% yield. Following the method described by Corey and Palani,
199
 
the diol 91 was then selectively oxidised using IBX to give the lactol 87 in 77% 






Scheme 2.03: Preparation of the lactol 87. 
 
Compound 88 was synthesised following the procedure described by Baeckstroem 
and co-workers.
200
 Radical bromination of methyl crotonate 93 using AIBN and N-
bromosuccinimide gave the bromide 94 in 67% yield. This compound was then 
treated with triphenylphosphine to afford the phosphonium salt 88 in 93% yield 
(Scheme 2.04).   
 
Scheme 2.04: Preparation of compound 88. 
 
Addition of n-BuLi to compound 88 in anhydrous tetrahydrofuran followed by the 
addition of the lactol 87 at 0 
o
C furnished the alcohol 89 in 39% yield 
(Scheme 2.05). The 
1
H NMR spectrum of the crude reaction mixture showed the 
reaction proceeded with complete selectivity for the 4E-alkene. The product was 
then dissolved in dichloromethane and treated with activated manganese dioxide to 
afford the aldehyde 83 in 76% yield (Scheme 2.05).  
 






H NMR spectrum of the product showed four signals at 7.85, 7.49, 6.81 and 
6.02 ppm that were attributed to the four vinylic hydrogens while the signals at 7.80, 
7.64, 7.56 and 7.46 ppm were ascribed to the four aromatic hydrogens (Figure 2.01). 
The vinylic signals at 6.81 and 7.85 ppm have a common coupling constant of 
15.5 Hz while the vinylic resonances at 6.02 and 7.49 ppm have a coupling constant 
of 15.4 Hz. This supports the 2E,4E-diene arrangement of 83. A signal at 10.21 ppm 






1H NMR spectrum of the aldehyde 83 in CDCl3. 
 
2.3  Investigating the selectivity of the Grignard reaction  
 
With aldehyde 83 in hand, attention was focused on the reaction between this 
compound and the Grignard reagent 82. It was anticipated that 82 would add to the 
aldehyde to give the alcohol 86 after the methyl ester was reduced (Scheme 2.01). 
However, the Grignard reagent could also add to the ester via a 1,2-addition or a 
Michael addition (Figure 2.02). To determine the selectivity of the Grignard reaction, 






Figure 2.02: Possible sites for the addition of a Grignard reagent. 
 
Pleasingly, the addition of one equivalent of ethylmagnesium bromide to the 
aldehyde 83 in anhydrous tetrahydrofuran at −45 
o
C afforded compound 96 as the 
sole product in 51% yield (Scheme 2.06). The methyl ester remained intact, as 
suggested by the signal at 167.6 ppm in the 
13
C NMR spectrum and the peak at 
1709 cm
-1
 in the IR spectrum of the crude reaction mixture. The 
1
H NMR spectrum 
of the product showed a triplet at 4.94 ppm that was ascribed to the methine 
hydrogen of the carbon bearing hydroxyl group while the appearance of two signals 
at 1.77 and 0.95 ppm were assigned to the methylene and methyl hydrogens of the 
newly formed ethyl group.  
                
Scheme 2.06: Addition of ethylmagnesium bromide to the aldehyde 83. 
 
Having selectively reacted ethylmagnesium bromide with compound 83, attention 
was shifted towards the preparation of the Grignard 82. The key feature of this 
Grignard reagent is the acetal group, which is used as a masked carboxylic acid in 
the synthesis of benzoresolvin E1. The Grignard reagent 82 was synthesised in 
3 steps starting from 2,3-dihydrofuran. Following the procedure by Stowell and 
Polito,
201
 2,3-dihydrofuran was treated with a catalytic amount of concentrated HCl 
(32% w/v) and pinacol in water to furnish the alcohol 98 in 65% yield (Scheme 
2.07). The alcohol was then converted into a chloro group using thionyl chloride and 





Scheme 2.07: Preparation of compound 99. 
 
In an attempt to synthesise the Grignard reagent 82, a 1 M solution of 99 in 
tetrahydrofuran was heated under reflux with magnesium turnings. After 4 hours, a 
complex mixture of signals was observed in the region of 0.50−4.00 ppm in the 
1
H 
NMR spectrum of the crude reaction mixture. These signals could be assigned to a 
combination of polymerised and thermally induced decomposition products, with 
cyclobutyl ether 100 identified as the major compound (Scheme 2.08). The 
1
H NMR 
spectrum of the crude reaction mixture showed a multiplet at 3.90 ppm that could be 
attributed to the methine hydrogen of 100 along with a cluster of signals between 
1.20−3.50 ppm that could be assigned to the methylene and methyl hydrogens. It 
was rationalised that the Grignard reagent 82 underwent a thermally induced intra-
molecular nucleophilic substitution reaction to afford the cyclobutyl ether 100 





Scheme 2.08: Thermally induced decomposition of the Grignard reagent 82. 
 
To prevent this competing reaction, the Grignard reaction was repeated at 0 
o
C. 
Pleasingly, the cyclobutyl ether 100 was not observed in the 
1
H NMR spectrum of 
the crude mixture after this change. Titrating the Grignard reagent 82 with BHT and 
1,10-phenanthroline in anhydrous tetrahydrofuran suggested that the yield of this 
reaction was 79% after 19 hours. 
Benzaldehyde was then used as a model compound to investigate the reactivity of 
the Grignard reagent 82. Addition of one equivalent of this Grignard to 
benzaldehyde at −84 
o
C furnished the alcohol 102 in 63% yield (Scheme 2.09). The 
1




was ascribed to the methine hydrogen of the newly formed benzylic alcohol. A 
doublet of doublets at 4.60 ppm was also observed in the spectrum. This could be 
assigned to the methine hydrogen of the acetal group. The IR spectrum of the 
product also showed a new peak at 3446 cm
-1
 that could be ascribed to the newly 
formed benzylic alcohol. 
             
Scheme 2.09: Addition of the Grignard reagent 82 to benzaldehyde. 
 
Following the same conditions described in the model system, the aldehyde 83 was 
treated with one equivalent of the Grignard reagent 82 at −84 
o
C to afford the alcohol 
103 in 32% yield after 5 hours (Scheme 2.10). Starting material was also recovered 
in 68% yield from the reaction mixture.  
 




H NMR spectrum of the product showed eight signals between 5.92−7.42 ppm 
that were ascribed to the four vinylic and four aromatic hydrogens. The two methine 
hydrogens of the acetal and the carbon bearing hydroxyl group were assigned to the 
two superimposed signals at 4.95 ppm while the singlet at 3.70 ppm was ascribed to 
the methyl hydrogens of the ester. The 
13
C NMR spectrum showed a signal at 




was observed at m/z = 388.2234 [M
+
] in the high resolution mass spectrum. This was 
consistent with the molecular formula required for C23 H32O5. 
Similar yields of compound 103 were afforded when the reaction mixture was 
warmed to −45 
o
C and 0 
o
C (Table 2.01, entries 2 and 3). Repeating the reaction with 
1.5 equivalents of the Grignard reagent 82 gave a complex mixture of products 
(Table 2.01, entry 4). The use of LnCl3•LiCl to promote the addition reaction of 82 
to the aldehyde was also explored.
203
 One equivalent of the Grignard 82 was added 
dropwise to a mixture of one equivalent of LnCl3•LiCl and compound 83 in 
anhydrous tetrahydrofuran. This furnished the alcohol 103 in 29% yield and starting 
material in 65% yield after 12 hours at 0 
o
C (Table 2.01, entry 5). Changing the 
solvent to diethyl ether also afforded the alcohol 103, however in a lower yield of 
12% (Table 2.01, entry 6).  








Entry   82 (eq.) Conditions        Result  
1 1.0 THF, −84 
o
C, 5 hrs     103 (32%) 
2 1.0  THF, −45 
o
C, 5 hrs     103 (32%) 
3 1.0  THF, 0 
o
C, 5 hrs     103 (31%) 
4 1.5 THF, 0 
o
C, 5 hrs     complex mixture            
5 1.0  LnCl3•LiCl (1 eq.), THF, 0 
o
C, 12 hrs     103 (29%) 
6 1.0  LnCl3•LiCl (1 eq.), Et2O, 0 
o




2.4  Preparation of the C13−C20 terminal chain 
 
In light of the low yields of compound 103, the addition of the Grignard reagent 82 
was postponed to a later stage in the synthesis. Instead, focus was shifted towards the 
synthesis of the Grignard reagent 84. This compound would provide the 14Z,16E-
diene fragment of benzoresolvin E1 (Figure 2.03). 
 
Figure 2.03: Benzoresolvin E1 and the Grignard reagent 84. 
 
The Grignard reagent 84 is a key intermediate in the synthesis of benzoresolvin E1 
and could be prepared from propargyl alcohol in 5 steps (Scheme 2.11). Propargyl 
alcohol could be brominated to afford the bromide 105. A Heck reaction with this 
compound and ethyl vinyl ketone could give the enyne portion of compound 106. 
The target compound 84 could then be synthesised from 106 in 3 steps by an Appel 
reaction, reduction of the ketone and preparation of the Grignard. 
 
Scheme 2.11: Proposed pathway for the synthesis of the Grignard reagent 84. 
 
Starting from propargyl alcohol, the bromide 105 was synthesised in 91% yield 
using silver nitrate and N-bromosuccinimide in acetone.
204
 This method proved 
superior to the bromination outlined by Brandsma which utilised potassium 
hypobromite as the oxidant.
205
 The enyne 106 could be prepared from the bromide 






 By coupling bromophenylacetylene 108 with a range of 
unactivated alkenes, Wen and co-workers prepared conjugated enynes such as 109 in 
high yields.
206
 These reactions were selective towards the E-alkene. 
 
Scheme 2.12: Heck coupling between styrene 107 and the bromide 108 reported by Wen.206   
 
Using the same conditions reported by Wen,
206
 the bromide 105 was treated with 
20 equivalents of methyl vinyl ketone, palladium acetate (5 mol%), 2.5 equivalents 
of potassium carbonate and a catalytic amount of BHT in dimethylformamide 
(Table 2.02, entry 1). Methyl vinyl ketone was used as a model compound for ethyl 
vinyl ketone as it is cheaper while BHT was used a radical scavenger to prevent 
polymerisation of the starting material and the product. The reaction turned black 
after stirring the mixture for 2 hours at 80 
o
C (Table 2.02, entry 1). The 
1
H NMR 
spectrum of the crude reaction mixture showed signals between 0.50−2.00 ppm with 
no resonances observed in the vinylic region, suggesting decomposition of the 
reaction mixture. Protecting the alcohol with a TBS group also gave the same result 
(Table 2.02, entry 2). The bromide 105 was then protected with a tetrahydropyranyl 
group (THP) and the reaction was repeated using the same conditions (Table 2.02, 
entry 3). This gave the enyne 112 in 16% yield after 2 hours along with an 
unidentified mixture of compounds.  
Table 2.02: Heck coupling reaction with the protected alcohol 111 and methyl vinyl ketone. 
 
 
Structural elucidation of the product 112 was based on the 
1





H NMR spectrum showed two signals at 6.59 and 6.46 ppm that could 
Entry R Reaction time    Product yield 
1      H   2 hrs   decomposition 
2 TBS 2 hrs   decomposition 




be assigned to the newly formed vinylic hydrogens (Figure 2.04). These hydrogens 
have a common coupling constant of 16.2 Hz which is consistent with the E-alkene 
of 112. The triplet at 4.78 ppm was ascribed to the methine hydrogen of the THP 
group while the two signals at 4.44 and 4.37 ppm could be assigned to the 
propargylic hydrogens. The 
13
C NMR spectrum showed a signal at 197.0 ppm that 
was ascribed to the ketone while the two resonances at 138.5 and 123.3 ppm were 
assigned to the vinylic carbons. Two signals at 97.2 and 96.0 ppm were also 




Figure 2.04: 1H NMR spectrum of compound 112 in CDCl3 (4.20−7.60 ppm). 
 
The low yields of 112 could be due to the hydrolysis of the THP group caused by the 
mild Lewis acidity of the Pd(OAc)2. Subsequently, propargyl alcohol was treated 
with benzoyl chloride to form the benzoate ester 113 (Scheme 2.13). It was 
anticipated that the ester would be more stable than the THP protecting group. 
Following the same conditions given in Table 2.02, compound 114 was afforded in 
23% yield after 2 hours (Scheme 2.13). The key signals in the 
1
H NMR spectrum of 
the product were observed at 6.63 and 6.52 ppm. These were ascribed to the two 
vinylic hydrogens. In an attempt to improve the yield of the product, the reaction was 
repeated and the mixture was stirred for 4 hours. Only trace amounts of the product 
was observed in the 
1
H NMR spectrum after this time, indicating that decomposition 
had occurred. This suggests that the α,β-unsaturated enyne system is unstable under 





Scheme 2.13: Heck reaction between methyl vinyl ketone and the bromide 113. 
 
In light of the low yields for the Heck products, an alternate pathway towards the 
Grignard reagent 84 was explored (Scheme 2.14). 2,4-Hexadiyne-1,6-diol 115 was 
the starting material for this synthesis. This compound was prepared on a large scale 
in 25% yield using propargyl alcohol, CuCl and O2.
205
 Following the pathway 
reported by Trost and Livingston,
208
 the aldehyde 118 was synthesised from 2,4-
hexadiyne-1,6-diol 115 in 3 steps (Scheme 2.14). Monosilylation of the diol 115 
using TBSCl, imidazole and DMAP furnished compound 116 in 70% yield. The 
propargylic alkyne was reduced to an alkene using LiAlH4 to afford compound 117 
in 85% yield. The appearance of two new resonances at 6.23 and 5.76 ppm in the 
1
H 
NMR spectrum of the product were ascribed to the newly formed vinylic hydrogens. 
These signals have a common coupling constant of 15.9 Hz. This is consistent with 
the coupling constant expected for an E-alkene. The allylic alcohol was then 
oxidised to an aldehyde to give compound 118 in 85% yield. The 
1
H NMR spectrum 
of the product showed a doublet at 9.53 ppm that was attributed to the aldehyde 
hydrogen. Unlike the Heck reaction in Scheme 2.13, this synthetic route allowed 
access to the enyne under milder conditions and gave higher yields of the product. 
 





The aldehyde 118 was then treated with 2.3 equivalents of ethylmagnesium bromide 
at −45 
o
C to afford the alcohol 119 as a racemic mixture in 81% yield (Scheme 
2.15). The racemic alcohol was used in the proceeding steps, with the (R)-alcohol of 
119 planned to be synthesised at a later stage. The
 1
H NMR spectrum of the product 
showed a new resonance at 4.07 ppm that was ascribed to the methine hydrogen of 
the carbon bearing the hydroxyl group. Two new signals at 1.55 (2 H) and 0.94 (3 
H) ppm were also observed in the 
1
H NMR spectrum. These were assigned to the 
methylene and methyl hydrogens of the ethyl group. Elemental analysis of the 
product was also consistent with the molecular formula of compound 119. 
 
Scheme 2.15: Synthesis of the alcohol 119. 
 
A two step procedure was developed to prepare compound 121 from compound 119 
(Scheme 2.16). This involved swapping the silyl protecting group from the primary 
alcohol to the secondary alcohol. To protect the secondary alcohol, a TBDPS group 
was chosen. TBDPS is stable under mildly acidic conditions, thus allowing the TBS 
on the primary alcohol to be removed without deprotecting the secondary alcohol. 









Treating the alcohol 119 with TBDPSCl, DMAP and imidazole gave compound 120 
in 76% yield (Scheme 2.16). The 
1
H NMR spectrum of the product showed two new 
multiplets between 7.38−7.63 ppm with an overall integration of ten hydrogens. 
These signals were ascribed to the aromatic hydrogens of the TBDPS group. The IR 
spectrum of the product showed the disappearance of the alcohol peak at 3398 cm
-1
 
which supported the silylation of the secondary alcohol.   
Compound 120 was then treated with a catalytic amount of CSA in ethanol at room 
temperature. This gave the alcohol 121 in 95% yield (Scheme 2.16). The 
1
H NMR 
spectrum of the product showed two multiplets between 7.39−7.65 ppm that were 
ascribed to the aromatic signals of the TBDPS group. This suggests that the 
protecting group on the secondary alcohol was not removed. The disappearance of 
the two signals at 0.92 and 0.13 ppm in the 
1
H NMR spectrum was also noted. These 
were ascribed to the TBS methyl groups of compound 120. The IR spectrum showed 
a new peak at 3402 cm
-1
 that was assigned to the primary alcohol. This is further 
evidence for the removal of the TBS group. 
 
2.5  Hydrosilylation approach 
 
A key feature of benzoresolvin E1 81 is the 14Z-alkene (Scheme 2.17). In the 
synthesis of resolvin E1 developed by Petasis and Allard,
180,182
 the Z-alkene was 
prepared by reducing the alkyne with a Zn(Cu/Ag) amalgam. The reduction was 
conducted at the end of the synthesis because the Z-alkene could isomerise to the 
more favourable E-alkene. In the system shown in Scheme 2.17, two different 
pathways could afford the 14Z-alkene of benzoresolvin E1. The primary alcohol of 
the key intermediate 121 could be converted into a bromo group via an Appel 
reaction, followed by the reaction with magnesium turnings to give the propargylic 
Grignard reagent 123. This compound could be added to the aldehyde 86 to give the 
key intermediate 85 shown in Scheme 2.01. Following the same method as Allard,
182
 
the alkyne could be reduced in the last step of the synthesis to form the 14Z-alkene. 
Alternatively, compound 121 could be converted into 124 in 3 steps (Scheme 2.17). 
The key step in this route is the silylation of the alkyne to afford an alkene. The 
bulky triethylsilyl group of 124 would improve the stability of the alkene, preventing 




earlier stage in the synthesis, with the removal of the silyl group affording the 14Z-
alkene at a later stage. 
 
Scheme 2.17: Two possible pathways to prepare the 14Z-alkene of benzoresolvin E1. 
 
Focusing on the latter approach, the hydrosilylation of the alkyne 121 could give two 
regioisomers, the α-isomer and the β-isomer (Scheme 2.18). Since the silyl group is 
removed at a later stage in the synthesis, either isomer could be used in the next step. 
However, only one isomer was wanted. This would avoid preparing future 
compounds as a mixture of isomers that have complex NMR spectra. 
 





A study by Rooke and Ferriera has shown that compounds with propargylic alcohols 
undergo hydrosilylation to give the α-isomer in high yields.
209
 One example of this 
was illustrated in Scheme 2.19.
209
 Using Karstedt’s catalyst 127 and triethylsilane, 
Rooke and Ferriera prepared compound 128 from compound 126 in a 19:1 ratio in 




Scheme 2.19: Rooke and Ferreira’s procedure for the hydrosilylation of the alkyne 126.209 
 
The high selectivity for the α-isomer was rationalised by the coordinative effects of 
the propargylic alcohol. Rooke and Ferriera have suggested that the propargylic 
alcohol could coordinate with platinum, as shown in the intermediate 129 
(Scheme 2.20).
209
 This hydrogen bonding interaction directs the triethylsilyl group 
towards the α-position.  
 
Scheme 2.20: Hydrogen bonded platinum intermediate 129. 
 
Adapting the procedure by Rooke and Ferriera, the alcohol 121 was treated with 1.1 
equivalents of triethylsilane and Karstedt’s catalyst (6 mol%) in anhydrous 
tetrahydrofuran (Table 2.03, entry 1). After stirring the reaction mixture at room 
temperature for 15 hours, compound 125 was afforded as a mixture of regioisomers 
in 78% yield. The 
1




ratio of the α and β-isomers. The key vinylic signals are shown is Figure 2.05 and 





1H NMR spectrum of the alcohol 125 in CDCl3 (5.40−6.45 ppm). 
 
Changing the solvent to dichloromethane gave a similar result (Table 2.03, entry 2). 
The reaction was also repeated with hexachloroplatinic acid, giving compound 125 
in 30% yield as a 65:35 mixture of regioisomers (Table 2.03, entry 3). The low yield 
for this reaction was rationalised by the acid mediated decomposition of the allylic 
alcohol. Unfortunately, attempts to separate the α and β-isomers via column 
chromatography were unsuccessful. In view of this, the reduction of the alkyne was 
postponed to a later stage in the synthesis. 
Table 2.03: Hydrosilylation of compound 121. 
 
* Based on the 1H NMR spectrum. 
Entry Conditions    α / β*    Yield  
1         Karstedt’s catalyst (6 mol %), SiEt3H (1.1 eq.), THF,  
        25 
o
C, 15 hrs 
   65:35 78% 
2         Karstedt’s catalyst (6 mol %),  SiEt3H (1.1 eq.), CH2Cl2,  
        25 
o
C, 15 hrs 
   64:36  76% 
3         H2PtCl6•6 H2O  (6 mol%), SiEt3H (1.1 eq.), THF, 25 
o
C,  
        15 hrs 




Focusing on the synthesis of the propargylic Grignard reagent 123 shown in 
Scheme 2.17, the primary alcohol of 121 was converted into a bromide via an Appel 
reaction. Treatment of compound 121 with N-bromosuccinimide and 
triphenylphosphine at room temperature afforded the bromide 122 in 52% yield 
(Scheme 2.21). The 
1
H NMR spectrum showed a new resonance at 4.06 ppm with an 
integration of two hydrogens. This was consistent with the chemical shift expected 
for the hydrogens at the propargylic position.
210
 The high resolution mass spectrum 
of the product also gave a molecular ion (m/z = 441.1254 [M
+
]) that was congruent 
with the formula required for C24 H29OBrSi.  
 
Scheme 2.21: Preparation of the bromide 122. 
 
To prepare the Grignard reagent 123, compound 122 in anhydrous tetrahydrofuran 
was treated with magnesium turnings at 0 
o
C. The reaction mixture was allowed to 
warm to room temperature and stirred for 4 hours. After this time, the mixture turned 
black. An aliquot of the reaction mixture was quenched with D2O and extracted with 
CDCl3. The 
1
H NMR spectrum showed a cluster of signals between 5.50−6.30 ppm 
and 0.20−1.50 ppm that could be assigned to vinylic and aliphatic hydrogens while 
the aromatic resonances between 7.39−7.66 ppm that were ascribed to the TBDPS 
group had disappeared. A possible mode of decomposition is shown in Scheme 2.22. 
The Grignard reagent 123 could eliminate TBDPSOMgBr to give the highly reactive 
cumulene 130. This compound could undergo a series of unwanted reactions, leading 
to decomposition. To prevent the rearrangement of compound 123, the reaction 
mixture was cooled to −84 
o
C upon initiation of the Grignard. Unfortunately, this 
also led to degradation.   
 







Revised Strategy for Benzoresolvin E1 
  
3.1  Revised synthesis of the terminal chain 
 
As the proposed Grignard 123 underwent an unexpected elimination reaction 
(Scheme 2.21), a stepwise procedure was developed. The Grignard reagent 123 
could be segmented into two smaller compounds, propargylmagnesium bromide 134 
and the iodide 28 (Scheme 3.01). The latter compound would form the C16−C20 
terminal chain of benzoresolvin E1. The aldehyde 132 could be treated with 
propargylmagnesium bromide 134 to afford the alcohol 133. This compound could 
undergo a Sonogashira reaction with the iodide 28 to give the enyne portion of the 
target compound. The final steps in the proposed synthesis involved the reduction of 
the alkyne to give the 14Z-alkene and removal of the silyl protecting group 
















3.2  Preparation of the C16−C20 portion of benzoresolvin E1 
 
Five syntheses have been reported for compound 28.
180,182,185,211,212 
The synthesis 
described by Petasis afforded 28 in 39% yield in 7 steps starting from glycidol 33 
(Scheme 1.05).
180
 This was the same method used by Allard (Scheme 1.16).
182
 Using 
a chiral pool strategy, the target compound 28 was prepared in 100% ee. The 
drawback of this method is that the starting material is expensive ($47.50/g, Sigma-
Aldrich).
213
 Thus, large scale production of 28 using this pathway is not practical. 
Furthermore, the antepenultimate step in the synthesis involved a Takai olefination 
(Scheme 1.05). This reaction has been reported to give unreliable yields of 
compound 28.
180
 The third synthetic pathway was devised by Amin 
(Scheme 1.19).
185
 Starting from propionyl chloride 77, the iodide 28 was afforded in 
16% yield in 4 steps. Unlike the starting material used by Petasis, propionyl chloride 
is cheap ($25.00/25 g, Sigma-Aldrich).
213
 This makes the preparation of the iodide 
28 viable for large scale production. The (R)-alcohol of 28 was also formed with 
high enantiomeric purity. This was achieved via an asymmetric reduction reaction 
using (S)-CBS catalyst and BH3•DMS to give the (R)-enantiomer in 96% ee 
(Scheme 1.19). 
 
Scheme 3.02: Petasis and Amin’s procedures for the preparation of compound 28.180,185 
 
The fourth and fifth routes to prepare the iodide 28 were reported by Rodriquez and 
Fumie.
211-212
 Both pathways use the same hydrostannation strategy. Focusing on the 
method developed by Rodriquez,
211
 the target compound was synthesised in 56% 
yield and 94% ee in 6 steps starting from propionyl chloride 77 (Scheme 3.03). The 




tributyltin hydride and AIBN, followed by a reaction with molecular iodine to afford 
the vinylic iodide moiety of 28.  
 
Scheme 3.03: Rodriquez’s synthesis of compound 28.211  
 
The iodide 28 could be prepared by adapting the reactions used by Amin and 
Rodriquez.
185,211
 Combining these synthetic pathways could give the target 
compound in a higher yield over a similar number of steps. In the planned synthesis, 
the target compound could be synthesised in 7 steps starting from 1-pentyn-3-ol 138 
(Scheme 3.04). Following the last 2 steps reported by Rodriquez,
211
  hydrostannation 
of the alkyne 139 could furnish the stannane 137 while treatment of this compound 
with iodine could give rac-28. Removal of the silyl group followed by oxidation of 
the allylic alcohol could then afford the ketone 79 in 2 steps. Using the asymmetric 
reduction reaction reported by Amin,
185
 the ketone 79 could be reduced to give the 
enantiomerically pure (R)-alcohol, followed by TBS protection of the alcohol to 
afford the iodide 28. 
 





The silyl ether 139 was prepared in 96% yield from 1-pentyn-3-ol 138 using TBSCl, 
imidazole and DMAP (Scheme 3.05).
211
 Following the same conditions reported by 
Rodriquez,
211
 compound 139 was heated under reflux with 1.1 equivalents of 
tributyltin hydride, a catalytic amount of AIBN and toluene. The 
1
H NMR spectrum 
of the crude reaction mixture after 2 hours showed all three possible isomers. This 
was inconsistent with the findings made by Rodriquez.
211
  
In light of this result, milder conditions for the hydrostannation reaction were tested. 
Following the procedure described by Gallagher and co-workers,
214
 the silyl ether 
139 was treated with 1.1 equivalents of tributyltin hydride and a catalytic amount of 
Pd(PPh3)2Cl2. This afforded the stannane 137 in 68% yield as the sole product 
(Scheme 3.05). The 
1
H NMR spectrum of the product showed the appearance of 
three multiplets at 1.47−1.52, 1.25−1.36 and 0.86−0.94 ppm. These signals were 
ascribed to the butyl chain of the stannane. The 
1
H NMR spectrum also showed two 
resonances at 6.03 and 5.90 ppm that were assigned to the vinylic hydrogens. These 
hydrogens have a common coupling constant of 19.1 Hz which supports the E-
alkene of compound 137.  
 
Scheme 3.05: Preparation of the stannane 137. 
 
The stannane 137 was stirred in a solution of iodine and anhydrous ether at room 
temperature to furnish rac-28 in 81% yield (Scheme 3.06). Two new signals were 
observed at 6.51 and 6.19 ppm in the 
1
H NMR spectrum. These were attributed to 
the vinylic hydrogens. These hydrogens have a common coupling constant of 









To remove the TBS group, compound 28 was treated with a catalytic amount of CSA 
in ethanol at room temperature. This gave the rac-alcohol 68 in 74% yield (Scheme 
3.07). The allylic alcohol was converted into a ketone using activated manganese 
dioxide to afford compound 79 in 75% yield. The 
13
C NMR spectrum of the product 
showed a new resonance at 198.0 ppm ascribed to the ketone. This was consistent 





Scheme 3.07: Preparation of the ketone 79. 
 
Following the same procedure reported by Amin,
185
 the ketone 79 in anhydrous 
tetrahydrofuran was treated with (S)-CBS catalyst (10 mol%) and 0.6 equivalents of 
BH3•DMS (Scheme 3.08). After stirring the reaction mixture for 3 hours at 0 
o
C, 
compound 68 was afforded in 81% yield. This was lower than the 87% yield 




H NMR spectrum of the product matched the 
1
H NMR spectrum of rac-alcohol 68. The specific rotation of compound 68 was 
−0.44 (c = 1.00, CH3OH). At the same temperature, Amin reported the specific 
rotation of the enantiomerically pure (R)-alcohol to be −0.46
o 
(c = 1.50, CH3OH).
185
 
This suggests that the (R)-alcohol of 68 was prepared in 96% ee. Subsequent 
treatment of this compound with TBSCl, DMAP and imidazole gave the target 
compound 28 in 82% yield. 
 
Scheme 3.08: Synthesis of the iodide 28. 
 
3.3  Scalable synthesis of the iodide 28 
 
The iodide 28 was prepared in 20% yield in 7 steps from the pathway shown in 
Scheme 3.04. This was higher than the yield obtained by Amin.
185 
To prepare 
compound 28 on a large scale, a modified synthesis starting from propionaldehyde 




making large quantities of the iodide 28 feasible. Propionaldehyde 60 can be 
purchased for $0.34/g
215
 while 2-methyl-3-butyn-2-ol 141 costs $3/kg.
216
  
Using butyraldehyde 141 and 2-methyl-3-butyn-2-ol 140, Boyall and co-workers 
reported an efficient 2 step synthesis for alkyne 144 (Scheme 3.09).
216
 The first step 
involved the asymmetric addition of 140 to compound 141 using zinc 
trifluromethanesulfonate, triethylamine and (-)-N-methylephedrine followed by 
protection of the secondary alcohol with a TIPS group. This afforded compound 143 
in 77% yield and 99% ee. Compound 143 was then treated with 18-crown-6 and 
potassium carbonate to furnish the alkyne 144 in 70% yield.  
 
Scheme 3.09: Boyall’s synthesis of the alkyne 144.216 
 
Compound 144 is similar to the silyl ether 139, which is a key intermediate in the 
previously developed synthesis of compound 28 (Scheme 3.04). A pathway similar 
to Boyall’s approach could be used to prepare the (R)-enantiomer of the silyl ether 
139. This pathway would intersect the synthesis in Scheme 3.04, providing an 
alternate route to the iodide fragment 28. Since (-)-N-methylephedrine cannot be 
purchased in Australia, the enantiomerically pure diol 142 could not be prepared in 
one step from propionaldehyde 60 and 2-methyl-3-butyn-2-ol 140. As such, a longer 
synthetic route was planned (Scheme 3.10). This involved the addition of 2-methyl-
3-butyn-2-ol 140 to propionaldehyde 60, followed by the oxidation of rac-142 and 
the reduction of the ketone 145 (Scheme 3.10). 
2-Methyl-3-butyn-2-ol 140 was treated with n-BuLi to form a lithium acetylide. This 
was added dropwise to a solution of propionaldehyde 60 in anhydrous 
tetrahydrofuran at −84 
o




was dissolved in anhydrous dichloromethane and stirred at room temperature with 
activated manganese dioxide to furnish the ketone 145 in 70% yield (Scheme 3.10). 
The 
13
C NMR spectrum of the product showed the appearance of a resonance at 
188.9 ppm that was assigned to the ketone while the 1H NMR spectrum was 
consistent with the spectroscopic data reported in the literature.
217
 Using the same 
conditions outlined in Scheme 3.08, the ketone was reduced with (S)-CBS catalyst 
(10 mol%) and BH3•DMS (Scheme 3.10). This afforded the (R)-alcohol 142 in 85% 
yield and 96% ee. The absolute configuration of the alcohol was determined by 
comparing the specific rotation of the desilylated target fragment 68, prepared in the 




Scheme 3.10: Scalable pathway for the synthesis of the (R)-alcohol 142. 
 
The secondary alcohol was then selectively protected using TBSCl, imidazole and 
DMAP at 25 
o
C (Scheme 3.11). This gave compound 146 in 92% yield. The 
1
H 
NMR spectrum of the product showed three new singlets at 0.90 (9 H), 0.12 (3 H) 
and 0.10 (3 H) ppm that were ascribed to the methyl hydrogens of the TBS group. 
This suggests that only one alcohol was silylated. Furthermore, the 
1
H NMR 
spectrum of the product was almost identical to the 1H NMR spectrum of compound 
143.
216
 This is the best evidence for the silylation of the secondary alcohol.   
    





Following the procedure developed by Boyall and co-workers,
216
 compound 146 was 
heated under reflux in toluene with potassium carbonate and 18-crown-6 
(Scheme 3.12). After 5 hours, the silyl ether 139 was afforded in 81% yield. 18-
Crown-6 was used to coordinate the potassium cation. This allowed the carbonate 
anion to deprotonate the tertiary alcohol, thus facilitating the fragmentation of 
compound 146 into the product and acetone. The specific rotation of the silyl ether 
139 was −0.40 (c = 1.00, CHCl3). This suggests that the product had not racemised 
under these conditions. Compound 139 intersects the synthesis shown in Scheme 
3.05 and was converted into the target fragment 28 in 2 steps following the 
hydrostannation approach. 
 
Scheme 3.12: Preparation of the key intermediate 28. 
 
3.4  Proposed synthesis of compound 147 
 
 
Having synthesised the C16−C20 portion of benzoresolvin E1, the Wittig olefination 
step described in Scheme 3.13 was revisited. Low yields of the olefination product 
were observed when the lactol 87 was reacted with the phosphonium salt 88. The 
equilibration of the lactol 87 with the aldehyde 92 could be responsible for the poor 
yields. To avoid this, the benzyl alcohol of compound 92 was protected. The 
protecting group chosen was a benzyl group. The benzyl ether could be deprotected 
in the presence of silyl ethers via single electron reductive conditions.
218-219
 This is 
important in the case of compound 148 which has two silyl protected allylic alcohols 
(Scheme 3.14). This approach would allow easy access to the benzyl alcohol at a 






Scheme 3.13: Wittig olefination of the lactol 87. 
 
The revised synthesis is shown in Scheme 3.14. The key intermediate in this route 
was the aldehyde 147. Benzoresolvin E1 could be prepared from this compound in 
4 steps. The aldehyde 147 could be synthesised from compound 148 by removing 
the benzyl group followed by oxidation of the alcohol. Compound 148 could be 
made by a Sonogashira reaction between the alkyne 149 and the iodide 28 followed 
by silyl group protection of the allylic alcohol. The terminal alkyne of 149 could be 
installed by the addition of propargylmagnesium bromide 134 to the aldehyde 150. 
Finally, a Wittig olefination with the aldehyde 151 and the phosphonium salt 88 






Scheme 3.14: Planned synthesis of compound 147. 
 
Using the method described by Bouzide and Sauve,
220
 the aldehyde 151 was 
synthesised in 2 steps (Scheme 3.15). Monobenzylation of the diol 91 with benzyl 
bromide afforded compound 152 in 87% yield. The reaction proceeded with 
excellent selectivity towards the monobenzylated product, giving only trace amounts 
of the dibenzylated compound. This selectivity was achieved by using silver oxide. 
The silver oxide coordinates to the two alcohols, making one of the hydrogens 
labile.
220
 This increases the nucleophilicity of one of the alcohols, facilitating the SN2 
reaction with benzyl bromide. The remaining hydroxyl proton is difficult to remove 
since it remains coordinated to the silver oxide. Thus, the addition of a second benzyl 
group is less likely to occur. Compound 152 was then oxidised using activated 
manganese dioxide to furnish the aldehyde 151 in 70% yield (Scheme 3.15). 
 
              




A Wittig olefination was attempted to form compound 153. Treatment of the 
phosphonium salt 88 with the aldehyde 151 in anhydrous tetrahydrofuran at 25 
o
C 
gave the product 153 as 1:1 mixture of the 4E and 4Z stereoisomers (Scheme 3.16). 
Complete isomerisation of the mixture to the desired 4E-isomer was achieved using 
catalytic amounts of iodine and potassium carbonate in hexanes. Potassium 
carbonate served to neutralise trace amounts of HI formed which could lead to 
decomposition of the newly formed benzodiene.  
 





H NMR spectrum of the product showed three vinylic signals at 7.18, 6.83 and 
6.00 ppm along with one vinylic signal embedded amongst the aromatic resonances 
at 7.43 ppm (Figure 3.01). The two signals at 7.43 and 6.00 ppm have a common 
coupling constant of 15.3 Hz while the signals at 7.18 and 6.83 ppm share a coupling 
constant of 15.5 Hz. This suggests that the product has two E-alkenes. A resonance 
at 167.6 ppm was observed in the 
13
C NMR spectrum while an absorbance at 
1713 cm
-1
 was shown in the IR spectrum. These signals were ascribed to the 
carbonyl group of the methyl ester.    
 





The ester 153 was reduced to the alcohol 154 using two equivalents of DIBAL at 
0 
o
C (Scheme 3.17). The product was then treated with activated manganese dioxide 
to afford the aldehyde 150 in 63% yield in two steps. A new signal at 9.50 ppm in 
the 
1





Scheme 3.17: Preparation of the aldehyde 150. 
 
With the aldehyde 150 in hand, the next step was to install the terminal alkyne. This 
could be achieved by treating the aldehyde 150 with propargylmagnesium bromide 
134. To prepare propargylmagnesium bromide, propargyl bromide in anhydrous 





Complete consumption of the starting material was achieved after 10 minutes, giving 
the Grignard reagent 134. The mercury(I) chloride additive was important for the 
initiation of the Grignard, with mercury forming an amalgam with the magnesium to 
activate its surface.
222
 The aldehyde 150 was then treated with propargylmagnesium 
bromide 134 at −17 
o
C (Scheme 3.18). The product rac-149 was afforded in 84% 
yield. The addition of the propargyl moiety was inferred by the mass spectrum 
(m/z = 341.1514 [M+23 (Na)]
+
), which was consistent with the molecular formula 
required for compound 149. The 
1
H NMR spectrum of the product showed the 
appearance of two signals at 2.50 and 2.54 ppm that were ascribed to the 
diastereotopic propargylic hydrogens and a resonance at 2.10 ppm that was attributed 
to the acetylenic hydrogen. The 
13
C NMR spectrum also showed three new 







Scheme 3.18 Addition of propargylmagnesium bromide to the aldehyde 150. 
 
Having prepared rac-149, a Sonogashira reaction with compound 28 was 
investigated. Preparation of the (R)-alcohol of 149 was postponed to see if the 
subsequent steps were viable. The Sonogashira reaction was performed by treating 
rac-149 and the iodide 28 with copper(I) iodide, piperidine and Pd(PPh3)4. The 
reaction proceeded smoothly, affording compound 155 in 83% yield as a mixture of 
diastereoisomers (Scheme 3.19). The product was confirmed by the disappearance of 
the acetylenic proton at 2.10 ppm in the 
1
H NMR spectrum along with the 
appearance of two resonances at 6.09 and 5.65 ppm that could be ascribed to the two 
vinylic hydrogens. These signals have a common coupling constant of 15.8 Hz 
which is consistent with the E-alkene of the product. In addition, the molecular ion at 
m/z = 539.2976 [M+23 (Na)]
+
 was consistent with the molecular formula of 
compound 155. Interestingly, both the 
1
H NMR and 
13
C NMR spectra showed no 
clear distinction between the two newly formed diastereoisomers due to the large 
distance between the two stereocenters.  
 




3.5  Removal of the benzyl group 
 
Having successfully constructed the benzodiene and enyne portions of the target 
compound, attention was focused on deprotecting the benzyl alcohol. To investigate 
the ideal conditions to remove the benzyl group, the silyl ether 156 was used as a 
model compound (Scheme 3.20). This compound has a benzodiene and an allylic 
silyl ether similar to compound 155. 
 
 
Scheme 3.20: Debenzylation of the model compound 156. 
 
Removal of benzyl ethers using hydrogen and palladium on carbon is the most 
traditional method however this is not viable for a system such as compound 155 
since the alkyne and the alkenes would also be reduced. Subsequently, a more 
condition specific approach using either lithium naphthalenide, sodium/ammonia or 
DIBAL was explored. Lithium naphthalenide is known to selectively cleave benzyl 
ethers attached to allylic and benzylic carbons.
223-224
 This is particularly important 
for compound 155 that has two benzyl groups either side of the ether. An example of 
this selectivity was reported by Liu and Yip.
224
 Using an excess of lithium 
naphthalenide, they were able to selectively remove the benzyl group in the presence 
of an allylic ether (Scheme 3.21). 
 
 
Scheme 3.21: Benzyl group deprotection of compound 158 devised by Liu and Yip.224 
 
Following the same conditions reported by Liu and Yip,
224
 compound 156 in 
anhydrous tetrahydrofuran was treated with one equivalent of lithium naphthalenide 
at −84 
o
C. No reaction was observed after 4 hours, as monitored by TLC (Table 3.01, 
entry 1). An increase in the number of equivalents of lithium naphthalenide along 
with increasing the reaction temperature to 0 
o
C gave the same result (Table 3.01, 




tested however this led to quantitative recovery of starting material. (Table 3.01, 
entries 5 and 6).
223
  
DIBAL was then investigated in an attempt to cleave the benzyl ether. This reagent 
is commonly used to debenzylate oligosaccharides via a radical induced pathway.
225
 
Following the conditions outlined by Pearce and Sinay,
226
 a solution of DIBAL (1 M 
in toluene) and compound 156 was stirred for 1 hour at room temperature. After this 
time, the formation of a new spot by TLC was noted (Table 3.01, entry 7). The 
1
H NMR spectrum of the new compound showed the disappearance of the 
resonances at 0.83 and 0.00 ppm that are ascribed to the methyl hydrogens of the 
silyl group. Thus, the product was assigned as the allylic alcohol 154. Heating the 
reaction mixture to 70 
o
C for 12 hours also gave compound 154 in 77% yield while 
heating the mixture to 140 
o
C in a sealed vessel led to decomposition (Table 3.01, 
entries 8 and 9). 
 





In light of these findings, a Lewis acid to mediate the debenzylation of compound 
156 was trialled. Lewis acids such as TMSI, BF3•OEt2, CH3AlCl2, FeCl3 and 
Zn(OTf)2 are known to effectively cleave benzyl ethers via an SN1  mechanism.
227-230
 
They can also deprotect silylated alcohols. This would not be an issue for the real 
system as the silyl group could be reintroduced on the allylic alcohol at a later stage 
in the synthesis. Using this approach, it was anticipated that the benzyl ether could 
be cleaved at two different sites. Pathway (a) would give benzyl alcohol 160 and the 





 (1 eq.), THF, −84 
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 (6 eq.), THF, 0 
o
C, 4 hrs       no reaction 
5 Na (6 eq.), NH3, THF, −84 
o
C, 5 mins       no reaction 
6 Na (6 eq.), NH3, THF, −84 
o
C, 12 hrs       no reaction 
7 DIBAL (150 eq.), 25 
o
C, 1 hr       154 (71%) 
8 DIBAL (150 eq.), 70 
o
C, 12 hrs       154 (77%) 
9 DIBAL (150 eq.), 140 
o




carbocation 161 while pathway (b) would afford the carbocation 162 and the target 
compound 163 (Scheme 3.22). Either pathway would give the benzyl alcohol, with 
hydrolysis of the carbocation 161 leading to the desired compound 163.  
 
Scheme 3.22: Proposed pathways for the Lewis acid mediated cleavage of the benzyl ether 156. 
 
The first Lewis acid that was tested was trimethylsilyl iodide (TMSI). Initial 
attempts to deprotect compound 156 in dichloromethane at 0 
o
C led to 
decomposition, with only alphatic signals in the 
1
H NMR spectrum of the crude 
reaction mixture observed (Table 3.02, entry 1). Repeating the reaction at −84 
o
C 
and changing the solvent to acetonitrile gave the same result (Table 3.02, entries 2 
and 3). Next, the Lewis acid BF3•OEt2 was trialled. Similar to entry 1, decomposition 
of 156 was observed when the compound was treated with an excess of BF3•OEt2 at 
0 
o
C (Table 3.02, entry 4). When the reaction was cooled to −84 
o
C, complete 
consumption of the starting material was noted, with compound 154 isolated in 86% 
yield from the reaction mixture (Table 3.02, entry 5). Changing the Lewis acid to 
methyl aluminium dichloride gave the same outcome, with 154 afforded in 82% 
yield after stirring the reaction mixture for 1 hour at −45 
o


















In view of these results, oxidative conditions were investigated. Reagents such as 
CrO3, RuO2 and DDQ have been shown to cleave benzyl ethers.
231-233
 The most 
promising of these reagents is DDQ, which was used in Hirama’s total synthesis of 
Ciguatoxin.
234
 Following the same conditions described by Hirama, compound 156 





NMR spectrum of the crude reaction mixture was not promising, with only a cluster 
of resonances observed in the aliphatic region (Table 3.03, entry 1). When the 
reaction was repeated at room temperature using one equivalent of DDQ, a complex 
mixture of compounds was afforded (Table 3.03, entry 2). The 
1
H NMR spectrum of 
the crude reaction mixture showed two singlets and two doublets between 
9.60−10.30 ppm that are in the region expected for an aldehyde. Furthermore, a 
cluster of signals were observed between 6.30−7.90 ppm. These could be aromatic 
and vinylic hydrogens. Based on this information, the reaction mixture could be an 
assortment of isomeric dialdehydes. 
 






Entry Conditions               Result  
1 TMSI (1.3 eq.), CH2Cl2, 0 
o
C, 1.5 hrs       decomposition 
2 TMSI (1.3 eq.), CH2Cl2, −84 
o
C, 1.5 hrs       decomposition 
3 TMSI (1.3 eq.), MeCN, −84 
o
C, 1.5 hrs       decomposition 
4 BF3•OEt2 (5 eq.), CH2Cl2, 0 
o
C, 3 hrs       decomposition 
5 BF3•OEt2  (5 eq.), CH2Cl2, −84 
o
C, 3 hrs       154 (86%) 
6 CH3AlCl2 (1 M, 1.2 eq.), CH2Cl2, 0 
o
C, 1 hr       decomposition 
7 CH3AlCl2 (1 M, 1.2 eq.), CH2Cl2, −45 
o
C, 1 hr       154 (82%) 
Entry Conditions       Result  
1 DDQ (10 eq.), CH2Cl2, 58 
o
C, 1 hr      decomposition 
2 DDQ (1 eq.), CH2Cl2, 25 
o




3.6  PMB protecting group strategy 
 
Since the benzyl group was difficult to remove, an alternate protecting group was 
explored. One group that could be used is a p-methoxybenzyl group (PMB). The 
methoxy functional group would improve the stability of the benzyl cation formed 
during cleavage of the ether. This would make the PMB group easier to remove 
using the oxidative conditions described in Table 3.03. In addition to changing the 
protecting group, the hydroxyacid portion of benzoresolvin E1 (red) would be 
installed before the enyne chain (purple). This would avoid forming the benzodiene 
and enyne units at an early stage in the synthesis, which could be unstable towards 
the conditions used to deprotect the PMB group (Figure 3.02).      
 
Figure 3.02: Compound 155 and the new target compound 164. 
 
To introduce the PMB group onto the benzyl alcohol, compound 91 in anhydrous 
dimethylformamide was treated with NaH, followed by the addition of NaI and p-
methoxybenzyl bromide at room temperature (Scheme 3.23).
235
 This afforded 
compound 165 in 49% yield. The benzyl alcohol was then oxidised using activated 
manganese dioxide to give the aldehyde 166 in 74% yield. 
 
Scheme 3.23: Preparation of the aldehyde 166. 
 
With the aldehyde 166 in hand, focus was shifted towards installing the hydroxyacid 
portion of the target compound via a Grignard reaction. Due to the instability of the 
Grignard 82 prepared in Scheme 2.08, the simpler Grignard reagent 170 was 
synthesised. An acid-catalysed cleavage of tetrahydrofuran, followed by silyl group 




in 3 steps (Scheme 3.24).
236-237
 Unlike compound 82 (Scheme 2.08), the 
Grignard reagent 170 is not prone to thermal decomposition.   
 
Scheme 3.24: Preparation of the Grignard reagent 170.236-237 
 
The Grignard reagent 170 was then added to the aldehyde 166 in anhydrous 
tetrahydrofuran at −84 
o
C (Scheme 3.25). This gave the silyl protected product in 
85% yield. Without further purification, the crude mixture was treated with TBAF at 
−84 
o
C to furnish the diol 171 in 65% yield (Scheme 3.25). The 
1
H NMR spectrum 
of the product showed a doublet of doublets at 4.87 ppm and a triplet at 3.58 ppm 
that could be ascribed to the methine and methylene hydrogens of the carbons 
bearing the hydroxyl groups.  
 
Scheme 3.25: Addition of the Grignard reagent 170 to compound 166. 
 
The primary and secondary alcohols were then oxidised using Jones reagent to afford 
the ketoacid 172 in 96% yield (Scheme 3.26). The 
1
H NMR spectrum of the crude 
reaction mixture after four and a half hours showed the disappearance of the signals 
at 4.87 and 3.58 ppm and the appearance of two resonances at 203.4 and 178.9 ppm 
in the 
13
C NMR spectrum. These were assigned to the carbonyl carbon of the ketone 
and the carboxylic acid respectively. The ketone was then reduced to an alcohol 
using two equivalents of DIBAL at −84 
o
C to give rac-164 in 93% yield. The 
13
C NMR and 
1
H NMR spectra showed the disappearance of a carbonyl resonance at 




newly formed benzylic hydrogen. The IR spectrum of the product also gave two 
absorbances at 3390 and 1681 cm
-1
 that were assigned to the alcohol and the 
carboxylic acid. 
 
Scheme 3.26: Synthesis of rac-164. 
 
3.7  Lactonisation strategy 
 
Having prepared the hydroxyacid 164, a suitable synthesis for the lactone 175 was 
explored. Converting the hydroxyacid to a lactone could be advantageous. It would 
allow the PMB protected alcohol to be deprotected and oxidised to form compound 
174 without the need for an alcohol or a carboxylic acid protecting group 
(Scheme 3.27). Compound 174 could undergo a Wittig olefination with the ylide of 
the phosphonium salt 88 to afford the ester 175. The enyne portion of 





Scheme 3.27: Proposed synthesis of compound 175. 
 
The lactone 173 could be synthesised using an acidic resin such as Amberlite
®
 IR-
120. Thus, compound 164 in ethanol was stirred with catalytic amounts of 
Amberlite
®
 IR-120 and 3Å molecular sieves at room temperature for 5 hours 
(Scheme 3.28). Purification of the crude reaction mixture by column 
chromatography afforded the starting material in 85% yield along with a product 
assigned as ethyl ester 176 in 12% yield. The 
1
H NMR spectrum of compound 176 
was similar to the starting material, apart from the appearance of two new resonances 
at 4.42 and 1.21 ppm that were ascribed to the methylene and methyl hydrogens of 
the ethyl ester. The 
1
H NMR and 
13
C NMR spectra of the crude reaction mixture also 
showed trace amounts of a compound that was tentatively assigned as the lactone 
173 (Scheme 3.28). The 
1
H NMR spectrum showed a doublet of doublets at 
5.56 ppm while a resonance at 171.8 ppm was observed in the 
13
C NMR spectrum. 
These are in the region expected for the methine hydrogen and the carbonyl carbon 





Scheme 3.28: Attempted acid-catalysed lactonisation of compound 164. 
 
In an attempt to increase the yield of compound 173, the reaction mixture was heated 
under reflux for 5 hours (Scheme 3.29). Interestingly the lactone was not observed 
after this time. Instead a product assigned as compound 177 was afforded in 99% 
yield.  
 




H NMR spectrum of the product showed only four aromatic signals between 
7.28−7.38 ppm while the signals attributed to the PMB group at 3.77, 4.43 and 
4.48 ppm had disappeared. This suggests that the PMB group was removed. The 
appearance of a quartet at 4.11 ppm and a triplet at 1.24 ppm suggest the formation 
of an ethyl ester which would support the structure of 177 (Scheme 3.29). Two 
additional signals at 3.36 (2 H) and 1.17 (3 H) were assigned to the methylene and 
methyl hydrogens of an ethyl ether (Scheme 3.29). Formation of the two ethyl 
groups was supported by the 
13
C NMR spectrum which showed two new methyl 
carbons at 15.5 and 14.4 ppm. 
It was postulated that compound 177 was synthesised by the mechanism shown in 




compound 176. This compound could be protonated to give the intermediate 178. 
Cleavage of the ether by an SN1 substitution could then afford compound 180 along 
with the resonance stabilised p-methoxybenzylic carbocation 179. Protonation of the 
primary benzyl alcohol followed by a second SN1 or SN2 substitution with ethanol 
would give compound 177. 
 
Scheme 3.30: Proposed mechanism for the synthesis of compound 177. 
 
Based on the 1H NMR and 
13
C NMR spectra of compound 177, the primary benzyl 
alcohol is eliminated instead of the secondary benzyl alcohol. A 3D molecular model 
of the intermediate 180 shows the secondary alcohol to be more sterically hindered 
than the primary alcohol (Figure 3.03). This is due to the bulky hydroxyacid chain. 





        
Figure 3.03: A 3D molecular representation of compound 180. 
 
A weaker acid such as trifluoroacetic acid was then tested. To a solution of 
compound 164 in anhydrous dichloromethane was added one equivalent of 
trifluoroacetic acid (Table 3.04, entry 1). After stirring the reaction mixture for 
12 hours at room temperature, the reaction mixture turned black. The 
1
H NMR 
spectrum of the crude mixture showed complete decomposition of compound 164. 
No signals were observed in the aromatic region, suggesting that the PMB ether was 
readily cleaved under these conditions. Repeating the reaction at 0 
o
C also gave the 
same result (Table 3.04, entry 2). 






In light of these findings, a milder source of acid was investigated. It was envisaged 
that a biphasic 1 M HCl/dichloromethane system would facilitate the lactonisation of 
164 without removing the PMB group. Pleasingly, a compound tentatively assigned 
as the lactone 173 was furnished in 99% yield after treating compound 164 with a 
1:1 mixture of 1 M HCl and dichloromethane at room temperature (Scheme 3.31).  
Entry Conditions          Result  
1 Trifluoroacetic acid (1 eq.), CH2Cl2, 25 
o
C, 12 hrs       decomposition 
2 Trifluoroacetic acid (1 eq.), CH2Cl2, 0 
o









H NMR spectrum of the crude mixture showed a doublet of doublets at 
5.56 ppm that was assigned to the methine hydrogen of the lactone (Figure 3.04). 
Two signals at 7.29 and 6.90 ppm were also observed in the 
1
H NMR spectrum 
along with a resonance at 3.81 ppm. These signals were ascribed to the aromatic 
hydrogens and the methoxy hydrogens of the PMB group, suggesting the ether was 
not cleaved under these conditions. The 
13
C NMR spectrum of the product showed a 
shift in the carbonyl resonance from 180.1 to 171.8 ppm. The formation of the 
lactone was also confirmed by the presence of an absorbance at 1731 cm
-1
 and the 
absence of the alcohol peak at 3390 cm
-1
. 
Interestingly, starting material was observed in the 
1
H NMR spectrum of the crude 
reaction mixture when it was allowed to stand in a solution of CDCl3 at room 
temperature. This was supported by the appearance of the signal at 4.77 ppm that 
was identical to the methine hydrogen of compound 164 (Figure 3.04). Under these 
conditions, the lactone 173 hydrolyses to compound 164. Figure 3.04 shows the 
1
H 
NMR spectrum of the reaction mixture, with equilibrium between the two 
compounds reached after 2 hours. After this time, the mixture exists as a 1:0.54 ratio 















Figure 3.04: Equilibration of the lactone 173 and compound 164 in CDCl3 after 2 hours. 
 
Since the lactone 173 readily equilibrates under standard laboratory conditions, 
attempts to isolate the product via column chromatography using basic and neutral 
alumina were unsuccessful. With this in mind, this pathway was abandoned as the 






Synthesis of Benzoresolvin E1:   
A Cross-Coupling Approach 
 
4.1 Revised synthetic pathway 
 
In light of the issues faced in Chapter 3, the synthesis of benzoresolvin E1 was 
redesigned. Benzoresolvin E1 could be prepared from compound 183 in 3 steps 
(Scheme 4.01). These steps are similar to the final steps in the synthesis of 
resolvin E1 developed by Allard.
182
 They involve the removal of the silyl protecting 
group, reduction of the alkyne and hydrolysis of the isopropyl ester. Following the 
same conditions as described in Scheme 3.19, the enyne of the intermediate 183 
could be synthesised by a Sonogashira reaction between the alkyne 184 and the 
iodide 28. The key reaction in the proposed synthesis is the Stille coupling between 
the stannane 185 and the bromide 186 to give the alkyne 184. Unlike the proposed 
synthesis of benzoresolvin E1 in Chapter 3, this approach would afford the 
benzodiene portion of the target compound with limited use of protecting groups. 
Thus, circumventing the problems encountered in the previous chapter. 
 




Focusing on the (R)-alcohol 186, this compound could be synthesised from the sulfur 
trioxide pyridine complex 187 in 5 steps (Scheme 4.02). Following a literature 
procedure,
238
 treatment of 187 with potassium hydroxide would afford the ring 
opened potassium salt 188, which could undergo an Appel reaction to give the 
bromide 189. Addition of propargylmagnesium bromide to this product could furnish 
rac-186. A tandem oxidation-reduction reaction could then give the (R)-enantiomer 
of alcohol 186. 
 
Scheme 4.02: Planned synthesis of the (R)-alcohol 186. 
Following the procedure described by Soullez and co-workers,
238
 addition of 
potassium hydroxide to a freshly prepared sulfur trioxide pyridine complex in water 
gave the isometrically pure 2E,4E-diene of 188 in 58% yield (Scheme 4.03).
239
 
Compound 188 was then treated with N-bromosuccinimide and triphenylphosphine 
to afford the bromide 189 in 20% yield as a 3:2 mixture of 2E,4E and 2E,4Z 




Scheme 4.03: Synthesis of the bromide 189. 
 
The aldehyde and vinylic hydrogens of the two isomers were assigned by comparing 
the 
1
H NMR spectrum of the product with the literature spectrum.
238
 These are 





Figure 4.01: Proton assignment for the isomers of 189. 
 
Attempts were made to improve the yield of compound 189 by increasing the 
reaction time, using freshly recrystallised N-bromosuccinimide and changing the 
bromine source (Table 4.01). Disappointingly, the yield remained low under these 
conditions. This could be attributed to the poor solubility of the starting material 188 
in dichloromethane.  




A tetrabutylammonium salt of alkoxide 188 was also prepared. The lipophilic 
counterion would increase the solubility of the starting material in dichloromethane, 
thus improving the yield of compound 189. To prepare the tetrabutylammonium salt, 
the potassium salt 188 was treated with tetrabutylammonium hydrogen sulfate at 
room temperature (Scheme 4.04).
239
 This gave compound 190 in quantitiative yields. 
When compound 190 was subjected to the same conditions in Scheme 4.03, the 
bromide 189 was afforded in 42% yield as a 1:1 mixture of isomers.   
Entry Conditions      Result  
1 PPh3, NBS, CH2Cl2, 25 
o
C, 9 hrs       20% 
2 PPh3, NBS, CH2Cl2, 25 
o
C, 24 hrs      21% 
3 PPh3, recrystallised NBS, CH2Cl2, 25 
o
C, 24 hrs      21% 
4 PPh3, Br2, CH2Cl2,  25 
o





Scheme 4.04: Preparation of the bromide 189 from the tetrabutylammonium salt 190. 
 
As there is a 1:1 mixture of stereoisomers, an isomerisation was attempted to 
equilibrate the mixture to the more thermodynamically stable 2E,4E-product. 
Following the procedure by Wang and co-workers,
240
 the bromide 189 was treated 
with a catalytic amount of iodine in anhydrous dichloromethane and stirred at room 
temperature for 8 hours. The 
1
H NMR spectrum of an aliquot taken after 3 hours 
showed an enrichment of the desired 2E,4E-isomer (71%). After prolonging the 
reaction time to 8 hours, the quantity of the 2E,4E-isomer was only marginally 
improved (76%), suggesting that equilibrium had been reached. This was consistent 
with the results obtained by Wang and co-workers.
240
 Attempts to separate the 
isomers by column chromatography or recrystallisation were unsuccessful.
240
 In 
view of this, the isomerisation was postponed until the subsequent step. 
To prepare the alcohol 186, compound 189 was treated with a 1 M solution of 
propargylmagnesium bromide in anhydrous ether at −17 
o
C. This gave rac-186 in 
75% yield as a 1:1 mixture of the stereoisomers (Scheme 4.05). The addition of the 
propargyl portion was supported by the 
1
H NMR spectrum, with the appearance of 
signals at 4.35, 2.55 and 2.12 ppm indicative of the methine, methylene and 
acetylenic hydrogens respectively. The disappearance of the carbonyl signal in the 
13
C NMR spectrum of the crude mixture suggested complete consumption of 
compound 189 while the absence of a signal around the 200−210 ppm region 





Scheme 4.05: Addition of propargylmagnesium bromide to the aldehyde 189. 
 
Having prepared rac-186, the synthesis of compound 185 was attempted. The 
tandem oxidation-reduction reaction for the planned synthesis of the (R)-alcohol 186 
was postponed to see if the proposed synthesis of the stannane 185 would work. To 
prepare 185, o-iodobenzoic acid 191 was used as the starting material 
(Scheme 4.06). This compound can be converted into o-iodobenzaldehyde 192 in 
3 steps.
241
 The addition of the Grignard reagent 170 to o-iodobenzaldehyde could 
afford the diol 193, with the product oxidised to the ketoacid 194 using Jones 
reagent. The carboxylic acid of 194 could be esterified with isopropyl alcohol and 
the ketone reduced to give the (S)-alcohol of 195. The final step in the planned 
synthesis is a Stille reaction between the iodide 195 and hexabutyldistannane to 





Scheme 4.06: Proposed synthesis of the stannane 185. 
 
Starting from o-iodobenzoic acid, the carboxylic acid was esterified with ethanol to 
afford compound 196 in 88% yield (Scheme 4.07). The ethyl ester of 196 was then 
reduced to an alcohol using DIBAL. Subsequent oxidation of the alcohol using 




Scheme 4.07: Preparation of o-iodobenzaldehyde 192. 
 
o-Iodobenzaldehyde was then treated with the Grignard reagent 170 in anhydrous 
ether at −84 
o
C followed by removal of the silyl group with CSA to afford the 
diol 193 in 67% yield over 2 steps (Scheme 4.08). The 
1
H NMR spectrum of the 
product showed a doublet of doublets at 4.90 ppm and a triplet at 3.67 ppm. These 
were ascribed to the methine and methylene hydrogens of the hydroxyl bearing 
carbons respectively. The IR spectrum also showed two absorbances at 3291 
and 3197 cm
-1




   
Scheme 4.08: Addition of the Grignard reagent 170 to o-iodobenzaldehyde 192.  
 
The benzylic alcohol and primary alcohol of compound 193 were oxidised using 
Jones reagent to furnish the ketoacid 194 in 80% yield (Scheme 4.09). The product 
showed two new resonances at 204.1 and 178.7 ppm in the 
13
C NMR spectrum. 
These were ascribed to the newly formed ketone and carboxylic acid. The 
IR spectrum also showed two absorbances at 1702 and 1688 cm
-1
 that were 
consistent with the absorbances expected for the ketone and carboxylic acid.  
 
Scheme 4.09: Preparation of the ketoacid 194. 
 
Adapting the procedure by Allard and co-workers,
182
 compound 194 was esterified 
with isopropyl alcohol and p-toluenesulfonic acid to afford the ketoester 197 
(Scheme 4.10). The 
1
H NMR spectrum of the product showed a methine resonance 
at 5.00 ppm and a methyl peak at 1.23 ppm that were attributed to the isopropyl 
ester. The 
13
C NMR spectrum also gave a new signal at 172.8 ppm that was assigned 
to the carbonyl carbon of the ester. This was upfield compared to the carboxylic acid 
resonance at 178.7 ppm.  
 
Scheme 4.10: Synthesis of the ketoester 197. 
 
With the ketoester 197 in hand, attention was focused on the synthesis of the (S)-
alcohol 195. This compound could be prepared using (R)-CBS catalyst and 




Using these reagents, Fu and co-workers selectively reduced compound 198, giving 
the (S)-alcohol 200 in 100% yield and 95% de.
242
  
                  
Scheme 4.11: A literature example of the asymmetric reduction of the ketone 198.242 
 
The striking similarity between the ketoester 197 and the keto-amide 198 suggest the 
(S)-alcohol 195 could be synthesised enantioselectively using these conditions. The 
proposed transition states for the CBS reduction are shown in Figure 4.02. The six 
membered transition state 202 is not favourable as the bulky aryl iodide in the 
pseudoaxial position clashes with the methyl substituent of the CBS catalyst. The 
transition state 201 however is less hindered and allows the hydride transfer to take 
place from the upper face of the ketone, thus giving the (S)-enantiomer.  
 
Figure 4.02: Proposed transition states for the reduction of the ketoester 197. 
 
Following the same conditions outlined by Fu,
242
 dropwise addition of 
0.6 equivalents of BH3•DMS to a solution of (R)-CBS (8 mol%) catalyst and the 
ketoester 197 in anhydrous tetrahydrofuran at 25 
o
C gave the alcohol 195 in 70% 
yield and 60% ee (Table 4.02, entry 1). Formation of the alcohol was confirmed by 
an increase in the m/z ratio by two units along with the appearance of a doublet of 
doublets at 4.85 ppm in the 
1
H NMR spectrum. The presence of the ester peak at 






spectrum suggested that the reduction was chemoselective. Repeating the reaction at 
0 
o
C and −84 
o
C improved the selectivity, giving compound 195 in 87% and 94% ee 
respectively (Table 4.02, entries 2 and 3).  
Table 4.02: Asymmetric reduction of compound 197 at varying temperatures. 
 
* Based on chiral HPLC. 
4.2 Racemisation of the alcohol 195 
 
In order to confirm the absolute stereochemical configuration of the alcohol 195, a 
crystal structure was required. Disappointingly, crystals for the oily residues of the 
alcohol 195 and its p-bromobenzoate derivative could not be attained with solvents 
such as ethanol, diethyl ether, petroleum spirits, chloroform and dichloromethane. In 
view of this, compound 195 was reduced to the enantiomerically pure diol 193 using 
DIBAL. Compound 193 was optically active, suggesting that racemisation had not 
occurred during the reduction. This compound was also a solid at room temperature, 
making it easier to grow crystals. Using chloroform as the solvent, crystals of 
compound 193 were obtained and the X-ray structure was determined by Brian 
Skelton at UWA. Unfortunately the crystals were spirocentric, suggesting 193 had 
racemised in solution. This finding prompted the investigation of the racemisation of 
compound 195 by monitoring the optical rotation (Figure 4.03). When left to stand in 
chloroform at room temperature, the enantiomerically pure alcohol of 195 
completely racemised over 10 days (T1/2 = 4 days). The same outcome was observed 
when 195 was left to stand in chloroform in the presence of 5 mol% of triethylamine 
due to the generation of the acidic ammonium species (Figure 4.03).  
Entry Conditions   Yield     ee*  
1 BH3•DMS (0.6 eq.), (R)-CBS (8 mol%), THF, 25 
o
C, 3 hrs 70% 60% 
2 BH3•DMS (0.6 eq.), (R)-CBS (8 mol%), THF, 0 
o
C, 5 hrs 71% 87% 
3 BH3•DMS (0.6 eq.), (R)-CBS (8 mol%), THF, −84 
o





          
 
Figure 4.03: Racemisation plot of compound 195 at 24 oC. 
 
To date, this is the first reported example of the racemisation of a benzylic alcohol 
with an ortho substituted aryl iodide. The racemisation of the alcohol in compound 
195 was rationalised by the steric effects provided by the bulky iodo group 
(Scheme 4.12). To relieve the steric strain at this position, the alcohol could 
eliminate to give the sp
2
 hybridised carbocation 203. Based on the racemisation 
study in Figure 4.03, this is promoted with acid produced from the chloroform. The 
carbocation 203 is less strained than the (S)-alcohol 195, thus acting as the driving 
force for racemisation at this position. Subsequent addition of a water molecule 




















Compound 195 in chloroform (1 M)





Scheme 4.12: Proposed pathway for the racemisation of compound 195. 
 
4.3 Stille coupling reaction 
 
Having established that the enantiomerically pure alcohol of 195 racemises under 
normal laboratory conditions, rac-195 was used in the remaining steps. 
Subsequently, focus was shifted towards the preparation of the stannane 185. This 
compound could be synthesised via a Stille reaction between rac-195 and 
hexabutyldistannane. Initial attempts to form the stannane 185 by heating rac-195 
and hexabutyldistannane with Pd(PPh3)4 in anhydrous toluene using the procedure 
described by Azizian and co-workers were unsuccessful.
243
 This led to quantitative 
recovery of starting material (Table 4.03, entries 1 and 2).  
Polar solvents such as tetrahydrofuran, dioxane and dimethylformamide have been 
shown to increase the rate of the transmetallation step and thus improve the rate of 
the Stille reaction.
244-245
 This is achieved by enhancing the nucleophilicity of the 
distannane reagent through a stable solvent-tin complex.
244-245
 Accordingly, the 
reaction was repeated using tetrahydrofuran as the solvent. After stirring the mixture 
for 12 hours at 60 
o
C, a new spot was observed by TLC (Table 4.03, entry 3). The 
appearance of a small resonance at 4.65 ppm in the 
1
H NMR spectrum of the crude 
reaction mixture could be ascribed to the benzylic hydrogen of 185. This signal is 
upfield compared to the same hydrogen of rac-195. This is consistent with the de-
shielding effect of the iodo functionality on that carbon, which is greater than the 
stannane group. The appearance of a cluster of aromatic signals between 




hydrogen of the isopropyl ester, add further evidence to support the formation of the 
stannane 185. Disappointingly, only a trace amount of 185 was observed when the 
reaction was stirred for a longer period of time (Table 4.03, entry 4). Changing the 
solvent to anhydrous dioxane and subjecting the reaction mixture to elevated 
temperatures gave the same outcome (Table 4.03, entries 5 and 6).  




To rationalise the poor reactivity of rac-195, a closer examination of the mechanism 
for the Stille reaction was required (Figure 4.04). The first step in the reaction is the 
oxidative addition of the palladium(0) catalyst across the aryl-iodide bond of 
compound 195 to give 204. This step is favourable for electron poor aromatic 
compounds such as the ketoester 197. Compound 195 however is an electron rich 
aromatic compound. This is owing to the ortho substituted benzyl alcohol. 
Compared to an electron poor aromatic system, more forcing conditions are required 
for the aryl-iodide bond to dissociate upon palladium(0) insertion, making it a poor 
substrate for the Stille reaction. Compound 195 is also sterically hindered due to the 
bulky ortho substituted hydroxyester chain. This makes 195 sluggish towards cross-
coupling. To circumvent this problem, different palladium catalysts and additives 
could be tested to accelerate the Stille reaction.
243-246
 These will be investigated in 
subsequent steps. 
Entry  Conditions              Result 
1 Sn2Bu6 (1.2 eq.), Pd(PPh3)4 (7 mol%), toluene, 60 
o
C, 12 hrs      no reaction 
2 Sn2Bu6 (1.2 eq.), Pd(PPh3)4 (7 mol%), toluene, 100 
o
C, 48 hrs      no reaction 
3 Sn2Bu6 (1.2 eq.), Pd(PPh3)4 (7 mol%), THF, 60 
o
C, 12 hrs      trace 
4 Sn2Bu6 (1.2 eq.), Pd(PPh3)4 (7 mol%), THF, 60 
o
C, 48 hrs      trace 
5  Sn2Bu6 (1.2 eq.), Pd(PPh3)4 (7 mol%), dioxane, 100 
o
C, 12 hrs      trace 
6  Sn2Bu6 (1.2 eq.), Pd(PPh3)4 (7 mol%), dioxane, 100 
o





Figure 4.04: Stille coupling mechanism for the stannane 185. 
 
In view of the poor reactivity of rac-195, the Stille reaction was repeated with the 
ketoester 197. This compound has an electron poor aromatic ring due to the electron 
withdrawing ketone. This would be favourable for oxidative addition since less 
energy is required to dissociate the aryl-iodide bond. Pleasingly, heating the 
ketoester 197 with hexabutyldistannane and Pd(PPh3)4 in anhydrous tetrahydrofuran 
for 12 hours afforded the desired stannane 207 in 16% yield and starting material in 
78% yield (Table 4.04, entry 1).  
The high resolution mass spectrum showed a molecular ion (m/z = 525.2407 
[M−57 (C4 H9)]
+
) that was consistent with the loss of a butyl group for the 
stannane 207. Five new resonances between 0.84−1.49 ppm were observed in the 
1
H 
NMR spectrum of the product. These were assigned to the butyl chain of the 
stannane. The 
13
C NMR spectrum also showed two new signals at 201.2 and 
172.9 ppm that could be ascribed to the ketone and ester functional groups. In light 
of this promising result, the reaction mixture was stirred for an additional 12 hours, 
giving the stannane 207 in 38% yield (Table 4.04, entry 2). The reaction mixture was 
also dosed twice with Pd(PPh3)4 and stirred for 48 hours to afford 207 in 42% yield 








Several precatalysts were also investigated to improve the yield of the stannane 207. 
Following the same conditions given in Table 4.04, the reaction was repeated with 
Pd(PPh3)2Cl2 (Table 4.05, entry 2). The 
1
H NMR spectrum of the crude sample 
showed a complex mixture of compounds, with numerous aromatic signals in the 
region of 7.30−8.00 ppm. The crude sample appeared to be a mixture of the starting 
material, the product and several other unidentified compounds. A palladium catalyst 
with a bidentate ligand was also tested. Catalysts with bidentate ligands such as 
Pd(dppf)2Cl2•DCM are known to have larger bite angles.
247-250
 They can promote the 
oxidative addition and reductive elimination steps, thus accelerating the Stille 
reaction.
247-250
 Disappointingly, when the reaction was repeated with 
Pd(dppf)2Cl2•DCM, a complex mixture of products was observed in the 1H NMR 
spectrum of the crude mixture (Table 4.05, entry 3).   




In view of these results, a different stannane was explored. Ideally, the Stille reaction 
would be repeated using hexamethyldistannane since it is less hindered than the 
Entry  Conditions   Result 
1 Sn2Bu6 (1.2 eq.), Pd(PPh3)4 (7 mol%), THF, 60 
o
C, 12 hrs  16% 
2 Sn2Bu6 (1.2 eq.), Pd(PPh3)4 (7 mol%), THF, 60 
o
C, 24 hrs   38% 
4  Sn2Bu6 (1.2 eq.), Pd(PPh3)4 (2 x 7 mol%), THF, 60 
o
C, 48 hrs  42% 
Entry  Conditions      Result 
1  Sn2Bu6 (1.2 eq.), Pd(PPh3)4 (7 mol%), THF, 60 
o
C, 48 hrs     207 (42%) 
2  Sn2Bu6 (1.2 eq.), Pd(PPh3)2Cl2 (7 mol%),  
 THF, 60 
o
C, 12 hrs 
    complex mixture 
3  Sn2Bu6 (1.2 eq.), Pd(dppf)2Cl2•DCM (7 mol%),   
 THF, 60 
o
C, 36 hrs 






 However, hexamethyldistannane is more toxic and was 
understandably avoided. An alternate strategy involves swapping coupling partners 
to give the iodide 197 and the stannane 209. This approach would circumvent the 
preparation of the sterically hindered stannane 207 (Scheme 4.13).   
    
Scheme 4.13: Stille reaction with compounds 197 and 209. 
 
To synthesise compound 209, the pathway developed by Michels and co-workers in 
Scheme 4.14 was implemented.
251
 Starting from 2,4-dinitro-1-chlorobenzene 210, 
the pyridinium salt 211 was afforded in 93% yield via a Zincke reaction. The 
reaction can be viewed as the nucleophilic aromatic substitution of 2,4-dinitro-1-
chlorobenzene with pyridine. Treatment of 211 with dimethylamine then gave 
compound 212 in 95% yield. The 
1
H NMR spectrum of the product showed four 
signals between 5.26−7.09 ppm that were assigned to the four vinylic hydrogens 




The aldehyde 212 was then converted into the stannane 213 via the addition of 
lithium tributyltin followed by elimination of lithium dimethylamide. Compound 
213 was afforded as the isometrically pure 2E,4E-isomer in 57% yield. This was 




H NMR spectrum of the 
product matched the spectroscopic data reported in the literature,
251
 with the 
appearance of four new resonances at 1.48−1.53, 1.25−1.37, 0.96 and 0.89 ppm 





Scheme 4.14: Preparation of the stannane 213. 
 
To synthesise compound 209, the same conditions in Scheme 4.05 were used. 
Accordingly, the aldehyde 213 in anhydrous ether at −17 
o
C was treated with 
propargylmagnesium bromide to give the 5E,7E-isomer of rac-209 in 73% yield 
(Scheme 4.15). The appearance of three signals at 4.34, 2.47 and 2.06 ppm in the 
1
H 
NMR spectrum of the product could be attributed to the newly formed methine, 
methylene and acetylenic hydrogens of the propargyl group. The 
13
C NMR spectrum 
also showed two signals at 80.5 and 71.1 ppm that were assigned to the acetylenic 
carbons and a resonance at 70.5 ppm ascribed to the hydroxyl bearing carbon. 
 
Scheme 4.15: Addition of propargylmagnesium bromide to the aldehyde 213. 
 
With compound 209 in hand, focus was shifted towards the synthesis of the (R)-
enantiomer. This could be formed from rac-209 by a sequential oxidation-reduction 
reaction. Studies have shown that under acidic and basic conditions, propargyl 
ketone substrates are unstable and can isomerise to allenes.
252-253




one pot oxidation and reduction was implemented using mild conditions to avoid 
isolating the ketone 214.  
Dess-Martin periodinane was initially tested as the oxidant (Table 4.06, entry 1). 
Complete consumption of the starting material was noted by TLC after 24 hours. 
After this time, the reaction mixture was treated with (R)-CBS catalyst and 




H NMR spectrum of the crude reaction mixture was not 
promising. Only the butyl signals of the stannane group were evident, with no 
signals observed in the vinylic or aliphatic region. Trace amounts of acetic acid 
released from the oxidant could account for this result. The acid could isomerise the 
propargylic ketone to a propargylic allene. This compound would be highly reactive 
and lead to degradation. The same outcome occurred when manganese dioxide was 
investigated as the oxidant, with complete decomposition of the starting material 
noted in the 
1
H NMR spectrum of the crude mixture (Table 4.06, entry 2). 
Decomposition of the reaction mixture was also observed when milder Swern 
oxidative conditions were used (Table 4.06, entry 3).  




Entry  Conditions Result 
1 1. DMP (1 eq.), CH2Cl2, 25 
o
C, 24 hrs 
2. (R)-CBS (7 mol%), BH3•DMS (0.6 eq.), CH2Cl2, 
−84 
o
C, 8 hrs   
decomposition 
2 1. MnO2 (10 eq.), CH2Cl2, 25 
o
C, 24 hrs 
2. (R)-CBS (7 mol%), BH3•DMS (0.6 eq.), CH2Cl2, 
−84 
o
C, 8 hrs   
decomposition 
3 1. Oxalyl chloride (1 eq.), DMSO (1 eq.), NEt3 (1 eq.), 
THF,  −84 
o
C, 5 hrs 
2. (R)-CBS (7 mol%), BH3•DMS (0.6 eq.), THF, −84 
o
C, 





Alternatively, an allenylboronate mediated asymmetric propargylation could be used 
to prepare the enantiomerically pure (R)-alcohol of compound 209. This reaction was 
only recently developed for substrates with aldehyde functional groups and was not 
fully established by the time this work was conducted. Consequently, the number of 
examples in the literature are limited.
254-257
 Following the procedure by Barnett and 
Schaus,
254
 future endeavours to prepare the (R)-alcohol of 209 could involve treating 
the aldehyde 213 with the allenylboronate 215 and BINOL (Scheme 4.14).  
 
Scheme 4.16: Proposed asymmetric propargylation of the aldehyde 213. 
 
To examine the feasibility of the remaining reactions in the synthesis, rac-209 was 
used in the subsequent steps. Focusing on the Stille reaction, the iodoester 196 was 
used as a model compound for the ketoester 197. Following the conditions by Farina 
and Roth,
258
 the iodoester 196 was stirred with compound 209, Pd(PPh3)4 and a 
catalytic amount of BHT in anhydrous dioxane (Table 4.07, entries 1 and 2).
244
 BHT 
was used a radical scavenger to prevent polymerisation of the starting material and 
the product. Disappointingly, the product was not formed under these conditions. 
Instead, only starting material was recovered from the reaction. This was also the 
case when the reaction was repeated in anhydrous dimethylformamide (Table 4.07, 
entry 3).  




Entry  Conditions      Result 
1  Pd(PPh3)4 (7 mol%), dioxane, BHT (cat.), 25 
o
C, 12 hrs      no reaction 
2  Pd(PPh3)4 (7 mol%), dioxane, BHT (cat.), 45 
o
C, 24 hrs      no reaction 
3  Pd(PPh3)4 (7 mol%), DMF, BHT (cat.), 25 
o




4.4 Dual reactivity of compound 209  
 
In view of these results, an additive to promote the Stille coupling between the 
iodoester 196 and compound 209 was explored. First reported by Liebeksind and 
Fengel in 1990,
259
 Cu(I) additives are used to accelerate the Stille coupling of 
sterically hindered substrates. Studies have shown that Cu(I) has a dual role.
260-261
 In 
ethereal solvents such as tetrahydrofuran and dioxane, Cu(I) acts as a free-ligand 
scavenger to inhibit autoretardation.
259
 In solvents such as dimethylformamide and 
N-methyl-2-pyrrolidinone, Cu(I) promotes the formation of an organocuprate species 
that is more reactive towards transmetallation.
258
 The addition of a Cu(I) additive 
could also facilitate the Sonogashira reaction between the terminal alkyne of 209 and 
the iodoester 196. Since two competing reactions could occur, a model reaction was 
investigated to determine the reactivity of the stannane and alkyne functional groups. 
When a mixture of the iodoester 196, compound 209, Pd(PPh3)4 and BHT in 
anhydrous dimethylformamide was treated with CuI at 25 
o
C, a product assigned as 
the stannane 217 was afforded in 50% yield (Table 4.08, entry 1). The 
1
H NMR 
spectrum of the product showed three signals at 1.47−1.51, 1.26−1.32 and 
0.83−0.94 ppm, suggesting the stannane moiety remained intact. The disappearance 
of the methine signal at 80.5 ppm in the 
13
C NMR spectrum that was ascribed to the 
terminal acetylenic carbon of compound 209 further supports the synthesis of the 
Sonogashira product 217. The high resolution mass spectrum also showed a 
molecular ion (m/z = 543.2296 [M−18 (H2O)]
+
) that was consistent with the loss of a 
water molecule for compound 217. The yield of 217 was improved to 80% by 
repeating the reaction with piperidine to accelerate the rate of the transmetallation 
















This is only the third reported coupling reaction that gave the Sonogashira product 
without forming the Stille product. The first reaction with this unique selectivity was 
described by Bruckner and co-workers in 2002.
263
 Using Pd(PPh3)2Cl2 (4 mol%), 
CuI (10 mol%) and diisopropylamine, Bruckner afforded the Sonogashira products 
220 and 221 as a 9:1 mixture in 79% yield from the alkyne 218 and the triflate 219 
(Scheme 4.17).    
 
Scheme 4.17: Bruckner’s Sonogashira reaction.263 
 
The second reaction was reported by Nazario et al. in 2011.
262
 Similar to Bruckner’s 
synthesis, the Sonogashira adduct 224 was the only product formed from the reaction 
between the iodide 222 and 1-heptyne 223 using Pd(PPh3)4 (5 mol%), CuI 
(10 mol%) and piperidine (Scheme 4.18).  
Entry Conditions    Yield of  
       217 
1     Pd(PPh3)4 (7 mol%), CuI (10 mol%), DMF, BHT (cat.), 25 
o
C, 12 hrs     50% 
2 Pd(PPh3)4 (7 mol%), CuI (10 mol%), piperidine (2 eq.), DMF, 
BHT (cat.), 25 
o
C, 4 hrs 




            
Scheme 4.18: Nazario’s Sonogashira reaction.262 
 
One advantage of the reaction described in Table 4.08 was the application of a 
sterically hindered substrate. Although the iodoester 196 was more hindered than the 
triflate 219 and the iodide 222,
262-263
 the Sonogashira product 217 was still formed in 
good yields (80%). This was comparable to the yields of compounds 220, 221 (79%) 
and 224 (91%) reported by Bruckner and Nazario.
262-263
   
Having synthesised compound 217, the reaction was repeated using two equivalents 
of the iodoester 196 at 45 
o
C to probe the reactivity of the stannane functional 
group (Scheme 4.19). Pleasingly, these changes furnished the Sonogashira-Stille 
product 225 in 72% yield after 12 hours along with the Sonogashira product 217 in 
18% yield. The tandem cross-coupling reaction was supported by the mass spectrum 
of the product (m/z = 441.1686 [M−18 (H2O)]
+
) which corresponded with the 
molecular formula required for the loss of a water molecule of compound 225. The 
1
H NMR spectrum of compound 225 showed two signals at 4.41 (4 H) and 1.41 
(6 H) ppm, suggesting the presence of two ethyl esters. This was supported by the 
appearance of two signals at 167.4 and 166.2 ppm in the 
13
C NMR spectrum that 





Scheme 4.19: Synthesis of the Sonogashira-Stille product 225. 
 
4.5 Sonogashira coupling reaction 
 
The application of this result was then applied to the preparation of compound 226. 
Following the same conditions outlined in Table 4.08, compound 209 and the 
iodide 28 were coupled together to afford the Sonogashira product 226 in 51% yield 
after stirring the reaction mixture at room temperature for 2 hours (Table 4.09, 
entry 1). Repeating the reaction in anhydrous toluene gave the product in 63% yield 
(Table 4.09, entry 2). The driving force for the latter reaction was the formation of 
the piperidine salt that precipitates from toluene. This could account for the 
increased yield of 226. Encouragingly, the Stille product was not observed in the 
1
H 
NMR spectrum of the crude reaction mixture when stoichiometric equivalents of 
















H NMR spectrum below shows the six vinylic signals of the Sonogashira 
product 226 (Figure 4.05). These were assigned using coupling constants. The 
13
C NMR spectrum also showed two quaternary signals at 85.7 and 81.7 ppm that 





Figure 4.05: 1H NMR spectrum of compound 226 in CDCl3 (5.50−6.70 ppm). 
 
To investigate the conditions required to couple the ketoester 197 and 
compound 226, the model reaction with compound 196 was revisited. Treatment of 
the iodoester 196 with compound 226 in anhydrous dimethylformamide at room 
Entry  Conditions Yield of    
    226 
1 Pd(PPh3)4 (7 mol%), CuI (10 mol%), piperidine (2 eq.), DMF, 
BHT (cat.), 25 
o
C, 2 hrs 
   51% 
2 Pd(PPh3)4 (7 mol%), CuI (10 mol%), piperidine (2 eq.), toluene,       
BHT (cat.), 25 
o





temperature gave two new compounds tentatively assigned as 227 and 228 (Table 
4.10, entry 1). The first product gave a molecular ion at m/z = 469.2786 [M
+
] that 
was consistent with the molecular formula for the Stille adduct 227. The 
1
H NMR 
spectrum of this compound was missing signals at 0.81−0.97, 1.25−1.36 and 
1.48−1.53 ppm, suggesting the loss of the stannane. The vinylic hydrogen of the 
starting material observed at 6.29 ppm was also replaced with a signal further 
downfield at 7.41 ppm. This is consistent with the anisotropic effect of the benzene 
ring. 









C NMR spectra. The 
1
H NMR spectrum of the product showed five 
vinylic signals between 5.63−6.35 ppm, with a combined integration of twelve 
hydrogens. Furthermore, seventeen signals were observed in the 
13
C NMR spectrum, 
with the six resonances between 108−147 ppm ascribed to the vinylic carbons. Only 
Entry Conditions     Result 
1 Pd(PPh3)4 (7 mol%), CuI (10 mol%), DMF,  
BHT (cat.), 25 
o
C, 12 hrs 
    227 (20%), 228 (65%) 
2 Pd(PPh3)4 (7 mol%), CuI (10 mol%), CH3CN,  
BHT (cat.), 25 
o
C, 12 hrs 
    227 (48%) 
3 Pd(PPh3)4 (2 x 7 mol%), CuI (10 mol%), CH3CN,  
BHT (cat.), 25 
o
C, 72 hrs 




six signals were in this region since the dimer 228 is symmetrical. A possible 
explanation for the formation of 228 was the gradual disproportionation of Cu(I) into 
Cu(0) and Cu(II). The driving force for this was the formation of a more stable 
Cu(II)-dimethylformamide complex that facilitates the oxidative coupling of two 
molecules of stannane 226 to give compound 228.  
To circumvent the dimerisation of the stannane 226, the reaction was repeated in 
acetonitrile. Previous studies by Kolthoff and Coetzee have shown that Cu(I) does 
not disproportionate into Cu(II) and Cu(0) when dissolved in acetonitrile.
264
 This can 
be explained with respect to the tetrahedral complex shown in Figure 4.06. By 
coordinating through the nitrogen donor pairs, acetonitrile forms a Cu[NCMe]4I 
tetrahedral complex. This stabilises the Cu(I) cation so it no longer disproportionates 
into Cu(II) to mediate the dimerisation of the stannane 226. 
 
Figure 4.06: Cu(I)-acetonitrile tetrahedral complex 229. 
 
When the reaction was repeated with acetonitrile, the Stille product 227 was 
furnished in 48% yield and 95% yield based on recovered starting material 
(Table 4.10, entry 2). Pleasingly, the dimer 228 was not observed in the 
1
H NMR 
spectrum of the crude reaction mixture. Adding another 7 mol% of Pd(PPh3)4 after 
12 hours and prolonging the reaction time to 72 hours gave compound 227 in 51% 
yield (Table 4.10, entry 3).  
Having optimised the Stille reaction for the model system, attention was focused on 
the real system. To remove the silyl group, the stannane 226 was treated with TBAF 
in anhydrous tetrahydrofuran at 25 
o
C. This afforded compound 230 in 66% yield 
(Scheme 4.20). The three singlets at 0.90 (9 H), 0.05 (3 H) and 0.03 (3 H) ppm 
ascribed to the TBS group of the starting material had disappeared. The IR spectrum 
of the product also showed a broad peak at 3381 cm
-1
 that was assigned to the two 





Scheme 4.20: Desilylation of the stannane 226. 
 
Following the same conditions used in the model reaction, a mixture of the ketoester 
197, compound 230, Pd(PPh3)4, CuI, BHT and anhydrous acetonitrile was stirred at 
25 
o
C (Scheme 4.21). After one hour, the appearance of a new spot with a lower Rf 
value than both the starting materials was observed by TLC. The reaction was stirred 
for a further 11 hours and subjected to column chromatography to give the Stille 
product 231 as a mixture of C12 epimers in 41% yield and 92% yield based on 
recovered starting material. Similar to compound 227, both the 
1
H NMR and 
13
C NMR spectra showed no clear distinction between the epimers due to the large 
distance between the two stereocenters. 
 
Scheme 4.21: Stille reaction between the ketoester 197 and compound 230. 
 
The 1H NMR spectrum of the product showed six signals between 5.64−7.01 ppm 
that were ascribed to the six vinylic hydrogens and three signals between 
7.30−7.58 ppm assigned to the four aromatic hydrogens. The resonances at 204.3 
and 172.9 ppm observed in the 
13
C NMR spectrum could be attributed to the ketone 
and isopropyl ester while the molecular ion at m/z = 461.2316 [M+23 (Na)]
+
 was 








Having prepared compound 231, only 3 steps remained in the synthesis of 
benzoresolvin E1. These included the reduction of the alkyne and ketone functional 
groups and hydrolysis of the isopropyl ester (Figure 4.07). 
 
Figure 4.07: Benzoresolvin E1 endgame. 
 
Following the procedure by Allard (Scheme 1.18),
182
 the alkyne of 231 was reduced 
to a Z-alkene using a Zn(Cu/Ag) amalgam.
265
 This afforded the 14Z,16E-diene 
portion of compound 232 (Scheme 4.22). Although the mechanism for the reduction 
is yet to be established, it is suggested that the reaction proceeds via a radical 
induced pathway.
265
   
 
Scheme 4.22: Reduction of the alkyne 231 using a Zn(Cu/Ag) amalgam. 
 
The newly formed alkene was confirmed by the appearance of two vinylic signals at 
6.17 and 5.50 ppm in the 
1
H NMR spectrum and the disappearance of the two 
acetylenic carbons at 86.3 and 81.3 ppm in the 
13
C NMR spectrum. The mass 
spectrum of the product also showed an increase in the m/z ratio by two units (m/z = 
463.2461 [M+23 (Na)]
+
) which was consistent with the molecular formula of 
compound 232. The newly formed vinylic hydrogens have a common coupling 
constant of 10.9 Hz. This is in the range expected for a Z-alkene. These hydrogens 
along with the six other vinylic hydrogens of compound 232 were assigned via a 2D-





          
 
Figure 4.08: 1H NMR spectrum of compound 232 in CDCl3 (5.40−7.10 ppm). 
 
The penultimate step in the synthesis involved the reduction of the ketone. Since the 
C5 alcohol readily racemised under normal laboratory conditions (Figure 4.03), the 
asymmetric reduction of compound 232 was not attempted. Instead, the ketone was 
reduced with NaBH4 to give a racemic mixture of the benzyl alcohol (Scheme 4.23). 
The 
1
H NMR spectrum of the product showed the appearance of a resonance at 
5.00 ppm ascribed to the benzylic hydrogen while the aromatic resonance at 
7.43 ppm was shifted up-field to 7.26 ppm. This change could be attributed to the 
electron donating effect of the benzyl alcohol.  
 
Scheme 4.23: Reduction of the benzylic ketone using NaBH4. 
 
To complete the synthesis of benzoresolvin E1, the ester was hydrolysed with LiOH 
(Scheme 4.24). This offered a milder alternative to NaOH, which was used in 
Allard’s synthesis (Scheme 1.18).
182
 Gratifyingly, the lithium carboxylate salt of 
benzoresolvin E1 was afforded in 95% yield. The synthesis of this compound had 
the longest linear sequence of 13 steps from 1-pentyn-3-ol 138, with an overall yield 
of 2%. The disappearance of the signals at 5.00 and 1.17 ppm in the 
1
H NMR 


























also supported by the molecular ion (m/z = 407.2422 [M
+
]) observed in the high 
resolution mass spectrum which was consistent with the molecular formula required 
for the loss of an isopropyl group. In an attempt to form the free acid of 
benzoresolvin E1, compound 234 was passed through silica gel. Surprisingly, an 
unknown compound was quantitatively recovered, possibly an acid mediated 
rearranged product. Unfortunately, the structure of this compound could not be 
determined.  
 




H NMR spectrum of the lithium carboxylate salt of benzoresolvin E1 showed 
excellent separation of all the proton resonances (Figure 4.10). These were fully 
assigned using 2D-NMR techniques. Although the product was formed as a mixture 
of diastereoisomers, the 
1
H NMR and 
13
C NMR spectra of these compounds were 
identical. The UV spectrum of the target compound is shown in Figure 4.09. The 
maximum absorption wavelength was observed at 272 nm. This wavelength is in the 
region characteristic of a conjugated triene and is consistent with the wavelength 
maxima (λmax = 270 nm) observed for resolvin E1.
171     







Figure 4.09: UV spectrum of the lithium carboxylate salt of benzoresolvin E1 in methanol. 

max














4.7 Stability study of benzoresolvin E1 
 
To investigate the stability of the lithium carboxylate salt of benzoresolvin E1 at 
25 
o
C, a phosphate buffered solution (pH 7.4) of the target compound in D2O was 
prepared. The 
1
H NMR spectra were obtained over a four day period and the key 
aromatic and vinylic resonances were compared. The 
1
H NMR spectra are shown in 
Figure 4.12. The signals of interest are at 6.14 and 5.48 ppm. These are ascribed to 
the vinylic hydrogens of the Z-alkene. Pleasingly, these remained unchanged over 
four days. This suggests that the 14Z,16E-diene of the terminal chain does not 
isomerise to the 14E,16E-diene. No differences were observed for the remaining 
aromatic and vinylic resonances. Since the diastereoisomers of 234 have the same 
1
H 
NMR spectra, it is unclear if the C5, C12 or C18 alcohols isomerise under these 
conditions.   
In comparison to the study conducted by Maddapati and Zhou,
195
 a solution of 
resolvin E1 under the same conditions readily led to decomposition. Although the 





H NMR study in Figure 4.12 suggests the chemical stability of this compound 
could be related to the configuration of the C6−C7 alkene. This inference was 
supported by Kobayashi and Ogawa who claim that the stability of resolvin E1 could 
be linked to the stability of the 6Z-alkene of the triene unit.
181
 By adding a benzene 
ring, isomerisation could no longer occur at this position (Figure 4.11). This appears 
consistent with the 
1
H NMR spectra of the target compound in D2O that remained 
unchanged over a four day period. Subsequently, the 
1
H NMR study suggests that at 
a physiological pH, the lithium carboxylate salt of benzoresolvin E1 has a superior 
chemical stability compared to the parent resolvin E1.     
 











4.8 Inhibition of BLT-1  
 
Using the procedure described by Winkler et al.,
266
 a radio-ligand binding assay was 
conducted by Eurofins Panlabs to evaluate the activity of benzoresolvin E1 towards 
the BLT-1 receptor. The concentration of benzoresolvin E1 required to displace 50% 
of tritium labelled leukotriene B4 from BLT-1 was 4.14 µM while the inhibitory 
constant was 1.05 µM. These values were compared to other compounds that target 
the BLT-1 receptor. Compound 235, also known as SC-41930, is a BLT-1 antagonist 
that was synthesised in 1989 by Djuric and co-workers (Figure 4.13).
267
 It has 
similar anti-inflammatory properties to resolvin E1.
268-269
 Studies by Tsai and 
Penning determined the IC50 and Ki values of 235 to be 4.10 µM and 1.00 µM 
respectively.
268-269
 This is comparable to benzoresolvin E1, suggesting that both 
compounds have a similar affinity for the BLT-1 receptor. 
 
Figure 4.13: A comparison of the IC50 and Ki values for benzoresolvin E1and SC-41930. 
 
Radio-ligand binding assays carried out by Arita and co-workers showed the 
enantiomerically pure resolvin E1 to have a Ki of 70 nM.
186
 This is 15 times lower 
than the Ki of benzoresolvin E1, suggesting that resolvin E1 has a greater affinity for 
the BLT-1 receptor. Two reasons could account for this difference. Firstly, this result 
demonstrates that the fused benzene ring weakens but retains the binding towards the 
BLT-1 receptor. This could suggest that the hydrophobic pocket at the active site of 
the receptor may not be large enough to accommodate the benzene ring. Secondly, 
the target compound is a mixture of the C5 and C12 diastereoisomers. Assuming one 
of the diastereosiomers is the active compound and they are all formed in the same 
amount, it could be speculated that benzoresolvin E1 has a Ki of 262 nM. Therefore, 
although purely conjectural, the target compound may only be 4 times less effective 





Formal Total Synthesis of rac-12 Resolvin E1 
 
5.1 Retrosynthesis of rac-12 resolvin E1 
 
With the synthesis of benzoresolvin E1 complete, the same cross-coupling strategy 
was used to prepare rac-12 resolvin E1. There are three total syntheses of 
resolvin E1. These were developed by Petasis, Kobayashi and Allard and are 
described in Chapter 1.
180-182
 For this synthesis, the triene portion of the target 
compound could be formed by a Stille reaction between the bromo-acetylide 236 and 
the stannane 230 (Scheme 5.01). Unlike the other procedures, an advantage of this 
synthesis is the limited use of protecting groups. If Amin’s procedure was used to 
prepare fragment 28,
185
 the planned route would also be the shortest linear synthesis 
of resolvin E1 to date. Having prepared compound 230, attention was focused on the 
synthesis of the bromo-acetylide 236.  
 





5.2 Preparation of the bromo-acetylide 236 
 
The starting material for the synthesis of the bromo-acetylide 236 was 1-heptyne 236 
(Scheme 5.02). Deprotonation of the acetylenic hydrogen with n-BuLi followed by 
the addition of paraformaldehyde afforded compound 237 in 87% yield.
270
 
Isomerisation of the internal alkyne 237 to the terminal alkyne 238 was performed 
using a Zipper reaction. Treatment of 237 with NaH in 1,2-ethylenediamine gave 
238 in 61% yield (Scheme 5.02). The driving force for this reaction is the formation 
of the acetylide anion which remained localised at the terminal position. The 
1
H 
NMR spectrum of the product matched the spectrum reported by Matovic,
271
 with 
the diagnostic signal at 2.82 ppm ascribed to the newly formed acetylenic hydrogen. 
Oxidation of the primary alcohol was achieved using Jones reagent at 0 
o
C, giving 
the carboxylic acid 239 in 70% yield (Scheme 5.02).  
 
Scheme 5.02: Preparation of compound 239. 
 
The carboxylic acid of 239 was esterified with isopropyl alcohol and catalytic 
amounts of p-toluenesulfonic acid to afford the ester 240 in 76% yield 
(Scheme 5.03). The 
1
H NMR spectrum of the product showed the appearance of two 
resonances at 5.00 and 1.22 ppm that were ascribed to the newly formed isopropyl 
ester. Oxidation of the propargylic position was then achieved using the copper(II) 
catalysed method described by Li and co-workers.
272
 This radical initiated process 
involved the treatment of compound 240 with t-butyl hydroperoxide, CuCl2•2 H2O 
and O2. The reaction was stopped after 24 hours to afford compound 241 in 52% 
yield and starting material in 44% yield (Scheme 5.03). Stirring the reaction mixture 




appearance of a new resonance at 186.3 ppm in the 
13
C NMR spectrum of the 
product was consistent with the newly formed ketone.  
Using the same conditions as described in Table 4.02, the ketoester 241 was treated 
with borane dimethyl sulfide and (R)-CBS catalyst to give the (S)-alcohol 242 in 
71% yield (Scheme 5.03). The reaction was chemoselective, with the isopropyl ester 
not reduced under these conditions. This was supported by the 
13
C NMR spectrum of 
the product which showed the loss of the ketone resonance at 186.3 ppm. The key 
signal at 173.1 ppm that was assigned to the carbonyl of the ester was still present. 
To determine the absolute configuration of the product, the specific rotation was 
compared to a literature value.
273
 The specific rotation of the product was −9.40 
(c = 1.00, CHCl3). At the same temperature, Heiss and co-workers reported the (R)-
enantiomer of alcohol 242 to have a specific rotation of +10.30
o 
(c = 2.60, CHCl3). A 
comparison of these values indicates that the product was the desired (S)-enantiomer 
and was afforded in 91% ee.   
 
Scheme 5.03: Preparation of the (S)-alcohol 242. 
 
The final step in the synthesis of the bromo-acetylide 236 was an acetylenic 
bromination reaction. Treatment of compound 242 with N-bromosuccinimide and 
silver nitrate in acetone afforded 236 in 70% yield (Scheme 5.04). The diagnostic 
signal in the 
13
C NMR spectrum of the product is at 80.9 ppm. This is a quarternary 
carbon and was ascribed to the acetylenic carbon bearing the bromide. In 
comparison, only a methine signal at 84.6 ppm was observed in the 
13
C NMR 






shown in the high resolution mass spectrum was also consistent with the molecular 
formula required for C10 H15BrO3. 
 
Scheme 5.04: Synthesis of the bromo-acetylide 236. 
 
5.3 Synthesis of the key intermediate 243 
 
To prepare the triene portion of rac-12 resolvin E1, compound 236 was subjected to 
a Stille reaction with the stannane 230. Treatment of these compounds with 
Pd(PPh3)2Cl2 and CuI in anhydrous acetonitrile afforded the Stille product 243 in 
65% yield as a mixture of C12 epimers (Table 5.01). Although the product was a 
mixture of epimers, the 
1
H NMR and 
13
C NMR spectra of these compounds were 
identical and showed no splitting of the signals. The 
1
H NMR spectrum of the 
product matched the spectroscopic data reported in the literature (Table 5.01).
182
 The 
spectrum showed three resonances at 4.45, 4.26 and 3.97 ppm that were ascribed to 
the three hydroxyl bearing methine hydrogens and five signals between 
5.67−6.58 ppm with an integration of six hydrogens. These were assigned to the six 
vinylic hydrogens. The 
13
C NMR spectrum of the product was also consistent with 
the structure of 243, with a signal at 174.8 ppm attributed to the carbonyl of the ester 
while the six signals in the range of 110−146 ppm were assigned to the six vinylic 
carbons. The product intersects the total synthesis of resolvin E1 developed by 
Allard and was only 2 steps from the target compound.
182
 These steps involved the 
reduction of the two alkynes to the Z-alkenes and hydrolysis of the isopropyl ester. 
Thus using a Stille coupling approach, the formal total synthesis of rac-12 





















* The 1H NMR spectra were recorded at 400 MHz for 243 and 500 MHz for the literature compound. 
  
Signal                    Stille product*  
Chemical Shift (ppm)          Multiplicity 
                 Literature product* 
   Chemical Shift (ppm)            Multiplicity 
1    0.91                    t          0.91              t 
2 1.51                    m          1.54              m 
3 3.97                    q          3.97              q 
4 6.00                    dd           6.01              dd  
5 5.67                    m          5.67              m 
6 2.52                    ddd          2.51              ddd 
7 4.26                    q          4.25              q 
8 5.89                    dd          5.88              dd 
9 6.35                    dd          6.35              dd 
10 6.58                    dd          6.57              dd 
11 5.67                    m          5.67              m 
12 4.45                    t          4.45              t 
13 1.65                    m          1.64              m 
14 2.33                    t          2.33              t 
15 1.75                    m          1.79              m 
16 5.00                    sp          4.97              sp 





Synthesis of a C18-Phenyl Analogue of Benzoresolvin E1 
 
6.1 C18-Phenyl analogue 244 
 
As benzoresolvin E1 was shown to bind to the BLT-1 receptor, analogues of this 
compound were targeted. The C18−C20 terminal portion of benzoresolvin E1 234 
could be substituted with a phenyl ring to give compound 244 (Figure 6.01). The 
phenyl ring would remove the alcohol at the C18 position, thus simplifying the 
synthesis of the target compound. It is yet to be determined if this alcohol plays a 
role in activating the BLT-1 and ChemR23 receptors. Molecular modelling studies 
suggest the alcohol could partake in hydrogen bonding with the surrounding amino 
acid residues at the receptor site (Figure 1.15). Substituting the alcohol with a phenyl 
ring would sever these interactions. It would also improve the hydrophobic 
interactions, such as - stacking, with the surrounding residues. These interactions 
may be more effective than the hydrogen bonding, thus improving the binding 
affinity of the molecule. Subsequently, the inclusion of a phenyl ring at the terminal 
chain may prolong the anti-inflammatory action of the molecule. 
           
Figure 6.01: Benzoresolvin E1 234 and the C18-phenyl analogue 244. 
 
An example of a phenyl substituted anti-inflammatory was illustrated by 
Gjorstrup.
274
 Through structure-activity relationship studies, Gjorstrup showed 
compound 246 to be a superior agonist compared to the precursor 245 
(Figure 6.02).
274
 These compounds target the liver X receptor (LXR) and retinoic 
acid receptor (RAR), both of which are responsible for cholesterol and fatty acid 
metabolism.
274




compound 246. This improved the hydrophobic interactions at the receptor site, thus 
increasing the efficacy of the agonist. A similar finding could be observed for the 
target compound 244. 
                 




6.2 Retrosynthesis of compound 244 
 
The target compound 244 could be prepared using the same cross-coupling strategy 
for benzoresolvin E1 (Scheme 6.01). A Sonogashira reaction between rac-209 and 
the bromide 248 could afford the key intermediate 247. This compound could be 
coupled with the iodide 197 to give the benzodiene portion of the target compound. 
Following the same approach as Allard for the synthesis of resolvin E1,
182
 the alkyne 
and the ketone could be reduced and the isopropyl ester hydrolysed to furnish the 
C18-phenyl analogue of benzoresolvin E1. 
 





Starting from trans-cinnamic acid, the bromide 248 was synthesised in 82% yield via 




H NMR spectrum of the product showed 
two new doublets at 7.22 and 6.86 pm with a coupling constant of 14.0 Hz. These 
are consistent with the vinylic signals of 248 reported by Kuang.
275
 Following the 
conditions given in Table 4.08, the alkyne 209 was coupled with compound 248. 
This gave the Sonogashira product 247 in 52% yield after stirring the reaction 
mixture for 7 hours at room temperature (Scheme 6.02). Six new resonances between 
5.74−6.91 ppm were observed in the 
1
H NMR spectrum of the product. These had 
coupling constants within the range of 15.5−18.6 Hz, supporting the three E-alkenes 
of 247 (Scheme 6.02). A cluster of signals with an integration of five hydrogens was 




Scheme 6.02: Synthesis of compound 247. 
 
The stannane 247 was then treated with the iodide 197, Pd(PPh3)4, CuI and BHT in 
anhydrous acetonitrile (Scheme 6.03). After stirring the reaction mixture for 
12 hours at room temperature, the Stille product 249 was formed in 27% yield and 




afforded the product in 31% yield. The low yields could be attributed to the poor 
solubility of the stannane 249 in acetonitrile. Despite this result, a change in the 
solvent was not necessary since the unreacted starting material was recovered in near 
quantitative yields. The diagnostic signal in the 
1
H NMR spectrum of the product 
was at 7.04 ppm. This was ascribed to the vinylic hydrogen adjacent to the benzene 
ring and was downfield to the vinylic hydrogen of compound 247 shown at 
6.31 ppm. This is consistent with the anisotropic effect of the benzene ring. The 
13
C NMR spectrum also showed two signals at 204.2 and 172.8 ppm that could be 
assigned to the ketone and ester functional groups. 
 
Scheme 6.03: Stille coupling between the iodide 197 and compound 247. 
 
The next step in the synthesis involved the reduction of the alkyne to give the 
14Z,16E-benzodiene terminal chain. Treatment of compound 249 with a freshly 
prepared Zn(Cu/Ag) amalgam
265
 gave the isometrically pure Z-alkene 250 in 74% 
yield (Scheme 6.04). The reduction of the alkyne was confirmed by the mass 
spectrum (m/z = 481.2372 [M+23 (Na)]
+
) which was two m/z units higher than the 
starting material. The 
1
H NMR spectrum showed two resonances at 5.57 and 
6.34 ppm that were ascribed to the newly formed vinylic hydrogens (Scheme 6.04). 
These hydrogens have a common coupling constant of 10.9 Hz and are indicative of 





Scheme 6.04: Reduction of the alkyne 249 using a Zn(Cu/Ag) amalgam. 
 
Having selectively reduced the alkyne, attention was focused on the reduction of the 
ketone. Treatment of compound 250 with 2.5 equivalents of NaBH4 at −45 
o
C 
afforded the diol 251 in 87% yield (Scheme 6.05). Compound 251 was isolated as a 
mixture of diastereoisomers that could not be separated by column chromatography. 
The product obtained from the reaction did not have a ketone. This was validated by 
the disappearance of the carbonyl signal at 204.1 ppm in the 
13
C NMR spectrum. The 
1
H NMR spectrum also showed a new resonance at 5.02 pm that was ascribed to the 
newly formed benzylic hydrogen (Scheme 6.05).  
 
Scheme 6.05: Reduction of the ketone 250. 
 
To complete the synthesis of the target compound, the isopropyl ester was 
hydrolysed with LiOH (Scheme 6.06). This gave the product 244 in 92% yield. The 
synthesis of this compound had the longest linear sequence of 11 steps from o-
iodobenzoic acid, with an overall yield of 5%. The disappearance of the signals at 
5.00 and 1.22 ppm in the 
1
H NMR spectrum and the resonance at 173.3 ppm in the 
13
C NMR spectrum suggest the isopropyl group had been removed. A molecular ion 
was also observed at m/z = 425.2324 [M+23 (Na)]
+
 in the high resolution mass 






Scheme 6.06: Hydrolysis of the isopropyl ester 251. 
 
Similar to benzoresolvin E1, the 
1
H NMR spectrum of the C18-phenyl analogue 244 
showed excellent separation of all the proton resonances (Figure 6.04). These were 
fully assigned using 2D-NMR techniques. Although the product was formed as a 
mixture of diastereoisomers, the 
1
H NMR and 
13
C NMR spectra of these compounds 
were identical. The UV spectrum of the product is shown in Figure 6.03. The 
maximum absorption wavelength was observed at 281 nm. This wavelength is in the 
region characteristic of a benzodiene and is similar to the wavelength maxima 
observed for benzoresolvin E1. 
 


































6.3 Inhibition of BLT-1 
 
 
To evaluate the activity of the C18-phenyl analogue 244 towards the BLT-1 receptor, 
a radio-ligand binding assay was conducted by Eurofins Panlabs using the procedure 
described by Winkler et al.
266
 The assay showed 244 binds to the receptor with 68% 
activity at a concentration of 10 µM. This is lower than benzoresolvin E1 which has 
an activity of 76% at the same concentration.
266
 This result demonstrates that the 
C18-phenyl substituent does not significantly reduce the binding affinity of the 
molecule compared to the C18-alcohol of benzoresolvin E1. Consequently, a 
hydrogen donor group at this position is important but not essential for enhancing the 








           
Figure 6.04: 1H NMR spectrum of the C18-phenyl analogue 244 in CD3OD. 






Synthesis of Benzoleukotriene B4 
 
7.1 Leukotriene B4 and benzoleukotriene B4 
 
In Chapter 4, a radio-ligand binding assay was undertaken to investigate the activity 
of benzoresolvin E1. The results showed that benzoresolvin E1 competed with 
tritium labelled leukotriene B4 to bind to the BLT-1 receptor. Leukotriene B4 is a 
pro-inflammatory lipid mediator and is an agonist of this receptor.
187
 Unlike 
resolvin E1, leukotriene B4 facilitates the recruitment of neutrophils, monocytes and 
eosinophils.
187
 It also stimulates the production of pro-inflammatory cytokines such 
as IL-4, IL-5, IL-6, IL-8 and IL-10.
18,269-270
 It was envisaged that a benzene 
annulated analogue of leukotriene B4, herein named benzoleukotriene B4, would also 
bind to the BLT-1 receptor. In view of this, the following chapter details 
investigations towards this compound.  
There are two key differences between benzoresolvin E1 and leukotriene B4. The 
first difference is the C16−C20 terminal chain (Figure 7.01, blue). Unlike 
benzoresolvin E1 which has an allylic alcohol at the C18 position, leukotriene B4 has 
a pentyl chain. This portion of the molecule is thought to fit in a long pocket at the 
active site of the BLT-1 receptor, thus improving the binding affinity of the molecule 
through hydrophobic interactions.
187
 Secondly, benzoresolvin E1 has a benzene-
annulated ring at the C6−C7 position (red). This was shown to improve the stability 
of resolvin E1 by blocking the isomerisation pathway (Figure 4.11). A benzene ring 
fused at the same position on leukotriene B4 could also have the same effect. 
 




7.2 Total synthesis of leukotriene B4 
 
There are 11 total syntheses of leukotriene B4, two of which are selected for 
review.
276-286
 A common approach to prepare the triene unit of leukotriene B4 was a 
Horner-Wadsworth-Emmons olefination. This strategy was used in five of the 
reported total syntheses.
276-280
 One example is shown in the retrosynthesis developed 
by Kerdesky and co-workers in 1993.
276
 The key intermediates in this synthesis are 
compounds 254 and 255. These were coupled together to give the 8E-alkene of the 
target compound (Scheme 7.01). 
 
Scheme 7.01: Retrosynthesis of leukotriene B4 developed by Kerdesky.
276 
 
The starting point for the synthesis of compound 254 was 4-chloroformylbutanoate 
256 (Scheme 7.02). Addition of the organolithium reagent 257 to this compound 
gave the alkylated product 258 in 72% yield. The ketone 258 was reduced to the (S)-
alcohol in 94% ee using S-Alpine-Borane
®
 and the secondary alcohol was protected 
with a TBDPS group. The THP protecting group was removed using bromine and 
1,2-bis(diphenylphosphino)ethane, the primary alcohol was converted into a bromide 
and the remaining compound was treated with NaHMDS and dimethyl phosphite to 





Scheme 7.02: Synthesis of compound 254.276 
 
The aldehyde 255 provided access to the C9−C20 portion of leukotriene B4. The 
starting point for this compound was (2R)-(-)-glycidol 4-nitrobenzoate 260 
(Scheme 7.03). Treatment of 260 with BF3•OEt2 and the organolithium reagent 261 
led to ring opening of the epoxide. The resulting alcohol was protected with a 
TBDPS group to afford compound 262 in 85% yield in 2 steps. Hydrolysis of the p-
nitrobenzoate using LiOH gave a primary alcohol. This was oxidised using TPAP to 
furnish the aldehyde 263. Finally, a Wittig olefination with the ylide 264 afforded 
the key intermediate 255 in 52% yield in 5 steps. 
 
Scheme 7.03: Synthesis of the aldehyde 255.276 
 
The final steps of the synthesis involved a Horner-Wadsworth-Emmons olefination 




C8−C9 position. Leukotriene B4 was then prepared in 3 steps and 68% yield from 
compound 265 by global deprotection of the silyl groups, reduction of the C6−C7 and 
C14−C15 alkynes using Lindlar’s catalyst and hydrolysis of the methyl ester.  
 
 
Scheme 7.04: Final steps in the synthesis of leukotriene B4.
276 
 
A cross-coupling strategy has also been used to form the triene portion of 
leukotriene B4. This was implemented in four total syntheses.
277, 280-282
 One example 
of this approach was detailed by Avignon-Tropis and co-workers in the preparation 
of the leukotriene B4 methyl ester 266 (Scheme 7.05).
277
 The key disconnection in 





Scheme 7.05: Retrosynthesis of the leukotriene B4 methyl ester 266 developed by Avignon-Tropis.
277 
 
Compound 26 is a common intermediate in four other total syntheses of 
leukotriene B4 and was prepared by Petasis and Allard for the total synthesis of 
resolvin E1.
180,182
 One reason for its widespread use is that it provides access to the 
C1-C5 hydroxyacid portion of the target compound in only 4 steps from methyl 4-
chloroformylbutanoate 256. The synthesis of compound 26 is shown in Scheme 
7.06. This is similar to the pathway detailed by Petasis in Scheme 1.03.
180
 The main 
difference was the reduction of the ketoester 31. In this synthesis, compound 31 was 
reduced to rac-32 while in the pathway developed by Petasis, the enantiomerically 




Scheme 7.06: Synthesis of compound 26.277 
 
Starting from the benzyl protected glycidol 268, the key fragment 267 was prepared 
in 10 steps (Scheme 7.07). Alkylation of 268 with the organolithium reagent 261 




alkene using Lindlar’s catalyst, the secondary alcohol was esterified with benzoyl 
chloride and the benzyl ether was cleaved under acidic conditions to give 
compound 270 in 78% yield over 3 steps. The resulting alcohol was oxidised using 
Swern conditions to give the aldehyde 271. This compound was treated with the 
ylide 272 to afford compound 273 in 70% yield in 2 steps. Removal of the benzoate 
ester and TMS group, protection of the allylic alcohol with a TBS group followed by 
a hydrozirconation reaction using Schwartz’s reagent gave compound 267 in 44% 
yield over 4 steps.  
 
Scheme 7.07: Synthesis of compound 267.277 
 
The antepenultimate step in the synthesis involved a Sonogashira reaction between 
the alkyne 26 and the iodide 267 (Scheme 7.08). This afforded compound 274 in 
73% yield. The target compound 266 was then prepared in 2 steps from 274 by 
global deprotection of the silyl groups and reduction of the C6−C7 and C14−C15 




by column chromatography to give the leukotriene B4 methyl ester 266 in 35% yield 
from compound 274. 
 
Scheme 7.08: Final steps in the synthesis of the leukotriene B4 methyl ester 266.
277 
 
7.3 Retrosynthesis of benzoleukotriene B4 
 
Benzoleukotriene B4 could be prepared by a similar strategy to Avignon-Tropis.
277
  
Instead of a Sonogashira reaction, a Stille reaction between the iodide 197 and the 
stannane 275 could give the benzodiene portion of the target compound 
(Scheme 7.09). Using the same approach for the preparation of benzoresolvin E1 
(Scheme 4.15), the stannane 275 could be synthesised by the addition of the 
Grignard 276 to the aldehyde 213. Having previously synthesised compounds 197 




                        
Scheme 7.09: Retrosynthesis of benzoleukotriene B4 253. 
 
Starting from 1-hexyne, the Grignard reagent 276 was synthesised in 3 steps. 
Treatment of 1-hexyne 223 with n-BuLi gave the lithium acetylide which was added 
to paraformaldehyde at −84 
o
C to afford the alcohol 277 in 88% yield 
(Scheme 7.10). The product showed an absorbance at 3502 cm
-1
 in the IR spectrum 
and a broad singlet at 2.89 ppm in the 
1
H NMR spectrum that was consistent with the 
newly formed primary alcohol. The alcohol was then converted into a bromo group 
via an Appel reaction, giving the bromide 278 in 77% yield. The loss of the alcohol 
absorbance in the IR spectrum of the crude reaction mixture suggested complete 
consumption of the starting material. Furthermore, the 
1
H NMR spectrum of the 




Scheme 7.10: Synthesis of the bromide 278. 
 
The bromide 278 in anhydrous ether at room temperature was treated with a Mg(Hg) 
amalgam. Using this method, Acharya and co-workers prepared the Grignard 276 in 
85% yield.
288




was added to a solution of the aldehyde 213 in anhydrous ether at −84 
o
C 
(Scheme 7.11). The reaction was monitored by TLC. Two new spots with similar Rf 
values compared to the starting material were observed after 15 minutes. The 
reaction mixture was stirred for a further two and a half hours until the starting 
material was completely consumed. Analysis of the 
1
H NMR spectrum for the crude 
sample revealed a 0.8:1.2 mixture of two new products tentatively assigned as 
compounds 275 and 279. Due to the similar polarities of these compounds, 
separation by column chromatography proved difficult. However, a small amount of 
275 and 279 was isolated and characterised by NMR spectroscopy.  
 




H NMR spectrum of the desired product 275 showed four vinylic signals in the 
region of 5.69−6.52 ppm along with three resonances at 1.46−1.51, 1.25−1.44 and 
0.93−0.97 ppm due to the stannane functional group. The signal at 2.17 ppm could 
be assigned to the methylene hydrogens in blue while the signals at 2.46 and 
2.41 ppm are ascribed to the propargylic hydrogens shown in red (Figure 7.02). 
These hydrogens are diastereotopic and gave a complex coupling pattern. The 
coupling constants of 2.4 and 2.5 Hz were attributed to the propargylic hydrogens 
(blue) at 2.17 ppm while the coupling constants of 7.0 and 16.4 Hz are indicative of 








The other compound in the reaction mixture was tentatively assigned as the allene 
279 based on the 
13
C NMR spectrum. The spectrum showed four signals between 
132−146 ppm that could be ascribed to the four vinylic carbons while the resonance 
at 72.6 ppm could be assigned to the carbon bearing the hydroxyl group. The key 
signals of interest are at 79.7, 107.5 and 204.2 ppm (Figure 7.03). These are 
characteristic of a disubstituted allene which is consistent with the structure of 
compound 279.  
 
Figure 7.03: A comparison of the key 13C NMR resonances for compounds 279 and 280 in CDCl3. 
 
Focusing on the allene functional group, the 
13
C NMR spectrum of compound 279 is 
similar to the literature compound 280.
289
 As shown in Figure 7.03, the allene signal 
at 204.2 ppm for compound 279 has a chemical shift similar to the disubstituted 
allene carbon of 280 which is observed at 204.3 ppm. The 
13
C NMR spectrum of 279 
showed a resonance at 79.7 ppm that could be ascribed to the terminal carbon of the 
allene. This is similar to the chemical shift at 77.5 ppm reported for compound 280. 
The resonance at 107.5 ppm for compound 279 was assigned to the remaining 
carbon. This is futher downfield compared to the signal observed for compound 280. 




Rearrangement of the Grignard reagent 276 at room temperature could account for 
the formation of the allene 279 (Scheme 7.12). Studies by Gaudemar and 
Yanagisawa suggest that compound 276 is in equilibrium with the Grignard 281.
292-
293
 In an attempt to suppress the formation of 281, compound 278 was treated with a 
Mg(Hg) amalgam at a cooler temperature of 0 
o
C followed by the addition of the 




H NMR spectrum of the crude reaction mixture 
showed an improvement in the yield of the stannane 275, with a 1:1 mixture of 275 






                 
Scheme 7.12: Equilibration of the Grignard reagent 276 with the allene 281. 
 
In light of this result, the reaction was repeated using an organolithium reagent. 
Unlike the Grignard 276, an organolithium reagent could be prepared at cryogenic 
temperatures. Oda and co-workers have shown that at −78 
o
C, compound 282 does 
not form allenic products in a similar reaction.
294
 For example, addition of this 
compound to the aldehyde 283 gave the stannane 284 in 95% yield without affording 
the allene isomer (Scheme 7.13). 
 
Scheme 7.13: Addition of the organolithium reagent 282 to the aldehyde 283.294 
 
To emulate these results, a lithium-halogen exchange between n-BuLi and 
compound 278 at −84 
o
C was planned to give the organolithium reagent 282 
(Scheme 7.14). This compound could be treated with the aldehyde 213 to afford the 




    
Scheme 7.14: Planned synthesis of the stannane 275 via a lithium-halogen exchange. 
 
Adapting the procedure described by Rajagopalan and Zweifel,
295
 compound 278 in 
anhydrous tetrahydrofuran was treated with one equivalent of n-BuLi at −84 
o
C. The 
reaction mixture was stirred at this temperature for 6 hours. One equivalent of the 
aldehyde 213 in anhydrous tetrahydrofuran was then added and the mixture was 
stirred for a further 6 hours at −84 
o
C. Disappointingly, the 
1
H NMR spectrum of the 
crude sample showed no improvement in the yield of 275, with a 1:1 mixture of 





















7.4 Epoxidation strategy 
 
A new two step strategy to synthesise the stannane 275 was implemented to 
overcome the rearrangement of the organolithium reagent 282 (Scheme 7.15). 
Converting the aldehyde to an epoxide followed by alkynylation at the terminal 
position could give the stannane 275. This pathway would eliminate the need to form 
propargylic Grignard or organolithium reagents such as compounds 276 and 282 that 
readily equilibrate. 
 
Scheme 7.15: Alternate pathway to prepare the stannane 275. 
 
Epoxidation of compound 213 could be achieved via a Corey-Chaykovsky reaction. 
This involves the addition of a sulfur ylide to an aldehyde to afford a terminal 
epoxide. The conditions are mild and the reaction gives good yields of the desired 
epoxide.
296
 A common sulfur ylide used in these reactions is dimethylsulfonium 
ylide. This ylide is easily formed by treating dimethylsulfonium iodide with a base 
such as NaH.
297
 Alternatively, trimethylsulfonium methanesulfonate 287 could be 
used as a viable substitute.
298
 Following the procedure developed by Travers,
299
 
compound 287 was synthesised from DMSO.  
Adapting the procedure by Kavanagh and co-workers,
297
 trimethylsulfonium 
methanesulfonate 287 in anhydrous tetrahydrofuran was treated with NaH at 0 
o
C to 
form the sulfur ylide (Scheme 7.16). This was added dropwise to a solution of the 
aldehyde 213 in anhydrous tetrahydrofuran at −45 
o
C. After 4 hours at this 
temperature, complete consumption of the starting material was observed and the 
formation of a new spot by TLC was noted. This compound was identified as the 




the formation a sulfonium cation intermediate that readily eliminates dimethyl 
sulfide to afford the epoxide 286. 
 




H NMR spectrum of the product showed the appearance of three new 
resonances at 3.36, 2.99 and 2.68 ppm that were ascribed to the three diastereotopic 
hydrogens of the newly formed epoxide (Figure 7.04). Four resonances between 
5.30−6.53 ppm were also observed in the 
1
H NMR spectrum. These were assigned to 
the four vinylic hydrogens. The 
13
C NMR spectrum of the product also showed two 
new signals at 52.4 and 49.4 ppm that are consistent with the methine and methylene 






Figure 7.04: 1H NMR spectrum of the epoxide 286 in CDCl3 (2.50−6.75 ppm). 
 
 
With the epoxide 286 in hand, the alkynylation step was investigated. Alkynylation 
of the epoxide could proceed at either the α or β-position (Table 7.01). This would 
give a mixture of the regioisomers 275 and 288. To direct the addition of the 
organolithium acetylide 261 to the unhindered β-position, the reaction mixture was 
cooled to −84 
o
C (Table 7.01, entry 1). No new products were observed after stirring 
the mixture for 2 hours, as judged by TLC. Warming the reaction mixture to 0 
o
C 
also gave the same result, with the starting material recovered in quantitative yields 




This result prompted the use of a mild Lewis acid such as lithium perchlorate. Chini 
and co-workers have shown that lithium perchlorate can direct the alkynylation of 
terminal epoxides towards the β-position, giving β-substituted products in greater 
than 95% yield.
300
 Following the conditions outlined by Chini,
300
 two equivalents of 
lithium perchlorate were added to a mixture of the epoxide 286 and the 
organolithium acetylide 261 in anhydrous tetrahydrofuran at 0 
o
C (Table 7.01, 
entry 3). The reaction was monitored over 24 hours. Only starting material was 
recovered from the crude mixture after this time. Likewise, no reaction was observed 
when anhydrous cerium chloride was used (Table 7.01, entry 4). 
 




When a stronger Lewis acid such as BF3•OEt2 was used, the starting material was 
completely consumed after 30 minutes. A new compound with the same Rf value as 
the stannane 275 was observed. This compound was isolated in 52% yield and was 
tentatively assigned as the alcohol 289 (Scheme 7.17).  
Entry  Conditions        Result 
1  286 (1 eq.), 261 (1 eq.), THF, −84 
o
C, 2 hrs no reaction 
2  286 (1 eq.), 261 (1 eq.), THF, 0 
o
C, 6 hrs no reaction 
3  286 (1 eq.), 261 (1 eq.), LiClO4 (2 eq.), THF, 0 
o
C, 24 hrs no reaction 
4  286 (1 eq.), 261 (1 eq.), CeCl3 (2 eq.), THF, 0 
o




        
Scheme 7.17: BF3•OEt2 mediated alkynylation of the epoxide 286. 
 
The 1H NMR and 
13
C NMR spectra of the product are similar but not identical to the 
spectra of the stannane 275 (Figure 7.05). The 
1
H NMR spectrum showed four 
signals between 5.70−6.52 ppm that are ascribed to the four vinylic hydrogens of the 
alcohol 289. The diagnostic vinylic signal is at 5.70 ppm. This is an apparent doublet 
of triplets which is different to the doublet of doublet multiplicity observed for the 
same vinylic signal of the stannane 275. The 
1
H NMR spectrum of the product also 
showed two resonances at 2.48 and 2.12 ppm that are attributed to two sets of 
methylene hydrogens. These have different chemical shifts to the stannane 275 
where the methylene resonances adjacent to the alkyne are at 2.46, 2.41 and 
2.17 ppm. The coupling pattern for these signals is also different. The resonance at 
2.48 ppm is an apparent triplet while the propargylic signals at 2.46 and 2.41 ppm of 
the stannane 275 have a more complex multiplicity. A 2D-COSY experiment of the 
product showed a correlation between the vinylic signal at 5.70 ppm and the 
methylene resonance at 2.48 ppm. In contrast, the stannane 275 showed no 
correlation between the vinylic signal at 5.69 ppm and the propargylic resonances at 
2.46 and 2.41 ppm. The 
13
C NMR spectrum of the product was also different to the 
spectrum of compound 275. The signal of interest was the carbon bearing the 
alcohol. This was observed at 62.3 ppm for the product and 70.8 ppm for the 






Figure 7.05: Key 1H NMR signals for compounds 289 and 275 in CDCl3 (2.20−6.60 ppm). 
 
The proposed mechanism in Scheme 7.18 could account for the synthesis of the 
alcohol 289. BF3•OEt2 was able to mediate the ring opening of the epoxide 286. This 
led to the formation of the resonance stabilised allylic carbocation 290 which was 
more favourable than the primary carbocation. A 1,2-hydride shift gave the aldehyde 
291, followed by the 1,2-addition of the organolithium reagent 261. Finally, a 





Scheme 7.18: Proposed mechanism for the formation of the alcohol 289. 
 
A change in the solvent was also explored for this reaction. The solvent system used 
was a 1:1 mixture of hexamethylphosphoramide/tetrahydrofuran (Scheme 7.19). 
Hexamethylphosphoramide could facilitate the coordination of the lithium cation, 
thus increasing the nucleophilicity of the acetylide anion.
301
 The reaction was 
repeated using the same conditions outlined in Table 7.01. No new products were 
observed after stirring the mixture for 2 hours at −84 
o
C. The same result occurred 
when the reaction mixture was warmed to 0 
o
C, with starting material recovered in 
quantitative yields. 
                                   
Scheme 7.19: Attempted alkynylation of the epoxide 286. 
 
In view of these results, the synthesis of benzoleukotriene B4 was abandoned. 
Although fragment 275 was prepared using a Grignard approach, the product was 
afforded as an inseparable mixture with the allene 279. Alternate methods to 




unsuccessful. To circumvent the problems encountered in this chapter, the stannane 
275 could be prepared via a Sonogashira reaction between compound 209 and 1-
iodopentane 292 (Scheme 7.20). Sp
3
-hybridised alkyl iodides are unfavourable 
substrates for the Sonogashira reaction as they readily undergo β-hydride 
elimination, giving undesirable alkene side-products.
302
 However, studies by 
Eckhardt and Fu have shown that carbene additives such as compound 293 can 
suppress β-hydride elimination, affording high yields of the Sonogashira products.
302
 
This method could be investigated in the future to prepare the stannane 275. 
 








Resolvin E1 is a short-lived anti-inflammatory lipid mediator. One of its proposed 
modes of degradation is isomerisation of the 6Z-alkene.
172
 This gives the 6E-isomer 
that is no longer anti-inflammatory.
177
 To inhibit this pathway, a benzene fused 
analogue of resolvin E1 was targeted (Figure 8.01). This was named 
benzoresolvin E1. The inclusion of the benzene ring at the C6−C7 position would 
improve the chemical stability of resolvin E1 by inhibiting the isomerisation 
pathway. 
 
Figure 8.01: Resolvin E1 and benzoresolvin E1. 
 
The initial synthetic pathway involved a Wittig reaction between the lactol 87 and 
the ylide of compound 88 followed by addition of the Grignard reagent 82 to afford 
the benzodiene and the C1−C5 hydroxyacid portion of the target compound 
(Chapter 1). Both reactions gave low yields of their respective products, the ester 83 
and compound 103 (Scheme 8.01). 
 




To prepare the C13−C20 portion of the target compound, propargyl alcohol was used 
as the starting material (Chapter 1). From this compound, the bromide 122 was 
synthesised in 4% yield in 8 steps. Compound 122 could be converted into the 
Grignard reagent 123 and added to the aldehyde 86 to give the key intermediate 85 
which is 3 steps from the target compound. Unfortunately, when the bromide 122 
was treated with magnesium turnings at 0 
o
C, decomposition of the reaction mixture 
was observed. A possible mode of degradation was the elimination of 
TBDPSOMgBr to give the highly reactive cumulene 130 (Scheme 8.02). Attempts to 
mitigate this rearrangement by cooling the reaction mixture to −84 
o
C upon Grignard 
initiation were unsuccessful.  
 
Scheme 8.02: Proposed mode of degradation for the Grignard reagent 123. 
 
In view of this, the Grignard reagent 123 was segmented into two smaller 
compounds, propargylmagnesium bromide and the iodide 28. This would circumvent 
the rearrangement observed in Scheme 8.02. A new pathway was developed for the 
synthesis of the iodide 28 (Scheme 8.03). Starting from 1-pentyn-3-ol, compound 28 
was prepared in 20% yield and 96% ee in 7 steps (Chapter 3). This was comparable 
to the yield reported in the literature.
211
 A scalable pathway for this compound was 
also developed using propionaldehyde and 2-methyl-3-butyn-2-ol. These compounds 
are cheap, making large quantities of the iodide 28 achievable.  
 
Scheme 8.03: Preparation of the iodide 28 from 1-pentyn-3-ol. 
 
With the iodide 28 in hand, the Wittig reaction between the lactol 87 and the ylide of 
compound 88 was revisited. By protecting the alcohol of 91 with a benzyl group, the 
Wittig product was furnished in 64% yield (Chapter 3). This was higher than the 




and reagents were tested to remove the benzyl group (Scheme 8.04). These led to 
either degradation or deprotection of the allylic alcohol. A similar result was 
observed when PMB was used as the protecting group (Chapter 3). In light of these 
shortcomings, a new protecting group free synthesis of benzoresolvin E1 was 
planned (Chapter 4). 
      
Scheme 8.04: Unsuccessful removal of the benzyl protecting group. 
 
This synthetic route utilised a sequential Sonogashira-Stille reaction between 
compounds 197, 209 and 28 (Scheme 8.05). From these compounds, the lithium 
carboxylate salt of benzoresolvin E1 was prepared in 6 steps. The synthesis of this 
compound had the longest linear sequence of 13 steps from 1-pentyn-3-ol 138, with 
an overall yield of 2%. The key fragment in the synthesis was the alcohol 209. This 
compound has two handles, a terminal alkyne and a stannane moiety. Using the 
iodide 196 as a model compound, the alkyne was shown to be more reactive than the 
stannane. This difference in reactivity was exploited to couple the alcohol 209 with 
the iodide 28, giving the Sonogashira product 226 as the sole product. Subsequent 
deprotection of the alcohol followed by a Stille reaction with compound 197 
afforded the key intermediate 231. Using this strategy, the benzodiene and enyne 
portions of the target compound were prepared in only 3 steps. 
 




Having synthesised benzoresolvin E1, the chemical stability of this compound was 
investigated. A 1H NMR study conducted at room temperature showed no change to 
the target compound over 4 days. In comparison to the study by Maddapati and 
Zhou,
195
 resolvin E1 was shown to degrade over the same period of time. This 
suggests that the benzene ring was significant in improving the stability of 
resolvin E1 (Chapter 4). In vitro studies also showed benzoresolvin E1 binds to the 
BLT-1 receptor with an inhibitory constant of 1.05 µM. This is comparable to the 
BLT-1 antagonist SC-41930 that has a Ki of 1.00 µM
269
 but is higher than the 
inhibitory constant of resolvin E1 (Ki = 70 nM),
186
 inferring that the fused benzene 
ring weakens but retains the binding towards the BLT-1 receptor. 
Using the same convergent strategy, the formal total synthesis of rac-12 resolvin E1 
was completed (Chapter 5). The key fragment in this pathway was the bromide 236. 
This compound was furnished in 91% ee and 7% yield in 7 steps. The linchpin of the 
synthesis was a Stille reaction between this compound and the stannane 230 
(Scheme 8.06). This allowed access to the enyne portion of resolvin E1 in only one 
step. The product of this reaction intersects the total synthesis of resolvin E1 




Scheme 8.06: Formal total synthesis of rac-12 resolvin E1. 
 
Using the Sonogashira-Stille coupling strategy, a C18-phenyl substituted analogue of 
benzoresolvin E1 was prepared (Chapter 6). This compound was synthesised in 
5 steps from compounds 197, 209 and 248 (Scheme 8.07). In vitro studies showed 
the phenyl analogue 244 binds to the BLT-1 receptor with 68% activity at 10 µM. 




that the C18-phenyl substituent does not significantly reduce the binding affinity of 
the molecule. 
 
Scheme 8.07: Synthesis of the C18-phenyl analogue 244. 
 
Significant advances were made towards the synthesis of a benzene annulated 
analogue of leukotriene B4 (Chapter 7). Using the strategy developed for 
benzoresolvin E1, the key intermediate 275 was furnished with the allene 279 
(Scheme 8.08). As these compounds were difficult to separate via column 
chromatography, a new two step method was devised. The epoxide 286 in this 
pathway was prepared in 71% yield using a Corey-Chaykovsky reaction. This 
compound was difficult to alkylate, with a range of conditions giving the stannane 
isomer 289 or recovered starting material. Future efforts to prepare compound 275 
could utilise a carbene additive to promote the Sonogashira reaction between 1-













9.1  General Procedure 
 
9.1.1  Reactions 
Anhydrous diethyl ether and tetrahydrofuran were freshly distilled from 
sodium/benzophenone under nitrogen. Anhydrous dichloromethane, toluene, ethanol, 
isopropyl alcohol, N,N-dimethylformamide and acetonitrile were freshly distilled 
from calcium hydride under nitrogen. Anhydrous acetone was freshly distilled from 
boric anhydride. Degassed solvents were prepared by the freeze-pump-thaw 






C, −45 °C and −84 
o
C refer 
to an ice, an ammonium chloride-ice, a sodium bromide-ice, a liquid nitrogen-
acetonitrile and a liquid nitrogen-ethyl acetate bath, respectively. Unless otherwise 
stated, all reactions were conducted in an atmosphere of nitrogen and the solvents 
used were anhydrous. All organic extracts were dried with anhydrous potassium 
carbonate, unless otherwise stated and filtered prior to removal of the solvent under 
reduced pressure.  
9.1.2  Purification of compounds 
Column chromatography was performed using Davisil
®
 silica gel, whilst radial 
chromatography was conducted using a Chromatotron Model 7924T (Harrison 
Research, Palo Alto, California) with Merck silica gel, PF254 visualising radial plates. 
In both chromatographic techniques, increasing proportions of ethyl acetate in light 
petroleum spirits were used as eluting solvents. Light petroleum refers to 
hydrocarbon fractions with boiling points between 40−60 °C. For acid-sensitive 
compounds, the silica gel was treated with 1% triethylamine in petroleum spirits. 
This is referred to as column conditioning. Fractions were monitored by TLC, with 
samples run on Merck alumina backed silica gel 60 F254 sheets. Compounds were 
visualised using ultraviolet light and then developed with a potassium permanganate 




9.1.3  Characterisation of compounds 
Melting points were determined using a Barnstead Electrothermal 9100 melting 
point apparatus. NMR spectra were processed on an Ultrashield Bruker 400 
spectrometer and were conducted at 298 K. All 1H NMR spectra were recorded at a 
frequency of 400 MHz while all 
13
C NMR spectra were recorded at a frequency of 




experiments. Chemical shifts were reported in ppm and the reference signals for 
CDCl3 were calibrated to 7.26 ppm and 77.16 ppm for the 1H NMR and 
13
C NMR 
spectra respectively. Infrared spectra were obtained on a Perkin Elmer FT-IR 
Spectrometer 100 using an attenuated total reflectance attachment with a universal 
single-bounce diamond-zinc selenide crystal ATR sampling accessory. High 
resolution electrospray ionisation (ESI) and atmospheric solids analysis probe 
(ASAP) ionisation accurate mass measurements (HRMS) were recorded in positive 
mode on a Waters Xevo Q-TOF (quadrupole-Time of Flight) instrument and were 
conducted by Dr Celine Kelso of the Department of Chemistry, University of 
Wollongong. Elemental analyses were performed by Robert Herman of the 
Department of Chemistry, Curtin University. Optical rotations were performed on a 
Rudolph Research Analytical Autopol I Polarimeter. Enantiomeric excesses were 
determined by chiral HPLC and were carried out by Dr Thanh Vinh Nguyen at the 
Research School of Chemistry, Australian National University. The UV spectra of 
benzoresolvin E1 and the C18-phenyl analogue were recorded at room temperature 
using a Perkin Elmer Lambda 35 UV/Vis spectrometer.  
9.1.4  Biological testing 
Radio-ligand binding assays were investigated to determine the activity of 
benzoresolvin E1 and the C18-phenyl analogue towards the BLT-1 receptor. These 










9.2  Chapter 2 experimental procedures 
 
9.2.1  Synthesis of the lactol 87 
 
Following the procedure by Mikami and Ohmura,
198
 DIBAL (1 M in toluene, 
8.20 mL, 8.20 mmol, 1.1 eq.) was added dropwise to a solution of phthalide (1.00 g, 
7.46 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (30 mL) at −84 
o
C.  The solution 
was stirred for two and a half hours while maintaining the temperature. The reaction 
was then quenched upon addition of a saturated aqueous solution of sodium sulfate 
(20 mL) and the suspension removed by filtration. The organic layer was removed 
under reduced pressure to afford a yellow liquid. The liquid was subjected to column 
chromatography. Elution with 70% ethyl acetate/light petroleum afforded a mixture 
of the lactol 87 and the aldehyde 92 (34:16) as a yellow liquid (345 mg, 34%). The 




H NMR (400 MHz, CDCl3): δ 10.09 (1 H, s, aldehyde), 7.87 (1 H, m, aldehyde), 
7.29−7.61 (7 H, m, lactol/aldehyde), 6.48 (1 H, br. s, lactol), 5.28 (1 H, s, lactol), 
5.00 (1 H, d, J = 12.8 Hz, lactol), 4.83 (1 H, s, lactol), 4.21 (1 H, br. s, aldehyde), 
3.41 (2 H, s, aldehyde) ppm.  
9.2.2  Preparation of the diol 91 
    
LiAlH4 (4.13 g, 0.11 mol, 1.6 eq.) at 0 
o
C was added in portions to a solution of 
phthalide (9.12 g, 0.07 mol, 1.0 eq.) in anhydrous tetrahydrofuran (240 mL). The 
reaction mixture was heated under reflux for 5 hours. The mixture was cooled to 
0 
o
C and quenched with deionised water (30 mL). The reaction mixture was filtered 
and the filtrate concentrated under reduced pressure to afford the diol 91 as a white 
solid (8.45 g, 90%); m.p. 64–65 
o




 The spectroscopic data 
matched that reported in the literature.
303





H NMR (400 MHz, DMSO): δ 7.38 (2 H, m), 7.21 (2 H, m), 5.05 (2 H, t, J = 
5.5 Hz), 4.54 (4 H, d, J = 5.5 Hz) ppm. 
9.2.3  Bromination of methyl crotonate 
                               
Following the procedure outlined by Baeckström and co-workers,
304
 a mixture of 
AIBN (328 mg, 2.00 mmol, 1 mol%), N-bromosuccinimide (24.89 g, 0.14 mol, 
0.7 eq.) and methyl crotonate (20.00 g, 0.20 mol, 1.0 eq.) in dichloroethane (100 mL) 
was heated under reflux for 16 hours. The mixture was cooled to room temperature 
and concentrated under reduced pressure to afford a yellow liquid. The liquid was 
subjected to column chromatography. Elution with 10% ethyl acetate/light petroleum 
gave compound 94 as a colourless oil (23.96 g, 67%). The spectroscopic data 




H NMR (400 MHz, CDCl3): δ 6.84 (1 H, m), 5.89 (1 H, d, J = 15.4 Hz), 3.90 (2 H, 
d, J = 7.4 Hz), 3.58 (3 H, s) ppm.  
9.2.4  Preparation of the phosphonium salt 88 
       
Adapting the procedure from Graden and co-workers,
305
 a solution of the bromide 94 
(2.67 g, 14.92 mmol, 1.0 eq.) and triphenylphosphine (3.91 g, 14.92 mmol, 1.0 eq.) 
in toluene (30 mL) was heated under reflux for 2 hours. The reaction mixture was 
filtered and the precipitate was washed with light petroleum (3 x 10 mL) and dried 
under vacuum to afford the phosphonium salt 88 as a white solid (6.12 g, 93%); m.p. 
180−182 
o









H NMR (400 MHz, DMSO): δ 7.93 (3 H, m), 7.79 (12 H, m), 6.65 (1 H, m), 6.12 






9.2.5  Wittig reaction with the lactol 87 and the phosphonium salt 88 
          
n-BuLi (1.6 M in hexanes, 0.91 mL, 1.45 mmol, 1.0 eq.) was added dropwise to the 
phosphonium salt 88 (640 mg, 1.45 mmol, 1.0 eq.) in anhydrous tetrahydrofuran 
(15 mL) at 0 
o
C. The reaction mixture was stirred at 0 
o
C for 20 minutes, then 
allowed to warm to room temperature and stirred for a further 10 minutes. A solution 
of the lactol 87 (197 mg, 1.45 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (2 mL) 
was added dropwise over 10 minutes and the mixture was stirred at room 
temperature for 16 hours. The mixture was concentrated under reduced pressure to 
afford an orange solid. The solid was subjected to column chromatography. Elution 
with 50% ethyl acetate/light petroleum gave the benzodiene as a colourless oil 
(123 mg, 39%). The oil was dissolved in anhydrous dichloromethane (10 mL) and 
reacted with activated manganese dioxide (492 mg, 5.66 mmol, 10.0 eq.) at room 
temperature for 24 hours. The resulting mixture was filtered and the filtrate 
concentrated under reduced pressure to give a yellow liquid. The liquid was 
subjected to column chromatography and the column was conditioned with 
triethylamine (1%). Elution with 20% ethyl acetate/light petroleum afforded the 
aldehyde 83 as a yellow oil (93 mg, 76%).      
1
H NMR (400 MHz, CDCl3): δ 10.21 (1 H, s), 7.85 (1 H, d, J = 15.5 Hz), 7.80 (1 H, 
d, J = 7.6 Hz), 7.64 (1 H, d, J = 7.6 Hz), 7.56 (1 H, m), 7.49 (1 H, dd, J = 
11.1, 15.4 Hz), 7.46 (1 H, m), 6.81 (1 H, dd, J = 11.1, 15.5 Hz), 6.02 (1 H, d, J = 
15.4 Hz), 3.77 (3 H, s) ppm; 
13
C NMR (100 MHz, CDCl3): CH), 167.2 (C), 
144.4 (CH), 138.0 (C), 136.5 (CH), 133.8 (CH), 133.2 (CH), 133.2 (C), 130.8 (CH), 
128.9 (CH), 127.3 (CH), 122.6 (CH), 51.7 (CH3) ppm; ATR-FTIR: 1694 (aldehyde 
and ester: C=O) cm
-1
; HRMS (ASAP): [M
+








9.2.6  Addition of ethylmagnesium bromide to the aldehyde 83 
               
 
Ethylmagnesium bromide (1 M, 0.42 mL, 0.42 mmol, 1.0 eq.) was added dropwise 
to a solution of the aldehyde 83 (90 mg, 0.42 mmol, 1.0 eq.) in anhydrous 
tetrahydrofuran (3 mL) at −45 
o
C. The reaction mixture was allowed to warm to 
room temperature and stirred for 16 hours. The reaction was quenched with a 
saturated aqueous solution of NH4Cl (4 mL) and the mixture stirred for 30 minutes. 
The reaction mixture was diluted with ether (30 mL), washed with deionised water 
(2 x 20 mL), dried and concentrated under reduced pressure to give a light brown 
liquid. The liquid was subjected to column chromatography. Elution with 30% ethyl 
acetate/light petroleum afforded the alcohol 96 as a colourless oil (52 mg, 51%). 
1
H NMR (400 MHz, CDCl3): δ 7.51 (3 H, m), 7.29 (3 H, m), 6.78 (1 H, dd, J = 11.1, 
15.3 Hz), 5.99 (1 H, d, J = 15.3 Hz), 4.94 (1 H, t, J = 6.3 Hz), 3.77 (3 H, s), 1.98 (1 
H, br. s), 1.77 (2 H, m), 0.95 (3 H, t, J = 7.4 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): 
C), 145.1 (CH), 142.7 (C), 137.6 (CH), 133.9 (C), 129.2 (CH), 128.3 (CH), 
127.7 (CH), 126.3 (CH), 126.3 (CH), 121.2 (CH), 72.6 (CH), 51.8 (CH3), 31.7 





] C15 H18O3 requires 247.1334; found: 247.1333. 
9.2.7  Acid-catalysed reaction of pinacol and 2,3-dihydrofuran 
 
Adapting the procedure from Stowell and Polito,
201
 a solution of 2,3-dihydrofuran 
(10.05 g, 0.14 mol, 1.0 eq.), HCl (32% w/v, 3.26 mL) and deionised water (32 mL) 
was stirred at room temperature for 1 hour. Pinacol (20.33 g, 0.17 mol, 1.2 eq.) was 
dissolved in warm deionised water (72 mL), added dropwise and the solution was 
heated at 70 
o
C for 15 hours. Phenolphthalein indicator (0.5 mL) was added and the 




with ether (100 mL), dried and concentrated under reduced pressure to afford a pink 
oil. The oil was subjected to column chromatography and the column was 
conditioned with triethylamine (1%). Elution with 50% ethyl acetate/light petroleum 
afforded compound 98 as a yellow oil (17.55 g, 65%). The spectroscopic data 
matched that provided by Stowell and Polito.
201
      
1
H NMR (400 MHz, CDCl3): δ 4.97 (1 H, t, J = 4.4 Hz), 3.54 (2 H, t, J = 5.4 Hz), 
2.96 (1 H, br. s), 1.59 (4 H, m), 1.10 (12 H, s) ppm.  
9.2.8  Treatment of the alcohol 98 with thionyl chloride  
 
Thionyl chloride (2.53 g, 1.54 mL, 0.02 mol, 1.0 eq.) was added dropwise to the 
alcohol 98 (4.00 g, 0.02 mol, 1.0 eq.) and triethylamine (2.15 g, 0.02 mol, 1.1 eq.) in 
toluene (55 mL) at 0 
o
C. The solution was then heated under reflux and stirred for 
1 hour. The reaction mixture was diluted with ether (60 mL), washed with deionised 
water (3 x 30 mL), dried and concentrated under reduced pressure to afford a yellow 
liquid. The liquid was subjected to column chromatography and the column was 
conditioned with triethylamine (1%). Elution with 10% ethyl acetate/light petroleum 
afforded compound 99 as a yellow oil (2.37 g, 54%).  
1
H NMR (400 MHz, CDCl3): δ
 
5.06 (1 H, t, J = 5.0 Hz), 3.58 (2 H, t, J = 6.7 Hz), 
1.88 (2 H, m), 1.74 (2 H, m), 1.19 (12 H, s) ppm; 
13
C NMR (100 MHz, CDCl3): 
CH), 81.8 (C), 45.1 (CH2), 33.7 (CH2), 27.8 (CH2), 24.4 (CH3), 22.2 (CH3) 
ppm; HRMS (ASAP): [M
+
] C10 H19ClO2 requires 207.0941; found: 207.0941.  
9.2.9  Preparation of the Grignard reagent 82 
 
A solution of compound 99 (1.16 g, 5.61 mmol, 1.0 eq.) and magnesium turnings 
(0.38 g, 15.71 mmol, 2.8 eq.) in anhydrous tetrahydrofuran (1 mL) was stirred at 




0.2 eq.) over 5 minutes. The solution was cooled to 0 
o
C upon initiation, diluted with 
anhydrous tetrahydrofuran (5 mL) and stirred at this temperature for 19 hours. After 
this time, the Grignard reagent 82 was afforded in 79% yield. The concentration of 
the Grignard was 0.79 M, as determined by titration with BHT and 1,10-
phenanthroline. 




The Grignard reagent 82 (0.79 M, 1.19 mL, 0.94 mmol, 1.0 eq.) was added dropwise 
to benzaldehyde (100 mg, 0.94 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (2 mL) 
at −84 
o
C and the mixture was stirred for 6 hours. The reaction was quenched with a 
saturated aqueous solution of NH4Cl (4 mL) and stirred for 30 minutes. The reaction 
mixture was diluted with dichloromethane (50 mL), washed with deionised water (2 
x 20 mL), dried and concentrated under reduced pressure to afford a yellow liquid. 
The liquid was subjected to column chromatography and the column was 
conditioned with triethylamine (1%). Elution with 40% ethyl acetate/light petroleum 
afforded compound 102 as a colourless oil (165 mg, 63%).  
1
H NMR (400 MHz, CDCl3): δ 7.23 (4 H, m), 7.22 (1 H, m), 4.96 (1 H, t, J = 
5.0 Hz), 4.60 (1 H, dd, J = 5.6, 7.6 Hz), 1.96 (1 H, br. s), 1.70 (2 H, m), 1.56 (2 H, 
m), 1.49 (1 H, m), 1.34 (1 H, m), 1.12 (12 H, s) ppm; 
13
C NMR (100 MHz, CDCl3): 
C), 128.5 (CH), 127.6 (CH), 126.0 (CH), 100.9 (CH), 81.8 (C), 81.8 (C), 
74.5 (CH), 39.1 (CH2), 36.2 (CH2), 24.4 (CH3), 22.2 (CH3), 21.0 (CH2) ppm; ATR-
FTIR: 3446 (OH) cm
-1
; HRMS (ASAP): [M
+





9.2.11  Addition of the Grignard reagent 82 to compound 83  
 
      
 
The Grignard reagent 82 (0.79 M, 1.00 mL, 0.79 mmol, 1.0 eq.) was added dropwise 
to the aldehyde 83 (170 mg, 0.79 mmol, 1.0 eq.) in anhydrous tetrahydrofuran 
(2 mL) at −84 
o
C and the mixture was stirred for 5 hours. The reaction was quenched 
with a saturated aqueous solution of NH4Cl (4 mL) and stirred for 30 minutes. The 
reaction mixture was diluted with dichloromethane (30 mL), washed with deionised 
water (2 x 20 mL), dried and concentrated under reduced pressure to afford a yellow 
liquid. The liquid was subjected to column chromatography and the column was 
conditioned with triethylamine (1%). Elution with 30% ethyl acetate/light petroleum 
afforded the alcohol 103 as a yellow oil (98 mg, 32%). 
1
H NMR (400 MHz, CDCl3): δ 7.42 (3 H, m), 7.22 (3 H, m), 6.72 (1 H, dd, J = 11.1, 
15.3 Hz), 5.92 (1 H, d, J = 15.3 Hz), 4.95 (2 H, m), 3.70 (3 H, s), 2.13 (1 H, br. s), 
1.69 (4 H, m), 1.54 (2 H, m), 1.10 (12 H, s) ppm; 
13
C NMR (100 MHz, CDCl3): 
167.6 (C), 145.1 (CH), 142.9 (C), 137.5 (CH), 133.7 (C), 129.2 (CH), 128.3 (CH), 
127.6 (CH), 126.3 (CH), 121.2 (CH), 100.8 (CH), 81.9 (C), 81.8 (C), 71.1 (CH), 
51.7 (CH3), 38.6 (CH2), 36.0 (CH2), 24.4 (CH3), 22.2 (CH3), 21.0 (CH2) ppm; ATR-
FTIR: 3455 (OH) and 1715 (C=O) cm
-1
; HRMS (ASAP): [M
+
] C23 H32O5 requires 








9.2.12  Synthesis of 3-bromopropargyl alcohol  
 
 
Adapting the procedure by Gjorstrup,
204
 propargyl alcohol (3.26 g, 0.06 mol, 1.0 eq.) 
was added dropwise to a solution of N-bromosuccinimide (11.18 g, 0.06 mol, 
1.08 eq.) and silver nitrate (0.99 g, 5.81 mmol, 0.1 eq.) in acetone (100 mL) at 0 
o
C. 
The reaction mixture was allowed to warm to room temperature and stirred for 
3 hours. The mixture was diluted with ether (3 x 40 mL), washed with deionised 
water (2 x 50 mL), dried and concentrated under reduced pressure to afford a 
colourless oil. The oil was subjected to column chromatography. Elution with 30% 
ethyl acetate/light petroleum gave 3-bromopropargyl alcohol 105 as a colourless oil 
(7.14 g, 91%). The 
1




H NMR (400 MHz, CDCl3): δ 4.24 (2 H, s), 2.80 (1 H, br. s) ppm. 
9.2.13  Heck reaction with methyl vinyl ketone and compound 111  
 
 
A mixture of the bromide 111 (610 mg, 2.78 mmol, 1.0 eq.), methyl vinyl ketone 
(1.95 g, 27.84 mmol, 10.0 eq.), potassium carbonate (962 mg, 6.96 mmol, 2.5 eq.), 
Pd(OAc)2 (31 mg, 0.14 mmol, 5 mol%) and BHT (1 crystal) was heated at 80 
o
C in 
anhydrous dimethylformamide (5 mL) for 2 hours. The resulting mixture was 
filtered. The filtrate was diluted with ether (50 mL), washed with aqueous CuSO4 (2 
x 30 mL), washed with deionised water (30 mL) and dried. The ethereal layer was 
concentrated under reduced pressure to give a dark, brown liquid. The liquid was 
subjected to column chromatography. The column was conditioned with 
triethylamine (1%). Elution with 30% ethyl acetate/light petroleum afforded the 
ketone 112 as a yellow oil (93 mg, 16%). 
1
H NMR (400 MHz, CDCl3): δ 6.59 (1 H, t, J = 1.9, 16.2 Hz), 6.46 (1 H, d, J = 




J = 1.9, 16.4 Hz), 3.82 (1 H, m), 3.54 (1 H, m), 2.24 (3 H, s), 1.82 (3 H, m), 1.61 (2 
H, m), 1.54 (1 H, m) ppm; 
13
C NMR (100 MHz, CDCl3): 197.0C), 138.5 (CH), 
123.3 (CH), 97.2 (CH), 96.0 (C), 83.1 (C), 62.1 (CH2), 54.7 (CH2), 30.3 (CH2), 27.7 
(CH3), 25.4 (CH2), 19.0 (CH2) ppm; ATR-FTIR: 1678 (C=O) cm
-1
; HRMS 
(ASAP): Molecular ion not found. 
9.2.14  Heck reaction with methyl vinyl ketone and compound 113 
 
 
A mixture of the bromide 113 (330 mg, 1.38 mmol, 1.0 eq.), methyl vinyl ketone 
(968 mg, 13.80 mmol, 10.0 eq.), potassium carbonate (477 mg, 3.45 mmol, 2.5 eq.), 
Pd(OAc)2 (16 mg, 0.07 mmol, 5 mol%) and BHT (1 crystal) was heated at 80 
o
C in 
anhydrous dimethylformamide (5 mL) for 2 hours. The resulting mixture was 
filtered. The filtrate was diluted with ether (25 mL), washed with aqueous CuSO4 (2 
x 15 mL), washed with deionised water (15 mL) and dried. The ethereal layer was 
concentrated under reduced pressure to give a dark, brown liquid. The liquid was 
subjected to column chromatography. Elution with 30% ethyl acetate/light petroleum 
afforded the ketone 114 as a yellow oil (72 mg, 23%).  
1
H NMR (400 MHz, CDCl3): δ 8.06 (2 H, d, J = 7.8 Hz), 7.59 (1 H, t, J = 7.9 Hz), 
7.46 (2 H, dd, J = 7.8, 7.9 Hz), 6.63 (1 H, dd, J = 1.9, 16.2 Hz), 6.52 (1 H, d, J = 
16.2 Hz), 5.09 (2 H, d, J = 1.9 Hz), 2.26 (3 H, s) ppm; 
13
C NMR (100 MHz, CDCl3): 
δ 196.9 (C), 165.9 (C), 139.1 (CH), 133.6 (CH), 130.0 (CH), 129.4 (C), 128.6 (CH), 
122.7 (CH), 93.3 (C), 83.7 (C), 53.1 (CH2), 27.9 (CH3) ppm; ATR-FTIR: 1724 
(ester C=O), 1677 (ketone C=O) cm
-1
; HRMS (ASAP): Molecular ion not found. 




Following the procedure by Brandsma,
205
 a mixture of propargyl alcohol (28.00 g, 




0.8 eq.) in water (65 mL) was stirred at room temperature for 22 hours under a 
constant supply of air. HCl (32% w/v, 6 mL) was then added dropwise to dissolve 
the Cu(OH)Cl solution and the mixture was stirred at room temperature for an 
additional 10 minutes. The reaction mixture was diluted with dichloromethane (4 x 
80 mL) and washed with deionised water (2 x 10 mL). The organic layer was dried 
and the solvent removed under reduced pressure to afford a brown solid. The solid 
was recrystallised from chloroform/ethyl acetate to give the diol 115 as white 
needles (13.75 g, 25%); m.p. 107–108 
o











H NMR (400 MHz, DMSO): δ 5.39 (2 H, t, J = 2.4 Hz), 4.18 (4 H, d, J = 2.4 Hz) 
ppm. 
9.2.16  Monosilylation of 2,4-hexadiyne-1,6-diol  
               
              
 
Following the procedure by Trost and Livingston,
208
 60% NaH in mineral oil 
(1.16 g, 27.25 mmol, 1.0 eq.) was added in small portions to the diol 115 (3.00 g, 
27.25 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (60 mL) at 0 ˚C. The reaction 
mixture was allowed to warm to room temperature and stirred for 2 hours upon 
which TBSCl (4.11 g, 27.25 mmol, 1.0 eq.) was added in small portions. The 
mixture was stirred for a further 3 hours, then quenched with methanol (6 mL). The 
reaction mixture was diluted with ether (4 x 50 mL), washed with deionised water (2 
x 50 mL), dried and concentrated under reduced pressure to afford a yellow liquid. 
The liquid was subjected to column chromatography and the column was 
conditioned with triethylamine (1%). Elution with 40% ethyl acetate/light petroleum 
gave compound 116 as a yellow liquid (4.28 g, 70%). The spectroscopic data 
matched that reported by Trost and Livingston.
208
                
1
H NMR (400 MHz, CDCl3): δ 4.38 (2 H, s), 4.34 (2 H, s), 1.78 (1 H, br. s), 0.90 (9 






9.2.17  Preparation of the aldehyde 118 
 
 
Adapting the procedure by Trost and Livingston,
208
 LiAlH4 (213 mg, 5.62 mmol, 
1.0 eq.) was added in small portions to the alcohol 116 (1.26 g, 5.62 mmol, 1.0 eq.) 
in anhydrous tetrahydrofuran (12 mL) at 0 
o
C. The reaction mixture was allowed to 
warm to room temperature and stirred for 2 hours. The reaction was quenched with a 
saturated aqueous solution of sodium sulfate (3 mL) and ethyl acetate (4 mL) and the 
resulting precipitate was removed by filtration. The filtrate was diluted with ether 
(3 x 40 mL), washed with deionised water (40 mL), dried and concentrated under 
reduced pressure to afford the alcohol 117 as a yellow oil (1.03 g, 85%). The crude 
oil was then taken up in anhydrous dichloromethane (30 mL) and stirred at room 
temperature with activated manganese dioxide (3.95 g, 45.49 mmol, 10.0 eq.) for 
three and a half days. The reaction mixture was filtered and the filtrate was 
concentrated under reduced pressure to give the aldehyde 118 as a yellow oil (0.87 g, 
85%). The 
1
H NMR spectrum matched the spectrum of the aldehyde 118 provided 




H NMR (400 MHz, CDCl3): δ 9.53 (1 H, d, J = 7.7 Hz), 6.72 (1 H, d, J = 15.9 Hz), 
6.43 (1 H, dd, J = 7.7, 15.9 Hz), 4.50 (2 H, s), 0.89 (9 H, s), 0.11 (6 H, s) ppm. 
9.2.18  Addition of ethylmagnesium bromide to the aldehyde 118 
 
 
Ethylmagnesium bromide (0.82 M, 2.63 mL, 2.15 mmol, 2.3 eq.) was added 
dropwise to the aldehyde 118 (210 mg, 0.94 mmol, 1.0 eq.) in anhydrous 
tetrahydrofuran (5 mL) at −45 
o
C and the mixture was stirred for 30 minutes. The 
reaction mixture was allowed to warm to room temperature and stirred for a further 
four and a half hours. A saturated aqueous solution of NH4Cl (3 mL) was then added 
dropwise at 0 
o
C and the mixture was stirred for 30 minutes. The reaction mixture 




concentrated under reduced pressure to afford an orange liquid. The liquid was 
subjected to radial chromatography and the column was conditioned with 
triethylamine (1%). Elution with light petroleum gave the alcohol 119 as a yellow 




H NMR (400 MHz, CDCl3): δ 6.10 (1 H, dd, J = 6.1, 15.9 Hz), 5.71 (1 H, d, J = 
15.9 Hz), 4.40 (2 H, s), 4.07 (1 H, m), 1.83 (1 H, br. s), 1.55 (2 H, m), 0.94 (3 H, t, 
J = 7.4 Hz), 0.90 (9 H, s), 0.12 (6 H, s) ppm; 
13
C NMR (100 MHz, CDCl3): 145.6 
CH), 109.8 (CH), 88.6 (C), 82.9 (C), 73.7 (CH), 52.3 (CH2), 30.0 (CH2), 26.0 
(CH3), 18.5 (C), 9.6 (CH3), −5.0 (CH3) ppm; ATR-FTIR: 3398 (OH) cm
-1
; 
Elemental Analysis: Found: C, 66.09%; H, 10.35%. C14H26O4Si calculated C, 
66.09%; H, 10.30%). 




A mixture of the alcohol 119 (770 mg, 3.03 mmol, 1.0 eq.), imidazole (412 mg, 
6.05 mmol, 2.0 eq.), TBDPSCl (998 mg, 3.63 mmol, 1.2 eq.) and DMAP (37 mg, 
0.30 mmol, 0.1 eq.) was stirred in anhydrous dichloromethane (30 mL) at room 
temperature for 21 hours. The reaction mixture was diluted with ether (50 mL), 
washed with deionised water (30 mL), dried and concentrated under reduced 
pressure to give a colourless liquid. The liquid was subjected to column 
chromatography and the column was conditioned with triethylamine (1%). Elution 
with light petroleum afforded compound 120 as a colourless oil (1.13 g, 76%).  
1
H NMR (400 MHz, CDCl3): δ 7.63 (4 H, m), 7.38 (6 H, m), 6.05 (1 H, dd, J = 6.0, 
15.9 Hz), 5.55 (1 H, d, J = 15.9 Hz), 4.52 (2 H, s), 4.16 (1 H, m), 1.46 (2 H, m), 1.07 
(9 H, s), 0.92 (9 H, s), 0.76 (3 H, t, J = 7.4 Hz), 0.13 (6 H, s) ppm; 
13
C NMR 
(100 MHz, CDCl3): CH), 136.0 (CH), 134.7 (C), 134.0 (C), 129.8 (CH), 
127.7 (CH), 109.3 (CH), 88.1 (C), 83.4 (C), 74.5 (CH), 52.7 (CH2), 30.5 (CH2), 27.2 
(CH3), 26.0 (CH3), 19.5 (C), 18.5 (C), 8.7 (CH3), −4.9 (CH3) ppm; HRMS (ASAP): 
[M
+




9.2.20  Synthesis of the alcohol 121  
                     
 
A mixture of compound 120 (850 mg, 1.72 mmol, 1.0 eq.) and CSA (5 mg, 0.02 
mmol) in ethanol (20 mL) was stirred at room temperature for 12 hours. The reaction 
mixture was diluted with ether (40 mL), washed with deionised water (2 x 30 mL), 
dried and concentrated under reduced pressure to give a yellow liquid. The liquid 
was subjected to column chromatography and the column was conditioned with 
triethylamine (1%). Elution with 30% ethyl acetate/light petroleum afforded the 
alcohol 121 as a colourless oil (620 mg, 95%).  
1
H NMR (400 MHz, CDCl3): δ 7.65 (4 H, m), 7.39 (6 H, m), 6.10 (1 H, dd, J = 5.8, 
15.9 Hz), 5.59 (1 H, d, J = 15.9 Hz), 4.37 (2 H, s), 4.19 (1 H, m), 1.69 (1 H, br. s), 
1.46 (2 H, m), 1.08 (9 H, s), 0.77 (3 H, t, J = 7.4 Hz) ppm; 
13
C NMR (100 MHz, 
CDCl3): CH), 136.0 (CH), 134.3 (C), 133.9 (C), 129.8 (CH), 127.7 (CH), 
108.9 (CH), 87.4 (C), 84.3 (C), 74.4 (CH), 51.8 (CH2), 30.14 (CH2), 27.2 (CH3), 
19.5 (C), 8.6 (CH3) ppm; ATR-FTIR: 3402 (OH) cm
-1
; HRMS (ESI): 
[M+23 (Na)]
+ 
C36H60O2Si3 requires 401.1913; found: 401.1926. 
9.2.21  Hydrosilylation of compound 121 
 
 
A mixture of the alcohol 121 (81 mg, 0.21 mmol, 1.0 eq.), triethylsilane (27 mg, 




tetrahydrofuran (1 mL) was stirred at room temperature for 15 hours. The reaction 
mixture was diluted with ether (5 mL), washed with deionised water (5 mL), dried 
and concentrated under reduced pressure to give a yellow liquid. The liquid was 
subjected to column chromatography and the column was conditioned with 
triethylamine (1%). Elution with light petroleum afforded a colourless oil that was a 
65:35 mixture of the α and β-isomers of 125 respectively (83 mg, 78%).  
1
H NMR (400 MHz, CDCl3): Key signals δ 6.26 (1 H, dd, J = 11.0, 14.6 Hz α-
isomer), 6.21 (1 H, d, J = 11.0 Hz α-isomer), 6.03 (1 H, d, J = 15.9 Hz β-isomer), 
5.81 (1 H, t, J = 5.8 Hz β-isomer), 5.68 (1 H, dd, J = 6.8, 14.6 Hz α-isomer), 5.50 (1 
H, dd, J = 6.8, 15.9 Hz β-isomer) ppm; ATR-FTIR: 3401 (OH) cm
-1
; HRMS (ESI): 
[M+23 (Na)]
+
 C30H46O2Si2 requires 517.2934; found: 517.2941.  
9.2.22  Synthesis of compound 122 via an Appel reaction 
 
 
Triphenylphosphine (386 mg, 1.47 mmol, 0.9 eq.) and N-bromosuccinimide 
(321 mg, 1.80 mmol, 1.1 eq.) were added to the alcohol 121 (620 mg, 1.64 mmol, 
1.0 eq.) in anhydrous dichloromethane (20 mL) at 0 
o
C. The reaction mixture was 
allowed to warm to room temperature and stirred for 8 hours. The mixture was 
diluted with dichloromethane (20 mL) and washed with deionised water (3 x 20 mL). 
The organic layer was dried and concentrated under reduced pressure to afford a 
yellow solid. The solid was subjected to radial chromatography and the column was 
conditioned with triethylamine (1%). Elution with light petroleum afforded 
compound 122 as colourless oil (376 mg, 52%). 
1
H NMR (400 MHz, CDCl3): δ 7.66 (4 H, m), 7.39 (6 H, m), 6.11 (1 H, dd, J = 5.6, 
15.9 Hz), 5.58 (1 H, d, J = 15.9 Hz), 4.20 (1 H, m), 4.06 (2 H, s), 1.44 (2 H, m), 1.07 
(9 H, s), 0.76 (3 H, t, J = 7.4 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): CH), 
136.0 (CH), 134.3 (C), 133.9 (C), 129.8 (CH), 127.7 (CH), 108.6 (CH), 85.4 (C), 
84.3 (C), 74.3 (CH), 30.1 (CH2), 27.2 (CH3), 19.5 (C), 15.7 (CH2), 8.6 (CH3) ppm; 
HRMS (ASAP): [M
+




9.3  Chapter 3 experimental procedures 
 
9.3.1  Silylation of 1-pentyn-3-ol  
 
A mixture of 1-pentyn-3-ol (500 mg, 5.94 mmol, 1.0 eq.), imidazole (607 mg, 
8.92 mmol, 1.5 eq.) and DMAP (73 mg, 0.59 mmol, 0.1 eq.) in anhydrous 
dimethylformamide (7 mL) was stirred at 0 
o
C for 10 minutes. TBSCl (940 mg, 
6.12 mmol, 1.0 eq.) was added in portions and the mixture was allowed to warm to 
room temperature and stirred for 23 hours. The reaction mixture was diluted with 
ether (10 mL), washed with an aqueous CuSO4 solution (2 mL) and washed with 
deionised water (2 x 10 mL). The organic layer was dried and concentrated under 
reduced pressure to give a colourless liquid. The liquid was subjected to column 
chromatography and the column was conditioned with triethylamine (1%). Elution 
with light petroleum afforded compound 139 as a colourless oil (1.13 g, 96%). The 




H NMR (400 MHz, CDCl3): δ 4.27 (1 H, t, J = 6.3 Hz), 2.35 (1 H, s), 1.68 (2 H, 
m), 0.96 (3 H, t, J = 7.4 Hz), 0.89 (9 H, s), 0.12 (3 H, s), 0.10 (3 H, s) ppm.  
9.3.2  Hydrostannation of the alkyne 139  
 
 
Following a similar procedure to Zhang et al.,
306
 Pd(PPh3)2Cl2 (42 mg, 0.06 mmol, 
2 mol%) was added in one portion to the alkyne 139 (600 mg, 3.02 mmol, 1.0 eq.) in 
anhydrous tetrahydrofuran (9 mL) at 0 
o
C. The reaction mixture was stirred for 
5 minutes at 0 
o
C, treated with tributyltin hydride (968 mg, 3.33 mmol, 1.1 eq.) and 
stirred for a further 10 minutes. The reaction mixture was concentrated under 
reduced pressure to afford a brown oil. The oil was subjected to column 
chromatography and the column was conditioned with triethylamine (1%). Elution 
with light petroleum afforded the stannane 137 as a colourless oil (1.01 g, 68%). The 







H NMR (400 MHz, CDCl3): δ 6.03 (1 H, d, J = 19.1 Hz), 5.90 (1 H, dd, J = 5.7, 
19.1 Hz), 3.96 (1 H, m), 1.47−1.52 (10 H, m), 1.25−1.36 (7 H, m), 0.86−0.94 (24 H, 
m), 0.05 (3 H, s), 0.04 (3 H, s) ppm.  




Iodine (214 mg, 1.69 mmol, 1.1 eq.) was added in one portion to compound 137 
(750 mg, 1.53 mmol, 1.0 eq.) in anhydrous ether (10 mL) at 0 
o
C. The mixture was 
allowed to warm to room temperature over 22 hours. The reaction mixture was 
washed with a solution of sodium metabisulfite (5% aq., 2 mL) and deionised water 
(2 x 10 mL) and then dried. The solvent was removed under reduced pressure to give 
a colourless liquid. The liquid was subjected to column chromatography and the 
column was conditioned with triethylamine (1%). Elution with light petroleum 
afforded rac-28 as a colourless oil (405 mg, 81%). The spectroscopic data matched 
that reported in the literature.
211  
1
H NMR (400 MHz, CDCl3): δ 6.51 (1 H, dd, J = 5.9, 14.4 Hz), 6.19 (1 H, d, J = 
14.4 Hz), 4.02 (1 H, m), 1.50 (2 H, m), 0.90 (9 H, s), 0.89 (3 H, t, J = 7.4 Hz), 0.05 
(3 H, s), 0.04 (3 H, s) ppm.  
9.3.4  Deprotection of rac-28 
 
 
A mixture of rac-28 (160 mg, 0.49 mmol, 1.0 eq.) and CSA (1 mg, 5.70 µmol) in 
ethanol (3 mL) was stirred at room temperature for 24 hours. The reaction mixture 
was washed with a solution of sodium bicarbonate (5% aq., 5 mL) and deionised 
water (2 x 10 mL) and then dried. The solvent was removed under reduced pressure 
to give rac-68 as a colourless liquid (77 mg, 74%). The 1H NMR spectrum matched 
the spectroscopic data provided by Amin and co-workers.
185





H NMR (400 MHz, CDCl3): δ 6.56 (1 H, dd, J = 6.3, 14.5 Hz), 6.33 (1 H, d, J = 
14.5 Hz), 4.01 (1 H, m), 2.17 (1 H, br. s), 1.54 (2 H, m), 0.92 (3 H, t, J = 7.4 Hz) 
ppm.  
9.3.5  Oxidation of rac-68 
 
 
Activated manganese dioxide (3.12 g, 35.84 mmol, 10.0 eq.) was added in one 
portion to rac-68 (760 mg, 3.58 mmol, 1.0 eq.) in anhydrous dichloromethane 
(15 mL). The reaction mixture was stirred at room temperature for 32 hours. The 
mixture was filtered and the filtrate concentrated under reduced pressure to give a 
yellow liquid. The liquid was subjected to column chromatography. Elution with 
30% ethyl acetate/light petroleum afforded the ketone 79 as a yellow oil (565 mg, 




H NMR (400 MHz, CDCl3): δ 7.81 (1 H, d, J = 15.0 Hz), 7.17 (1 H, d, J = 
15.0 Hz), 2.54 (2 H, q, J = 7.3 Hz), 1.10 (3 H, t, J = 7.3 Hz) ppm.  
9.3.6  Asymmetric reduction of the ketone 79 
 
 
(S)-(-)-2-Methyl-CBS-oxazaborolidine (16 mg, 0.06 mmol, 10 mol%) was added to a 
solution of BH3•DMS (26 mg, 32.52 µL, 0.34 mmol, 0.6 eq.) in anhydrous 
tetrahydrofuran (1 mL) at room temperature and stirred for 15 minutes. The solution 
was cooled to 0 
o
C and the ketone 79 (120 mg, 0.57 mmol, 1.0 eq.) in anhydrous 
tetrahydrofuran (2 mL) was added dropwise over 2 hours. The reaction mixture was 
stirred at 0 
o
C for a further hour. Methanol (2 mL) and a saturated aqueous solution 
of NH4Cl (2 mL) were then added successively. The mixture was diluted with 
dichloromethane (15 mL). The organic layer was dried and concentrated under 
reduced pressure to give a colourless liquid. The liquid was subjected to column 




alcohol 68 as a colourless oil (98 mg, 81%) in 96% ee. The 
1
H NMR spectrum 




H NMR (400 MHz, CDCl3): δ 6.56 (1 H, dd, J = 6.3, 14.5 Hz), 6.33 (1 H, d, J = 




 = −0.44 (c = 1.00, CH3OH), lit. []
25
𝐷
 = −0.46 (c = 1.50, CH3OH).
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9.3.7  Silylation of the alcohol 68 
 
A mixture of the alcohol 68 (98 mg, 0.46 mmol, 1.0 eq.), imidazole (47 mg, 
0.69 mmol, 1.5 eq.) and DMAP (6 mg, 0.05 mmol, 0.1 eq.) in anhydrous 
dimethylformamide (4 mL) was stirred at 0 
o
C for 10 minutes. TBSCl (70 mg, 
0.46 mmol, 1.0 eq.) was added in small portions and the mixture was allowed to 
warm to room temperature and stirred for 24 hours. The reaction mixture was diluted 
with ether (10 mL), washed with an aqueous CuSO4 solution (2 mL) and washed 
with deionised water (2 x 10 mL). The organic layer was dried and concentrated 
under reduced pressure to give a colourless liquid. The liquid was subjected to 
column chromatography and the column was conditioned with triethylamine (1%). 
Elution with light petroleum afforded compound 28 as a colourless oil (124 mg, 





H NMR (400 MHz, CDCl3): δ 6.51 (1 H, dd, J = 5.9, 14.4 Hz), 6.19 (1 H, d, J = 
14.4 Hz), 4.02 (1 H, m), 1.50 (2 H, m), 0.90 (9 H, s), 0.89 (3 H, t, J = 7.4 Hz), 0.05 
(3 H, s), 0.04 (3 H, s) ppm.  
9.3.8  Addition of 2-methyl-3-butyn-2-ol to propionaldehyde     
 
 
Following a similar procedure to Muehlebach et al.,
307
 n-BuLi (1.6 M in hexanes, 




(1.06 g, 12.60 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (30 mL) at −84 
o
C. The 
solution was stirred for 1 hour at this temperature followed by dropwise addition of 
propionaldehyde (732 mg, 12.60 mmol, 1.0 eq.). The reaction mixture was allowed 
to warm to room temperature over two and a half hours. A saturated aqueous 
solution of NH4Cl (10 mL) was then added in one portion. The mixture was diluted 
with ethyl acetate (50 mL) and washed with deionised water (3 x 10 mL). The 
organic layer was dried and concentrated under reduced pressure to give a colourless 
liquid. The liquid was subjected to column chromatography. Elution with 70% ethyl 
acetate/light petroleum afforded rac-142 as a colourless oil (1.13 g, 63%). The oil 
was diluted with anhydrous dichloromethane (60 mL) and stirred with activated 
manganese dioxide (6.90 g, 0.08 mol, 10.0 eq.) at room temperature for 3 days. The 
reaction mixture was filtered and the filtrate concentrated under reduced pressure to 
give a yellow liquid. The liquid was subjected to column chromatography. Elution 
with 30% ethyl acetate/light petroleum afforded the ketone 145 as a yellow oil 
(779 mg, 70%). The spectroscopic data matched that reported in the literature.
217
                
1
H NMR (400 MHz, CDCl3): δ 3.39 (1 H, br. s), 2.51 (2 H, q, J = 7.4 Hz), 1.50 (6 H, 
s), 1.07 (3 H, t, J = 7.4 Hz) ppm. 
9.3.9  Asymmetric reduction of the ketone 145 
 
 
(S)-(-)-2-Methyl-CBS-oxazaborolidine (119 mg, 0.43 mmol, 10 mol%) was added to 
a solution of BH3•DMS (650 mg, 0.81 mL, 8.56 mmol, 2.0 eq.) in anhydrous 
tetrahydrofuran (10 mL) and stirred at room temperature for 15 minutes. The 
solution was cooled to 0 
o
C and the ketone 145 (600 mg, 4.28 mmol, 1.0 eq.) in 
anhydrous tetrahydrofuran (10 mL) was added dropwise over 2 hours. The reaction 
mixture was stirred for a further hour. Methanol (6 mL) was then added at 0 
o
C 
followed by a saturated aqueous solution of NH4Cl (5 mL). The mixture was diluted 
with dichloromethane (15 mL) and the organic layer extracted. The organic layer 
was dried and the solvent removed under reduced pressure to give a colourless 




acetate/light petroleum afforded the diol 142 as a colourless oil (517 mg, 85%) in 
96% ee. The spectroscopic data matched that reported in the literature.
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1
H NMR (400 MHz, CDCl3) δ 4.33 (1 H, t, J = 6.5 Hz), 2.24 (2 H, br. s), 1.73 (2 H, 
m), 1.51 (6 H, s), 0.99 (3 H, t, J = 7.4 Hz) ppm; []
20
𝐷
 = −3.11 (c = 1.00, CH3OH). 
9.3.10  Monosilylation of the diol 142 
 
 
A mixture of the diol 142 (330 mg, 2.32 mmol, 1.0 eq.), imidazole (237 mg, 
3.48 mmol, 1.5 eq.) and DMAP (28 mg, 0.23 mmol, 0.1 eq.) in anhydrous 
dichloromethane (7 mL) was stirred for 10 minutes at 0 
o
C. TBSCl (350 mg, 
2.32 mmol, 1.0 eq.) was added in small portions and the mixture was allowed to 
warm to room temperature and stirred for 24 hours. The resulting mixture was 
diluted with ethyl acetate (10 mL), washed with an aqueous CuSO4 solution (2 mL) 
and washed with deionised water (2 x 10 mL). The organic layer was dried and 
concentrated under reduced pressure. The resulting oil was subjected to column 
chromatography and the column was conditioned with triethylamine (1%). Elution 
with 30% ethyl acetate/light petroleum afforded compound 146 as a colourless oil 
(548 mg, 92%).  
1
H NMR (400 MHz, CDCl3): δ 4.29 (1 H, t, J = 6.4 Hz), 1.89 (1 H, br. s), 1.65 (2 H, 
m), 1.50 (6 H, s), 0.94 (3 H, t, J = 7.4 Hz), 0.90 (9 H, s), 0.12 (3 H, s), 0.10 (3 H, s) 
ppm; 
13
C NMR (100 MHz, CDCl3): δ 88.7 (C), 83.9 (C), 65.3 (C), 64.3 (CH), 31.9 
(CH2), 31.6 (CH3), 31.5 (CH3), 26.0 (CH3), 18.4 (C), 9.9 (CH3), −4.3 (CH3), −4.8 
(CH3) ppm; ATR-FTIR: 3352 (OH) cm
-1
; HRMS (ASAP): [M−H2O]
+
 C14H28O2Si 
requires 239.1831; found: 239.1829; []
25
𝐷








9.3.11  Preparation of the alkyne 139  
 
 
Following the same procedure as Boyall et al.,
216
 a mixture of the alcohol 146 
(590 mg, 2.30 mmol, 1.0 eq.), K2CO3 (318 mg, 2.30 mmol, 1.0 eq.) and 18-crown-6 
(608 mg, 2.30 mmol, 1.0 eq.) in toluene (6 mL) was heated under reflux for 5 hours. 
The solvent was removed under reduced pressure and the mixture diluted with ether 
(2 mL). The ethereal solution was washed with deionised water (5 x 3 mL), dried 
and concentrated under reduced pressure. The resulting oil was subjected to column 
chromatography and the column was conditioned with triethylamine (1%). Elution 
with light petroleum afforded the alkyne 139 as a colourless oil (370 mg, 81%). The 




H NMR (400 MHz, CDCl3): δ 4.27 (1 H, t, J = 6.3 Hz), 2.35 (1 H, s), 1.68 (2 H, 






(c = 1.00, CH3Cl). 
9.3.12  Preparation of the aldehyde 151 
 
A mixture of the diol 91 (4.24 g, 30.69 mmol, 1.0 eq.), silver oxide (10.67 g, 
46.03 mmol, 1.5 eq.) and benzyl bromide (5.77 g, 33.76 mmol, 1.1 eq.) in anhydrous 
dichloromethane (100 mL) was stirred for 6 hours at room temperature. The reaction 
mixture was filtered and the solvent removed under reduced pressure to give a brown 
liquid. The liquid was subjected to column chromatography. Elution with 40% ethyl 
acetate/light petroleum afforded the alcohol 152 as a light brown oil (6.09 g, 87%). 
The oil was redissolved in anhydrous dichloromethane (180 mL). Activated 
manganese dioxide (26.68 g, 0.31 mol, 10.0 eq.) was added and the mixture was 
stirred at room temperature for 3 days. The reaction mixture was filtered and the 
solvent removed under reduced pressure to give a yellow liquid. The liquid was 




afforded the aldehyde 151 as a yellow oil (4.86 g, 70%). The 1H NMR spectrum 




H NMR (400 MHz, CDCl3): δ 10.23 (1 H, s), 7.87 (1 H, d, J = 7.6 Hz), 7.70 (1 H, 
d, J = 7.6 Hz), 7.61 (1 H, dd, J = 7.6, 7.6 Hz), 7.48 (1 H, dd, J = 7.6, 7.6 Hz), 
7.25−7.45 (5 H, m), 4.99 (2 H, s), 4.67 (2 H, s) ppm. 
 
9.3.13  Synthesis of the ester 153 
 
n-BuLi (1.6 M in hexanes, 1.66 mL, 2.65 mmol, 1.2 eq.) was added dropwise to the 
phosphonium salt 88 (1.07 g, 2.43 mmol, 1.1 eq.) in anhydrous tetrahydrofuran 
(15 mL) at 0 
o
C. The reaction mixture was stirred for 20 minutes at 0 
o
C and allowed 
to warm to room temperature over 10 minutes. Compound 151 (500 mg, 2.21 mmol, 
1.0 eq.) in anhydrous tetrahydrofuran (10 mL) was added dropwise to the solution at 
room temperature and the resulting mixture was stirred for 17 hours. The mixture 
was dried and concentrated under reduced pressure to afford an orange liquid. The 
liquid was subjected to column chromatography. Elution with 10% ethyl 
acetate/light petroleum gave an orange oil as a 1:1 mixture of 2E,4E:2E,4Z isomers 
(538 mg, 79%). The oil (538 mg, 1.75 mmol, 1.0 eq.) was then dissolved in hexane 
(285 mL) and stirred with iodine (155 mg, 1.22 mmol, 0.7 eq.) and anhydrous 
potassium carbonate (1.21 g, 8.73 mmol, 5.0 eq.) at room temperature for two and a 
half hours. The reaction mixture was filtered and the filtrate washed with a solution 
of sodium metabisulfite (5% aq., 2 x 30 mL) and deionised water (30 mL). The 
organic layer was dried and concentrated under reduced pressure to afford the 
2E,4E-isomer of 153 as a yellow oil (436 mg, 81%). The 1H NMR spectrum of the 
crude sample showed no 2E,4Z-isomer.   
1
H NMR (400 MHz, CDCl3): δ 7.61 (1 H, d, J = 6.9 Hz), 7.26−7.48 (9 H, m), 7.18 
(1 H, d, J = 15.5 Hz), 6.83 (1 H, dd, J = 11.1, 15.5 Hz), 6.00 (1 H, d, J = 15.3 Hz), 
4.59 (2 H, s), 4.50 (2 H, s), 3.80 (3 H, s) ppm; 
13




δ167.6C), 145.2 (CH), 138.0 (C), 137.7 (CH), 136.1 (C), 135.5 (C), 130.1 (CH), 
128.9 (CH), 128.6 (CH), 128.5 (CH), 128.2 (CH), 128.0 (CH), 127.9 (CH), 126.1 
(CH), 121.1 (CH), 72.5 (CH2), 70.1 (CH2), 51.7 (CH3) ppm; ATR-FTIR: 1713 
(C=O) cm
-1
; HRMS (ASAP): [M
+
] C20H20O3 requires 309.1491; found: 309.1487. 
9.3.14  Reduction of the ester 153  
 
DIBAL (1 M in toluene, 10.76 mL, 10.76 mmol, 2.1 eq.) was added dropwise to the 
ester 153 (1.58 g, 5.12 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (112 mL) at 
0 
o
C. The mixture was stirred for 2 hours while maintaining the temperature. A 
saturated aqueous solution of sodium sulfate (40 mL) was added dropwise to the 
reaction mixture, resulting in a fine suspension. The suspension was filtered and the 
filtrate was dried and concentrated under reduced pressure to give an orange liquid. 
The liquid was subjected to column chromatography. Elution with 30% ethyl 
acetate/light petroleum afforded the alcohol 154 as an orange oil (1.21 g, 84%).  
1
H NMR (400 MHz, CDCl3):δ 7.56 (1 H, d, J = 7.7 Hz), 7.22−7.44 (8 H, m), 6.85 
(1 H, d, J = 15.5 Hz), 6.72 (1 H, dd, J = 10.2, 15.5 Hz), 6.42 (1 H, dd, J = 10.2, 
15.2 Hz), 5.96 (1 H, dt, J = 5.9, 15.2 Hz), 4.60 (2 H, s), 4.57 (2 H, s), 4.25 (2 H, d, 
J = 5.9 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): δ138.3 (C), 136.6 (C), 135.2 (C), 
132.8 (CH), 132.0 (CH), 130.1 (CH), 129.8 (CH), 129.8 (CH), 128.6 (CH), 128.3 
(CH), 128.1 (CH), 127.8 (CH), 127.6 (CH), 125.7 (CH), 72.3 (CH2), 70.4 (CH2), 
63.5 (CH2) ppm; ATR-FTIR: 3385 (OH) cm
-1
; HRMS (ASAP): [M
+
] C20H19O2 
requires 280.1464; found: 280.1463.  
9.3.15  Oxidation of the alcohol 154  
 
A mixture of the alcohol 154 (1.20 g, 4.28 mmol, 1.0 eq.) and activated manganese 
dioxide (3.72 g, 42.80 mmol, 10.0 eq.) in anhydrous dichloromethane (80 mL) was 




filtrate concentrated under reduced pressure to give a yellow liquid. The liquid was 
subjected to column chromatography and the column was conditioned with 
triethylamine (1%). Elution with 20% ethyl acetate/light petroleum afforded the 
aldehyde 150 as a yellow oil (894 mg, 75%). 
1
H NMR (400 MHz, CDCl3): δ 9.50 (1 H, d, J = 7.9 Hz), 7.61 (1 H, d, J = 8.9 Hz), 
7.21−7.27 (9 H, m), 7.05 (1 H, dd, J = 10.9, 15.2 Hz), 6.81 (1 H, dd, J = 10.9, 
15.4 Hz), 6.15 (1 H, dd, J = 7.9, 15.2 Hz), 4.51 (2 H, s), 4.46 (2 H, s) ppm; 
13
C NMR (100 MHz, CDCl3):δ 193.5 (C), 152.3 (CH), 139.7 (CH), 137.9 (C), 
136.3 (C), 135.0 (C), 131.7 (CH), 130.2 (CH), 129.3 (CH), 128.5 (CH), 128.5 (CH), 
128.0 (CH), 127.9 (CH), 127.7 (CH), 126.2 (CH), 72.2 (CH2), 70.1 (CH2) ppm; 
ATR-FTIR: 1674 (C=O) cm
-1
; HRMS (ASAP): [M
+
] C19H18O2 requires 279.1385; 
found: 279.1399. 
9.3.16  Propargylation of the aldehyde 150  
 
Propargyl bromide (80% w/v in toluene, 118 mg, 0.79 mmol, 1.1 eq.) was added in 
one portion to a mixture of magnesium turnings (38 mg, 1.58 mmol, 2.0 eq.), iodine 
(5 mg, 0.04 mmol) and HgCl2 (10 mg, 0.04 mmol) in anhydrous ether (1 mL) at 
0 
o
C. The reaction mixture was stirred for 20 minutes at 0 
o
C then cooled to −17 
o
C. 
Compound 150 (200 mg, 0.72 mmol, 1.0 eq.) in anhydrous ether (4 mL) was added 
dropwise at −17 
o
C and the mixture was stirred for two and a half hours. The mixture 
was warmed to 0 
o
C and a saturated aqueous solution of NH4Cl (3 mL) was added 
dropwise. The mixture was diluted with ether (15 mL) and washed with deionised 
water (2 x 10 mL). The organic layer was dried and concentrated under reduced 
pressure to give a yellow liquid. The liquid was subjected to column chromatography 
and the column was conditioned with triethylamine (1%). Elution with 30% ethyl 
acetate/light petroleum afforded rac-149 as a yellow oil (192 mg, 84%).
  
1
H NMR (400 MHz, CDCl3): δ 7.56 (1 H, d, J = 7.7 Hz), 7.23−7.45 (8 H, m), 6.87 
(1 H, d, J = 15.5 Hz), 6.72 (1 H, dd, J = 10.4, 15.5 Hz), 6.46 (1 H, dd, J = 10.4, 




2.54 (1 H, ddd, J = 2.6, 5.5, 16.7 Hz), 2.50 (1 H, ddd, J = 2.6, 5.5, 16.7 Hz), 2.15 (1 
H, br. s), 2.10 (1 H, t, J = 2.6 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): δ 138.3 (C), 
136.5 (C), 135.2 (C), 134.2 (CH), 132.1 (CH), 130.5 (CH), 129.9 (CH), 129.8 (CH), 
128.6 (CH), 128.4 (CH), 128.1 (CH), 127.8 (CH), 127.7 (CH), 125.7 (CH), 80.4 
(CH), 72.3 (CH2), 71.2 (C), 70.5 (CH), 70.3 (CH2), 27.8 (CH2) ppm; ATR-FTIR: 
3390 (OH) cm
-1
; HRMS (ESI): [M+23 (Na)]
+
 C22H22O2 requires 341.1517; found: 
341.1514. 
9.3.17  Sonogashira reaction between rac-149 and compound 28 
 
Compound 28 (360 mg, 1.10 mmol, 1.0 eq.), Pd(PPh3)4 (89 mg, 0.08 mmol, 
7 mol%), CuI (21 mg, 0.11 mmol, 10 mol%), piperidine (188 mg, 2.21 mmol, 
2.0 eq.) and BHT (1 crystal) were added in one portion to the alkyne 149 (351 mg, 
1.10 mmol, 1.0 eq.) in degassed anhydrous toluene (1 mL) and the mixture was 
stirred for 12 hours at room temperature. The mixture was diluted with ether (10 mL) 
and washed with deionised water (3 x 10 mL). The organic layer was dried and 
concentrated under reduced pressure to give a yellow liquid. The liquid was 
subjected to column chromatography and the column was conditioned with 
triethylamine (1%). Elution with 30% ethyl acetate/light petroleum afforded 
compound 155 as a yellow oil (473 mg, 83%).  
1
H NMR (400 MHz, CDCl3): δ 7.55 (1 H, dd, J = 1.4, 7.7 Hz), 7.24−7.36 (8 H, m), 
6.85 (1 H, d, J = 15.5 Hz), 6.71 (1 H, dd, J = 10.6, 15.5 Hz), 6.46 (1 H, dd, J = 10.6, 
15.3 Hz), 6.09 (1 H, dd, J = 5.4, 15.8 Hz), 5.90 (1 H, dd, J = 6.3, 15.3 Hz), 5.65 (1 
H, dt, J = 1.6, 15.8 Hz), 4.59 (2 H, s), 4.57 (2 H, s), 4.40 (1 H, m), 4.10 (1 H, m), 




H, br. s), 1.51 (2 H, m), 0.90 (9 H, s), 0.87 (3 H, t, J = 7.5 Hz), 0.05 (6 H, s) ppm; 
13
C NMR (100 MHz, CDCl3): δ 146.2 (CH), 138.3 (C), 136.6 (C), 135.2 (C), 134.6 
(CH), 131.9 (CH), 130.3 (CH), 130.0 (CH), 129.8 (CH), 128.6 (CH), 128.4 (CH), 
128.1 (CH), 127.9 (CH), 127.7 (CH), 125.7 (CH), 108.7 (CH), 85.6 (C), 81.8 (C), 
73.7 (CH), 72.4 (CH2), 70.8 (CH), 70.3 (CH2), 30.8 (CH2), 29.0 (CH2), 26.0 (CH3), 
18.4 (C), 9.4 (CH3), −4.4 (CH3), −4.7 (CH3) ppm; ATR-FTIR: 3400 (OH) cm
-1
, 
HRMS (ESI): [M+23 (Na)]
+
 C33H44O3Si requires 539.2957; found: 539.2976. 
9.3.18  Silylation of the alcohol 154 
 
 
A mixture of the alcohol 154 (510 mg, 1.82 mmol, 1.0 eq.), imidazole (186 mg, 
2.73 mmol, 1.5 eq.) and DMAP (22 mg, 0.18 mmol, 0.1 eq.) in anhydrous 
dimethylformamide (7 mL) was stirred at 0 
o
C for 10 minutes. TBSCl (274 mg, 
0.18 mol, 1.0 eq.) was added in portions and the mixture was allowed to warm to 
room temperature and stirred for 11 hours. The reaction mixture was diluted with 
ether (15 mL), washed with an aqueous CuSO4 solution (5 mL) and washed with 
deionised water (2 x 15 mL). The organic layer was dried and concentrated under 
reduced pressure to give a yellow liquid. The liquid was subjected to column 
chromatography and the column was conditioned with triethylamine (1%). Elution 
with light petroleum afforded compound 156 as a colourless oil (639 mg, 89%). 
1
H NMR (400 MHz, CDCl3): δ 7.44 (1 H, d, J = 7.0 Hz), 7.03−7.26 (8 H, m), 6.85 
(1 H, d, J = 15.5 Hz), 6.76 (1 H, dd, J = 10.0, 15.5 Hz), 6.31 (1 H, dd, J = 10.0, 
15.1 Hz), 5.78 (1 H, dt, J = 5.2, 15.1 Hz), 4.49 (2 H, s), 4.45 (2 H, s), 4.17 (2 H, d, 
J = 5.2 Hz), 0.83 (9 H, s), 0.00 (6 H) ppm; 
13
C NMR (100 MHz, CDCl3): δ 138.4 
(C), 136.9 (C), 135.1 (C), 133.8 (CH), 130.7 (CH), 130.4 (CH), 129.7 (CH), 128.8 
(CH), 128.6 (CH), 128.3 (CH), 128.1 (CH), 127.8 (CH), 127.4 (CH), 125.7 (CH), 
72.3 (CH2), 70.4 (CH2), 63.8 (CH2), 26.1 (CH3), 18.6 (C), −5.0 (CH3) ppm; 
HRMS (ASAP): [M
+





9.3.19  Preparation of the aldehyde 166 
 
60% NaH in mineral oil (1.75 g, 43.77 mmol, 1.4 eq.) was added in portions to a 
mixture of the diol 91 (4.32 g, 31.27 mmol, 1.0 eq.) and NaI (234 mg, 1.56 mmol) in 
anhydrous dimethylformamide (60 mL) at 0 
o
C. The mixture was stirred for 
30 minutes followed by dropwise addition of p-methoxybenzyl bromide (6.92 g, 
34.39 mmol, 1.1 eq.). The mixture was allowed to warm to room temperature and 
stirred for a further 16 hours. The reaction was quenched with a saturated aqueous 
solution of NH4Cl (20 mL) and the mixture stirred for 30 minutes. The reaction 
mixture was diluted with ether (120 mL), washed with an aqueous CuSO4 solution 
(10 mL), washed with deionised water (2 x 60 mL), dried and concentrated under 
reduced pressure to give a yellow liquid. The liquid was subjected to column 
chromatography. Elution with 40% ethyl acetate/light petroleum afforded the alcohol 
165 as a yellow oil (3.96 g, 49%). The oil was redissolved in anhydrous 
dichloromethane (120 mL) and treated with activated manganese dioxide (13.32 g, 
0.15 mol, 10.0 eq.). The reaction mixture was stirred at room temperature for 2 days. 
After this time, the mixture was filtered and the solvent removed under reduced 
pressure to give the aldehyde 166 as a yellow oil (3.93 g, 74%). The 
1
H NMR 




H NMR (400 MHz, CDCl3): δ 10.22 (1 H, s), 7.87 (1 H, dd, J = 7.4, 7.8 Hz), 7.67 
(1 H, d, J = 7.4 Hz), 7.59 (1 H, d, J = 7.4 Hz), 7.47 (1 H, dd, J = 7.4, 7.8 Hz), 7.31 (2 
H, d, J = 8.8 Hz), 6.90 (2 H, d, J = 8.8 Hz), 4.95 (2 H, s), 4.59 (2 H, s), 3.81 (3 H, s) 
ppm. 
9.3.20  Acid-catalysed synthesis of 4-bromo-1-butanol 
 
 
Following the procedure by Supuran and co-workers,
309
 HBr (48%, 233.77 g, 






C. The reaction mixture was allowed to warm to room temperature and stirred 
for 5 hours. The mixture was cooled to 0 
o
C and diluted with dichloromethane 
(150 mL). A saturated aqueous solution of sodium hydroxide (50 mL) was then 
added dropwise. The organic layer was washed with deionised water (2 x 50 mL), 
dried and concentrated under reduced pressure to give 4-bromo-1-butanol as a 





H NMR (400 MHz, CDCl3): δ 3.67 (2 H, t, J = 6.4 Hz), 3.44 (2 H, t, J = 6.7 Hz), 
2.43 (1 H, br. s), 1.94 (2 H, m), 1.70 (2 H, m) ppm. 
9.3.21  Silylation of 4-bromo-1-butanol 
 
A mixture of 4-bromo-1-butanol (15.30 g, 0.1 mol, 1.0 eq.), imidazole (10.21 g, 
0.15 mol, 1.5 eq.) and DMAP (1.22 g, 0.01 mol, 0.1 eq.) in anhydrous 
dimethylformamide (50 mL) was stirred at 0 
o
C for 10 minutes. TBSCl (15.07 g, 
0.1 mol, 1.0 eq.) was added in portions and the mixture was stirred at room 
temperature for 18 hours. The reaction mixture was diluted with ether (100 mL), 
washed with an aqueous CuSO4 solution (5 mL) and washed with deionised water (2 
x 30 mL). The organic layer was dried and concentrated under reduced pressure to 
give a yellow liquid. The liquid was subjected to column chromatography and the 
column was conditioned with triethylamine (1%). Elution with light petroleum 
afforded the bromide 169 as a colourless oil (18.17 g, 68%). The 
1
H NMR spectrum 




H NMR (400 MHz, CDCl3): δ 3.64 (2 H, t, J = 6.2 Hz), 3.44 (2 H, t, J = 6.8 Hz), 








9.3.22  Addition of the Grignard reagent 170 to compound 166 
 
 
A mixture of the bromide 169 (7.19 g, 26.88 mmol, 2.6 eq.) and magnesium turnings 
(1.26 g, 51.70 mmol, 5.0 eq.) in anhydrous tetrahydrofuran (26 mL) was stirred at 
room temperature for 10 minutes with gradual addition of 1,2-dibromoethane 
(194 mg, 1.03 mmol, 0.1 eq.). The reaction mixture was warmed to 45 
o
C upon 
initiation and stirred for 3 hours. After this time, the mixture was cooled to −84 
o
C 
and the aldehyde 166 (2.65 g, 0.01 mol, 1.0 eq.) was added dropwise. The reaction 
mixture was stirred for a further 2 hours. A saturated aqueous solution of NH4Cl 
(10 mL) was then added dropwise at 0 
o
C. The mixture was diluted with 
dichloromethane (30 mL) and washed with deionised water (2 x 20 mL). The organic 
layer was dried and concentrated under reduced pressure to give a yellow liquid. The 
liquid was subjected to column chromatography. Elution with 5% ethyl acetate/light 
petroleum afforded the silyl protected ether 171 as a yellow oil (3.91 g, 85%). The 
oil (396 mg, 0.89 mmol, 1.0 eq.) was taken up in anhydrous tetrahydrofuran (5 mL) 
and added dropwise to a solution of TBAF (1 M in tetrahydrofuran, 1.07 mL, 
1.07 mmol, 1.2 eq.) at −84 
o
C. The mixture was allowed to gradually warm to room 
temperature over 22 hours. The mixture was then concentrated under reduced 
pressure to give a yellow liquid that was subjected to column chromatography. 
Elution with 70% ethyl acetate/light petroleum afforded the diol 171 as a colourless 
oil (191 mg, 65%). 
1
H NMR (400 MHz, CDCl3): δ 7.48 (1 H, d, J = 7.5 Hz), 7.38 (1 H, dd, J = 7.5, 
7.8 Hz), 7.24−7.30 (4 H, m), 6.88 (2 H, d, J = 8.8 Hz), 4.87 (1 H, dd, J = 4.8, 8.4 
Hz), 4.65 (1 H, d, J = 11.2 Hz), 4.49 (2 H, s), 4.48 (1 H, d, J = 11.2 Hz), 3.80 (3 H, 




H, m), 1.38 (1 H, m) ppm; 
13
C NMR (100 MHz, CDCl3): δ 159.5 (C), 144.0 (C), 
134.9 (C), 130.3 (CH), 129.8 (CH), 129.8 (C), 129.0 (CH), 127.5 (CH), 126.3 (CH), 
114.0 (CH), 72.3 (CH2), 70.6 (CH2), 70.4 (CH), 62.8 (CH2), 55.4 (CH3), 36.8 (CH2), 
32.6 (CH2), 22.7 (CH2) ppm; ATR-FTIR: 3385 (2 x OH) cm
-1
; HRMS (ESI): 
[M+23 (Na)]
+ 
C20H26O4 requires 353.1729; found: 353.1731. 




Jones reagent (1 M, 0.95 mL, 0.95 mmol, 3.4 eq.) was added dropwise to a solution 
of the diol 171 (92 mg, 0.28 mmol, 1.0 eq.) in acetone (30 mL) at 0 
o
C and the 
mixture was stirred for four and a half hours. Methanol (2 mL) was then added 
dropwise at this temperature, resulting in a suspension. The suspension was filtered 
and the filtrate diluted with ethyl acetate (60 mL). The reaction mixture was washed 
with deionised water (10 mL) and brine (2 x 10 mL). The organic layer was dried 
and concentrated under reduced pressure to give the ketoacid 172 as a white solid 






H NMR (400 MHz, CDCl3): δ 7.65 (2 H, d, J = 7.7 Hz), 7.48 (1 H, dd, J = 7.7, 
7.8 Hz), 7.25−7.30 (3 H, m), 6.88 (2 H, d, J = 8.6 Hz), 4.80 (2 H, s), 4.52 (2 H, s), 
3.80 (3 H, s), 2.98 (2 H, t, J = 7.2 Hz), 2.43 (2 H, t, J = 7.2 Hz), 2.01 (2 H, m) ppm; 
13
C NMR (100 MHz, CDCl3): δ 203.4 (C), 178.9 (C), 159.4 (C), 139.1 (C), 137.0 
(C), 131.7 (CH), 130.4 (C), 129.5 (CH), 128.4 (CH), 128.4 (CH), 127.2 (CH), 113.9 
(CH), 72.7 (CH2), 70.3 (CH2), 55.4 (CH3), 40.1 (CH2), 33.2 (CH2), 19.2 (CH2) ppm; 













9.3.24  Reduction of the ketone 172 
 
 
DIBAL (25% w/v in toluene, 0.32 mL, 0.45 mmol, 2.1 eq.) was added dropwise to 
the ketoacid 172 (74 mg, 0.22 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (2 mL) at 
−84 
o
C. The reaction mixture was allowed to warm to 0 
o
C and stirred for three and a 
half hours. Methanol (2 mL) and a saturated aqueous solution of sodium sulfate 
(2 mL) were added successively, resulting in a fine suspension. The reaction mixture 
was filtered and the filtrate concentrated under reduced pressure to give rac-164 as a 
colourless oil (74 mg, 93%). 
1
H NMR (400 MHz, CDCl3): δ 7.44 (1 H, d, J = 7.2 Hz), 7.43 (1 H, br. s), 7.16−7.26 
(5 H, m), 6.85 (2 H, d, J = 8.6 Hz), 4.77 (1 H, m), 4.48 (1 H, d, J = 11.5 Hz), 4.43 (1 
H, d, J = 11.5 Hz), 4.37 (2 H, s), 3.77 (3 H, s), 2.28 (2 H, m), 1.93 (2 H, m), 1.72 (2 
H, m) ppm; 
13
C NMR (100 MHz, CDCl3): δ 180.1 (C), 159.3 (C), 144.0 (C), 134.3 
(C), 130.1 (C), 129.6 (CH), 129.4 (CH), 128.4 (CH), 127.0 (CH), 126.1 (CH), 113.9 
(CH), 71.9 (CH2), 69.7 (CH2), 69.6 (CH), 55.3 (CH3), 37.8 (CH2), 35.8 (CH2), 22.3 
(CH2) ppm; ATR-FTIR: 3390 (OH) and 1681 (C=O) cm
-1
; HRMS (ASAP): [M
+
] 
C20H24O5 requires 345.1702; found: 345.1704. 
9.3.25  Acid-catalysed esterification of compound 164  
 
A mixture of compound 164 (15 mg, 0.04 mmol, 1.0 eq.), Amberlite
®
 IR−120 
(4 crystals) and crushed 3Å molecular sieves (2 sieves) in anhydrous ethanol (3 mL) 
was heated under reflux for 5 hours. Amberlite
®
 IR−120 and 3Å molecular sieves 
were removed by filtration and the filtrate was concentrated under reduced pressure 
to afford compound 177 as a yellow oil (12 mg, 99%).  
1
H NMR (400 MHz, CDCl3): δ 7.38 (1 H, dd, J = 1.7, 7.7 Hz), 7.34 (1 H, dd, J = 




H, d, J = 12.5 Hz), 4.68 (1 H, d, J = 12.5 Hz), 4.55 (1 H, dt, J = 4.7, 8.1 Hz), 4.11 (2 
H, q, J = 7.1 Hz), 3.36 (2 H, m), 2.51 (1 H, br. s), 2.32 (2 H, m), 1.86 (2 H, m), 1.71 
(2 H, m), 1.24 (3 H, t, J = 7.1 Hz), 1.17 (3 H, t, J = 7.0 Hz) ppm; 
13
C NMR 
(100 MHz, CDCl3): δ 173.8 (C), 141.0 (C), 138.5 (C), 129.4 (CH), 128.3 (CH), 
127.8 (CH), 127.5 (CH), 79.6 (CH), 64.4 (CH2), 63.5 (CH2), 60.4 (CH2), 36.6 (CH2), 
34.2 (CH2), 21.9 (CH2), 15.5 (CH3), 14.4 (CH3) ppm; HRMS (ESI): Molecular ion 
not found 
9.3.26  Acid-catalysed lactonisation of compound 164 
 
A mixture of compound 164 (32 mg, 0.09 mmol, 1.0 eq.), 1 M HCl (2 mL) and 
dichloromethane (2 mL) was stirred at room temperature for 19 hours. The organic 
layer was extracted with dichloromethane (2 x 10 mL) and the solvent removed 
under reduced pressure to give the lactone 173 (30 mg, 99%) as a colourless oil. 
Attempts to purify the product via column chromatography proved unsuccessful. 
1
H NMR (400 MHz, CDCl3): δ 7.47 (1 H, d, J = 7.6 Hz), 7.24−7.47 (4 H, m), 6.90 
(3 H, d, J = 8.7 Hz), 5.56 (1 H, dd, J = 3.1, 11.0 Hz), 4.65 (1 H, d, J = 11.4 Hz), 4.47 
(3 H, m), 3.81 (3 H, s), 2.64 (1 H, m), 2.57 (1 H, m), 2.11 (1 H, m), 1.93 (3 H, m) 
ppm; 
13
C NMR (100 MHz, CDCl3): δ 171.8 (C), 159.5 (C), 139.2 (C), 134.4 (C), 
130.1 (CH), 130.0 (C), 129.8 (CH), 128.9 (CH), 128.2 (CH), 126.8 (CH), 114.0 
(CH), 78.5 (CH), 72.0 (CH2), 70.1 (CH2), 55.4 (CH3), 30.6 (CH2), 29.5 (CH2), 19.0 











9.4  Chapter 4 experimental procedures 
 
9.4.1  Synthesis of potassium glutaconaldehyde 188 
 
 
Following the procedure outlined by Becher,
239
 pyridinium sulfonic acid (12.03 g, 
0.08 mol, 1.0 eq.) was added in small portions to a solution of potassium hydroxide 
(17.39 g, 0.31 mol, 4.1 eq.) in deionised water (110 mL) at −28 
o
C. The mixture was 
gradually warmed to room temperature and stirred for 3 hours and then heated to 
39 
o
C and stirred for a further 30 minutes. The reaction mixture was cooled to 0 
o
C to 
precipitate compound 188 as light brown prisms (5.97 g, 58%). The 1H NMR 




H NMR (400 MHz, DMSO): δ 8.64 (1 H, d,
 
J = 9.2 Hz), 7.04 (2 H, t, J = 13.1 Hz), 
5.11 (2 H, m) ppm. 
9.4.2  Synthesis of the bromide 189 
 
 
Tetrabutylammonium hydrogen sulfate (1.94 g, 5.73 mmol, 1.0 eq.) was added in 
one portion to compound 188 (0.78 g, 5.73 mmol, 1.0 eq.) in deionised water 
(12 mL) at 0 
o
C. The mixture was allowed to warm to room temperature and stirred 
for 1 hour. The reaction mixture was then basified to pH 10 with NaOH (1 M, 
10 mL) and extracted with dichloromethane (3 x 20 mL). The organic layer was 
dried and the solvent removed under reduced pressure to afford tertbutylammonium 
glutaconaldehyde as a light pink solid in a quantitative yield (1.94 g). The solid 
(300 mg, 0.84 mmol, 1.0 eq.) was dissolved in anhydrous dichloromethane (10 mL) 
and treated with triphenylphosphine (209 mg, 0.80 mmol, 0.9 eq.) and N-
bromosuccinimide (173 mg, 0.97 mmol, 1.1 eq.). The mixture was stirred at room 
temperature for 8 hours after which it was diluted with dichloromethane (20 mL) and 
washed with deionised water (3 x 10 mL). The organic layer was dried and 




subjected to column chromatography and the column was conditioned with 
triethylamine (1%). Elution with 20% ethyl acetate/light petroleum afforded the 
bromide 189 as a red oil in a 1:1 mixture of 2E,4E:2E,4Z isomers (60 mg, 42%). The 




H NMR (400 MHz, CDCl3): δ 9.64 (1 H, d, J = 7.9 Hz, 2E,4Z), 9.52 (1 H, d, J = 
7.8 Hz, 2E,4E), 7.41 (1 H, dd, J = 10.5, 15.5 Hz, 2E,4Z), 6.94−7.03 (3 H, m, 2E,4E), 
6.88 (1 H, dd, J = 7.1, 10.5 Hz, 2E,4Z), 6.71 (1 H, d, J = 7.1 Hz, 2E,4Z), 6.27 (1 H, 
dd, J = 7.9, 15.5 Hz, 2E,4Z), 6.13 (1 H, dd, J = 7.8, 15.5 Hz, 2E,4E) ppm. 
9.4.3  Addition of propargylmagnesium bromide to compound 189 
 
 
Propargyl bromide (80% w/v in toluene, 137 mg, 0.92 mmol, 1.1 eq.) was added in 
one portion to a mixture of magnesium turnings (41 mg, 1.68 mol, 2.0 eq.), iodine 
(5 mg, 0.04 mmol) and HgCl2 (11 mg, 0.04 mmol) in anhydrous ether (1 mL) at 
0 
o
C. The reaction mixture was stirred for 20 minutes at 0 
o
C then cooled to −17 
o
C. 
Compound 189 (135 mg, 0.84 mmol, 1.0 eq.) in anhydrous ether (2 mL) was added 
dropwise and the mixture was stirred for two and a half hours. The mixture was 
warmed to 0 
o
C and a saturated aqueous solution of NH4Cl (3 mL) was added 
dropwise. The mixture was diluted with ether (15 mL) and washed with deionised 
water (2 x 10 mL). The organic layer was dried and concentrated under reduced 
pressure to give a yellow liquid. The liquid was subjected to column chromatography 
and the column was conditioned with triethylamine (1%). Elution with 30% ethyl 
acetate/light petroleum afforded rac-186 as a yellow oil (126 mg, 75%). 
1
H NMR (400 MHz, CDCl3): δ 6.75 (1 H, dd, J = 10.8, 13.5 Hz, 5E,7E), 6.67 (2 H, 
m, 5E,7Z), 6.39 (1 H, d, J = 13.5 Hz, 5E,7E), 6.27 (1 H, dd, J = 10.8, 15.3 Hz, 




5E,7E), 4.35 (1 H, m, 5E,7Z), 4.28 (1 H, m, 5E,7E), 2.55 (2 H, m, 5E,7Z), 2.53 (1 H, 
ddd, J = 2.7, 5.9, 16.7 Hz, 5E,7E), 2.46 (1 H, ddd, J = 2.7, 5.9, 16.7 Hz, 5E,7E), 2.12 
(1 H, t, J = 2.7 Hz, 5E,7Z), 2.09 (1 H, t, J = 2.7 Hz, 5E,7E) ppm; 
13
C NMR (100 
MHz, CDCl3): δ 137.8 (CH, 5E,7Z), 136.6 (CH, 5E,7E), 134.7 (CH, 5E,7Z), 131.8 
(CH, 5E,7E), 128.7 (CH, 5E,7E), 127.0 (CH, 5E,7Z), 110.0 (CH, 5E,7Z), 109.5 (CH, 
5E,7E), 80.0 (CH, both isomers), 71.4 (C, both isomers), 70.3 (CH, 5E,7Z), 70.0 
(CH, 5E,7E), 27.6 (CH2, 5E,7Z), 27.6 (CH2, 5E,7E) ppm; ATR-FTIR: 3325 (OH) 
cm
-1
; Elemental Analysis: Found: C, 47.74%; H, 4.55%. C8H9BrO calculated C, 
47.79%; H, 4.51%). 
9.4.4  Esterification of o-iodobenzoic acid 
 
 
A mixture of o-iodobenzoic acid (6.00 g, 24.19 mmol, 1.0 eq.), concentrated H2SO4 
(16 mL) and anhydrous ethanol (100 mL) was heated under reflux for 7 hours. The 
mixture was cooled to 0 
o
C, quenched with deionised water (60 mL) and extracted 
with ether (200 mL). The organic layer was dried and the solvent removed under 
reduced pressure to afford the ester 196 as a colourless oil (5.88 g, 88%). The 
1
H 




H NMR (400 MHz, CDCl3): δ 7.97 (1 H, d, J = 7.9 Hz), 7.78 (1 H, d, J = 7.9 Hz), 
7.34 (1 H, dd, J = 7.4, 7.9 Hz), 7.13 (1 H, dd, J = 7.4, 7.9 Hz), 4.39 (2 H, q, J = 
7.2 Hz), 1.41 (3 H, t, J = 7.2 Hz) ppm. 




DIBAL (25% w/v in toluene, 31.23 mL, 46.62 mmol, 2.2 eq.) was added dropwise to 
the ester 196 (5.85 g, 21.19 mmol, 1.0 eq.) in anhydrous dichloromethane (20 mL) at 
−84 
o
C. The reaction mixture was allowed to warm to 0 
o
C and stirred for 4 hours. 




added successively, resulting in a fine suspension. The mixture was filtered and the 
filtrate concentrated under reduced pressure to give o-iodobenzyl alcohol as a 
colourless oil (0.46 g, 90%). The oil was redissolved in anhydrous dichloromethane 
(50 mL). Activated manganese dioxide (16.58 g, 0.19 mol, 10.0 eq.) was added and 
the mixture was stirred at room temperature for 2 days. The reaction mixture was 
filtered and the solvent removed under reduced pressure to give o-iodobenzaldehyde 
as a yellow oil (3.41 g, 77%). The 
1





H NMR (400 MHz, CDCl3): δ 10.08 (1 H, s), 7.96 (1 H, d, J = 7.9 Hz), 7.90 (1 H, 
d, J = 7.9 Hz), 7.48 (1 H, dd, J = 7.0, 7.9 Hz), 7.30 (1 H, dd, J = 7.0, 7.9 Hz) ppm. 
9.4.6  Addition of the Grignard reagent 170 to compound 192 
 
 
A solution of compound 169 (2.78 g, 10.40 mmol, 1.2 eq.) and magnesium turnings 
(506 mg, 20.79 mmol, 2.4 eq.) in anhydrous ether (26 mL) was stirred at room 
temperature for 10 minutes with gradual addition of 1,2-dibromoethane (163 mg, 
0.87 mmol, 0.1 eq.). The reaction mixture was heated under reflux upon initiation 
and stirred for 1 hour. The mixture was cooled to −84 
o
C and o-iodobenzaldehyde 
(2.01 g, 8.66 mmol, 1.0 eq.) in anhydrous ether (10 mL) was added dropwise. The 
reaction mixture was stirred for 2 hours. A saturated aqueous solution of NH4Cl 
(10 mL) was then added dropwise at 0 
o
C. The mixture was diluted with 
dichloromethane (30 mL) and washed with deionised water (2 x 20 mL). The organic 
layer was dried and concentrated under reduced pressure to give a yellow liquid. The 
liquid was subjected to column chromatography. Elution with 5% ethyl acetate/light 




(2.99 g, 7.10 mmol) was taken up in ethanol (20 mL) and CSA (83 mg, 0.36 mmol) 
was added. The reaction mixture was stirred at room temperature for 24 hours. The 
mixture was diluted with ethyl acetate (40 mL) and washed with a saturated aqueous 
solution of sodium carbonate (10 mL) and deionised water (2 x 10 mL). The organic 
layer was dried and concentrated under reduced pressure to give the diol 193 as a 
white solid. The solid was recrystallised from chloroform/light petroleum to give the 




H NMR (400 MHz, CDCl3): δ 7.79 (1 H, d, J = 7.9 Hz), 7.50 (1 H, d, J = 7.9 Hz), 
7.36 (1 H, dd, J = 7.7, 7.9 Hz), 6.96 (1 H, dd J = 7.7, 7.9 Hz), 4.90 (1 H, dd, J = 3.8, 
8.2 Hz), 3.67 (2 H, t, J = 6.0 Hz), 1.81 (2 H, br. s), 1.77 (1 H, m), 1.50−1.73 (5 H, m) 
ppm; 
13
C NMR (100 MHz, CDCl3): δ 146.7 (C), 139.5 (CH), 129.3 (CH), 128.8 
(CH), 127.1 (CH), 97.7 (C), 77.4 (CH), 62.9 (CH2), 37.6 (CH2), 32.5 (CH2), 22.2 
(CH2) ppm; ATR-FTIR: 3291 (OH) and 3197 (OH) cm
-1
; HRMS (ASAP): [M
+
] 
C11H15IO2 requires 307.0195; found: 307.0204. 




Jones reagent (1.3 M, 9.25 mL, 12.02 mmol, 3.2 eq.) was added dropwise to the diol 
193 (1.15 g, 3.76 mmol, 1.0 eq.) in acetone (45 mL) and the mixture was stirred for 
4 hours at 0 
o
C. Methanol was then added dropwise at this temperature, resulting in a 
suspension. The suspension was filtered and the filtrate diluted with ethyl acetate 
(60 mL). The reaction mixture was washed with deionised water (10 mL) and brine 
(2 x 10 mL). The organic layer was dried and concentrated under reduced pressure to 
give the ketoacid 194 as a white solid which was recrystallised from chloroform/light 




H NMR (400 MHz, CDCl3): δ 7.90 (1 H, d, J = 8.0 Hz), 7.30−7.48 (2 H, m), 7.11 
(1 H, m), 2.98 (2 H, t, J = 7.1 Hz), 2.51 (2 H, t, J = 7.1 Hz), 2.07 (2 H, tt, J = 7.1, 
7.1 Hz) ppm;
 13
C NMR (100 MHz, CDCl3): δ 204.1 (C), 178.7 (C), 144.6 (C), 140.7 









] C11H11IO3 requires 318.9831; found: 318.9839. 
9.4.8  Esterification of the ketoacid 194 
 
 
p-Toluenesulfonic acid (60 mg, 0.35 mmol, 0.1 eq.) was added in one portion to the 
ketoacid 194 (1.11 g, 3.49 mmol, 1.0 eq.) in anhydrous isopropyl alcohol (5 mL) at 
room temperature. The reaction mixture was heated for 16 hours at 65 
o
C. The 
mixture was diluted with dichloromethane (20 mL) and washed with NaHCO3 
(5% aq., 4 mL) and deionised water (2 x 5 mL). The organic layer was dried and 
concentrated under reduced pressure to give a yellow liquid. The liquid was 
subjected to column chromatography. Elution with 10% ethyl acetate afforded the 
ketoester 197 as a colourless oil (1.09 g, 87%).  
1
H NMR (400 MHz, CDCl3): δ 7.90 (1 H, d, J = 7.7 Hz), 7.30−7.47 (2 H, m), 7.11 
(1 H, m), 5.00 (1 H, sp, J = 6.3 Hz), 2.96 (2 H, t, J = 7.2 Hz), 2.40 (2 H, t, J = 7.2 
Hz), 2.06 (2 H, tt, J = 7.2 Hz), 1.23 (6 H, d, J = 6.3 Hz) ppm; 
13
C NMR (100 MHz, 
CDCl3): δ 204.3 (C), 172.8 (C), 144.8 (C), 140.7 (CH), 131.7 (CH), 128.2 (CH), 
127.8 (CH), 91.0 (C), 67.9 (CH), 41.1 (CH2), 33.7 (CH2), 22.0 (CH3), 19.4 (CH2) 





] C14H17IO3 requires 361.0301; found: 361.0318. 
9.4.9  Asymmetric reduction of the ketoester 197 
 
                       
(R)-(+)-2-Methyl-CBS-oxazaborolidine (40 mg, 0.14 mmol, 8 mol%) was added to a 
solution of BH3•DMS (14 mg, 17.12 µL, 0.18 mmol, 0.1 eq.) in anhydrous 
tetrahydrofuran (5 mL) and stirred at room temperature for 15 minutes. The solution 
was cooled to −84 
o
C and the ketoester 197 (650 mg, 1.80 mmol, 1.0 eq.) in 
anhydrous tetrahydrofuran (19 mL) was added in one portion followed by dropwise 




reaction mixture was stirred for a further 6 hours. Methanol (6 mL) and a saturated 
aqueous solution of NH4Cl (8 mL) were then added successively and the mixture 
was diluted with dichloromethane (30 mL). The organic layer was dried and 
concentrated under reduced pressure to give a colourless liquid. The liquid was 
subjected to column chromatography and the column was conditioned with 
triethylamine (1%). Elution with 20% ethyl acetate/light petroleum afforded the 
alcohol 195 as a colourless oil (458 mg, 70%) in 94% ee. 
1
H NMR (400 MHz, CDCl3): δ 7.77 (1 H, d, J = 7.8 Hz), 7.50 (1 H, d, J = 7.8 Hz), 
7.34 (1 H, dd, J = 7.7, 7.8 Hz), 6.94 (1 H, dd, J = 7.7, 7.8 Hz), 4.98 (1 H, sp, J = 
6.3 Hz), 4.85 (1 H, dd, J = 3.3, 8.8 Hz), 2.35 (1 H, br. s), 2.34 (2 H, t, J = 7.0 Hz), 
1.75−1.90 (3 H, m), 1.63 (1 H, m), 1.21 (6 H, d, J = 6.3 Hz) ppm; 
13
C NMR 
(100 MHz, CDCl3): δ 173.4 (C), 146.5 (C), 139.4 (CH), 129.3 (CH), 128.7 (CH), 
127.0 (CH), 97.6 (C), 77.0 (CH), 67.8 (CH), 37.3 (CH2), 34.4 (CH2), 22.0 (CH3), 





 = −41.30o 
(c = 1.00, CHCl3); HRMS (ESI): [M+23 (Na)]
+
 C14H19IO3 requires 385.0277; 
found: 385.0279. 
9.4.10  Treatment of hexabutylditin with the ketoester 197 
 
 
The ketoester 197 (72 mg, 0.20 mmol, 1.0 eq.), Pd(PPh3)4 (32 mg, 0.02 mmol, 2 x 
7 mol%) and hexabutylditin (139 mg, 0.24 mmol, 1.2 eq.) were added in one portion 
to degassed tetrahydrofuran (10 mL) at room temperature. The reaction mixture was 
heated to 60 
o
C and stirred for 48 hours. The solvent was removed under reduced 
pressure and the remaining liquid was subjected to column chromatography. Elution 
with 10% ethyl acetate/light petroleum afforded the stannane 207 as a colourless oil 
(44 mg, 42%). 
1
H NMR (400 MHz, CDCl3): δ 7.98 (1 H, d, J = 7.6 Hz), 7.69 (1 H, d, J = 7.2 Hz), 
7.48 (1 H, dd, J = 7.2, 7.6 Hz), 7.35 (1 H, dd, J = 7.2, 7.6 Hz), 5.01 (1 H, sp, J = 
6.2 Hz), 3.07 (2 H, t, J = 7.2 Hz), 2.38 (2 H, t, J = 7.2 Hz), 2.04 (2 H, tt, J = 7.2 Hz), 




= 7.2 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): δ 201.2 (C), 172.9 (C), 146.2 (C), 
141.6 (C), 137.7 (CH), 132.1 (CH), 129.6 (CH), 128.2 (CH), 67.8 (CH), 37.4 (CH2), 
33.9 (CH2), 29.4 (CH2), 27.6 (CH2), 22.0 (CH3), 20.1 (CH2), 13.9 (CH3), 11.2 (CH2) 
ppm; ATR-FTIR: 1731 (ester: C=O) and 1675 (ketone: C=O) cm
-1
; HRMS 
(ASAP): [M−57 (C4 H9)]
+ 
C26H44O3Sn requires 525.2391; found: 525.2407. 




Following the procedure by Michels et al.,
251
 a mixture of pyridine (1.38 g, 
17.48 mmol, 1.0 eq.), 2,4-dinitro-1-chlorobenzene (3.54 g, 17.48 mmol, 1.0 eq.) and 
acetone (17 mL) was heated under reflux for 24 hours. The reaction mixture was 
cooled, filtered and the resulting precipitate was washed with light petroleum (3 x 
5 mL) to give compound 211 as a white solid (4.58 g, 93%). The 
1
H NMR spectrum 




H NMR (400 MHz, DMSO): δ 9.38 (2 H, br. s), 9.12 (1 H, s), 8.97 (1 H, d, J = 
8.7 Hz), 8.93 (1 H, t, J = 7.9 Hz), 8.43 (3 H, m) ppm. 




Following the procedure by Michels et al.,
251
 dimethylamine (25% w/v in water, 
5.76 g, 31.95 mmol, 2.5 eq.) was added dropwise to compound 211 (3.6 g, 
12.78 mmol, 1.0 eq.) in ethanol (60 mL) at room temperature. The reaction mixture 
was heated under reflux for 1 hour. The mixture was cooled to 0 
o
C and NaOH (4 M, 
50 mL) was added in small portions. The mixture was diluted with chloroform 
(100 mL) and washed with deionised water (2 x 20 mL). The organic layer was dried 
and the solvent removed under reduced pressure to give a black solid. The solid was 
subjected to column chromatography and the column was conditioned with 




brown solid (1.52 g, 95%). The 
1
H NMR spectrum matched the spectrum reported 




H NMR (400 MHz, CDCl3): δ 9.24 (1 H, d, J = 8.4 Hz), 7.09 (1 H, dd, J = 11.6, 
14.3 Hz), 6.77 (1 H, d, J = 12.6 Hz), 5.83 (1 H, dd, J = 8.4, 14.3 Hz), 5.26 (1 H, t, 
J = 12.6 Hz), 2.94 (6 H, s) ppm. 





Following the procedure by Michels et al.,
251
 n-BuLi (1.6 M in hexanes, 10.41 mL, 
16.67 mmol, 1.5 eq.) was added dropwise to a solution of anhydrous 
diisopropylamine (1.46 g, 14.44 mmol, 1.3 eq.) in anhydrous tetrahydrofuran 
(20 mL) at 0 
o
C and the reaction mixture was stirred for 20 minutes. Tributyltin 
hydride (3.56 g, 12.22 mmol, 1.1 eq.) was then added dropwise and the mixture was 
stirred at 0 
o
C for a further 20 minutes. Compound 212 (1.39 g, 11.11 mmol, 1.0 eq.) 
in anhydrous tetrahydrofuran (5 mL) was added dropwise at 0 
o
C and the reaction 
mixture was allowed to gradually warm to room temperature over 10 minutes. The 
reaction was quenched with acetyl chloride (3 mL) and the mixture was stirred for 
10 minutes at room temperature. A saturated aqueous solution of NaHCO3 (30 mL) 
was added dropwise and the reaction mixture was stirred for a further 10 minutes. 
The mixture was diluted with dichloromethane (20 mL) and washed with deionised 
water (2 x 10 mL). The organic layer was dried and the solvent removed under 
reduced pressure to give a black liquid. The liquid was subjected to column 
chromatography and the column was conditioned with triethylamine (1%). Elution 
with 10% ethyl acetate/light petroleum afforded the stannane 213 as a red oil (2.35 g, 
57%). The 
1




H NMR (400 MHz, CDCl3): δ 9.55 (1 H, d, J = 8.0 Hz), 7.03 (1 H, d, J = 18.8 Hz), 
6.99 (1 H, dd, J = 10.1, 15.2 Hz), 6.79 (1 H, dd, J = 10.1, 18.8 Hz), 6.05 (1 H, dd, J 
= 8.0, 15.2 Hz), 1.48−1.53 (5 H, m), 1.25−1.37 (7 H, m), 0.96 (5 H, t, J = 8.2 Hz), 





9.4.14  Propargylation of compound 213 
 
 
Propargyl bromide (80% w/v in toluene, 485 mg, 3.26 mmol, 1.1 eq.) was added in 
one portion to a mixture of magnesium turnings (144 mg, 5.93 mmol, 2.0 eq.), iodine 
(4 mg, 0.03 mmol) and HgCl2 (9 mg, 0.03 mmol) in anhydrous ether (1 mL) at 0 
o
C. 
The reaction mixture was stirred for 20 minutes at 0 
o
C then cooled to −17 
o
C. 
Compound 213 (1.10 g, 2.96 mmol, 1.0 eq.) in anhydrous ether (2 mL) was added 
dropwise and the mixture was stirred for two and a half hours. A saturated aqueous 
solution of NH4Cl (3 mL) was then added dropwise at 0 
o
C. The mixture was diluted 
with ether (15 mL) and washed with deionised water (2 x 10 mL). The organic layer 
was dried and concentrated under reduced pressure to give a yellow liquid. The 
liquid was subjected to column chromatography and the column was conditioned 
with triethylamine (1%). Elution with 20% ethyl acetate/light petroleum afforded 
rac-209 as a colourless liquid (890 mg, 73%). 
1
H NMR (400 MHz, CDCl3): δ 6.52 (1 H, dd, J = 9.6, 18.9 Hz), 6.29 (1 H, d, J = 
18.9 Hz), 6.26 (1 H, dd, J = 9.6, 16.3 Hz), 5.70 (1 H, dd, J = 6.5, 16.3 Hz), 4.34 (1 
H, m), 2.47 (2 H, ddd, J = 2.6, 5.4, 16.7 Hz), 2.06 (1 H, t, J = 2.6 Hz), 2.05 (1 H, br. 
s), 1.47−1.52 (6 H, m), 1.25−1.31 (6 H, m), 0.89 (6 H, m), 0.88 (9 H, t, J = 7.3 Hz) 
ppm; 
13
C NMR (100 MHz, CDCl3): δ 145.8 (CH), 136.2 (CH), 134.7 (CH), 132.3 
(CH), 80.5 (CH), 71.1 (C), 70.5 (CH), 29.2 (CH2), 27.8 (CH2), 27.4 (CH2), 13.8 
(CH3), 9.6 (CH2) ppm; ATR-FTIR: 3333 (OH) cm
-1
; HRMS (ASAP): 
[M−18 (H2O)]
+ 







9.4.15  Sonogashira reaction between the iodide 196 and compound 209 
 
 
Compound 209 (50 mg, 0.12 mmol, 1.0 eq.), Pd(PPh3)4 (10 mg, 0.01 mmol, 
7 mol%), CuI (2 mg, 0.01 mmol, 10 mol%), piperidine (21 mg, 0.24 mmol, 2.0 eq.) 
and BHT (1 crystal) were added in one portion to the iodide 196 (34 mg, 0.12 mmol, 
1.0 eq.) in degassed anhydrous dimethylformamide (1 mL) and the mixture was 
stirred for 4 hours at room temperature. The reaction mixture was diluted with ether 
(10 mL) and washed with deionised water (3 x 10 mL). The organic layer was dried 
and concentrated under reduced pressure to give a colourless liquid. The liquid was 
subjected to column chromatography and the column was conditioned with 
triethylamine (1%). Elution with 20% ethyl acetate/light petroleum afforded 
compound 217 as a colourless oil (54 mg, 80%). 
1
H NMR (400 MHz, CDCl3): δ 7.97 (1 H, d, J = 7.9 Hz), 7.51 (1 H, d, J = 7.3 Hz), 
7.48 (1 H, dd, J = 7.3, 7.9 Hz), 7.34 (1 H, dd, J = 7.3, 7.3 Hz), 6.53 (1 H, dd, J = 9.8, 
18.7 Hz), 6.32 (1 H, dd, J = 9.8, 15.3 Hz), 6.26 (1 H, d, J = 18.7 Hz), 5.78 (1 H, dd, 
J = 6.1, 15.3 Hz), 4.46 (1 H, m), 4.39 (2 H, q, J = 7.1 Hz), 3.84 (1 H, d, J = 5.1 Hz), 
2.78 (1 H, dd, J = 4.1, 16.9 Hz), 2.65 (1 H, dd, J = 4.1, 16.9 Hz), 1.47−1.51 (6 H, m), 
1.38 (3 H, t, J = 7.1 Hz), 1.26−1.32 (6 H, m), 0.83−0.94 (15 H, m) ppm;
 13
C NMR 
(100 MHz, CDCl3): δ 166.2 (C), 146.2 (CH), 135.1 (CH), 134.2 (CH), 133.7 (CH), 
132.9 (CH), 132.0 (CH), 131.9 (C), 130.5 (CH), 127.6 (CH), 124.4 (C), 92.4 (C), 
82.6 (C), 70.6 (CH), 61.5 (CH2), 29.7 (CH2), 29.2 (CH2), 27.4 (CH2), 14.4 (CH3), 









9.4.16  Synthesis of compound 225 
 
 
Compound 209 (69 mg, 0.17 mmol, 1.0 eq.), Pd(PPh3)4 (14 mg, 0.01 mmol, 
7 mol%), CuI (3 mg, 0.02 mmol, 10 mol%), piperidine (29 mg, 0.34 mmol, 2.0 eq.) 
and BHT (1 crystal) were added in one portion to the iodide 196 (93 mg, 0.34 mmol, 
2.0 eq.) in degassed anhydrous dimethylformamide (1 mL) at room temperature. The 
mixture was heated for 12 hours at 45 
o
C. The reaction mixture was diluted with 
ether (10 mL) and washed with deionised water (3 x 10 mL). The organic layer was 
dried and the solvent removed under reduced pressure to give a yellow liquid. The 
liquid was subjected to column chromatography and the column was conditioned 
with triethylamine (1%). Elution with 40% ethyl acetate/light petroleum afforded 
compound 225 as a yellow oil (51 mg, 72%). 
1
H NMR (400 MHz, CDCl3): δ 8.00 (1 H, d, J = 7.8 Hz), 7.88 (1 H, d, J = 7.8 Hz), 
7.62 (1 H, d, J = 7.8 Hz), 7.55 (1 H, d, J = 7.8 Hz), 7.48 (2 H, m), 7.41 (1 H, d, J = 
15.4 Hz), 7.36 (1 H, dd, J = 7.8, 7.8 Hz), 7.30 (1 H, dd, J = 7.8, 7.8 Hz), 6.73 (1 H, 
dd, J = 10.6, 15.4 Hz), 6.60 (1 H, dd, J = 10.6, 15.2 Hz), 6.01 (1 H, dd, J = 6.1, 
15.2 Hz), 4.57 (1 H, m), 4.41 (4 H, q, J = 7.1 Hz), 3.95 (1 H, d, J = 4.3 Hz), 2.83 (1 
H, dd, J = 4.2, 16.9 Hz), 2.70 (1 H, dd, J = 4.2, 16.9 Hz), 1.41 (6 H, t, J = 7.1 Hz) 
ppm; 
13
C NMR (100 MHz, CDCl3): δ 167.4 (C), 166.2 (C), 138.7 (C), 135.5 (CH), 
133.8 (CH), 132.0 (C), 131.9 (CH), 131.9 (CH), 131.4 (CH), 131.4 (CH), 131.1 
(CH), 130.6 (CH), 130.6 (CH), 129.1 (C), 127.7 (CH), 127.2 (CH), 126.8 (CH), 









 C26H26O5 requires 441.1678; found: 441.1686. 
9.4.17  Sonogashira reaction between compound 209 and the iodide 28 
 
 
The iodide 28 (66 mg, 0.20 mmol, 1.2 eq.), Pd(PPh3)4 (14 mg, 0.01 mmol, 7 mol%), 
CuI (3 mg, 0.02 mmol, 10 mol%), piperidine (34 µL, 0.34 mmol, 2.0 eq.) and BHT 
(1 crystal) were added in one portion to compound 209 (69 mg, 0.17 mmol, 1.0 eq.) 
in degassed anhydrous toluene (1 mL) and the mixture was stirred for 2 hours at 
room temperature. The mixture was diluted with ether (10 mL) and washed with 
deionised water (3 x 10 mL). The organic layer was dried and concentrated under 
reduced pressure to give a colourless liquid. The liquid was subjected to column 
chromatography and the column was conditioned with triethylamine (1%). Elution 
with 5% ethyl acetate/light petroleum afforded the stannane 226 as a colourless oil 
(64 mg, 63%). 
1
H NMR (400 MHz, CDCl3): δ 6.52 (1 H, dd, J = 10.0, 18.7 Hz), 6.29 (1 H, d, 
J = 18.7 Hz), 6.22 (1 H, dd, J = 10.0, 16.0 Hz), 6.07 (1 H, dd, J = 5.4, 16.0 Hz), 
5.72 (1 H, dd, J = 6.5, 15.8 Hz), 5.64 (1 H, dd, J = 1.6, 15.8 Hz), 4.33 (1 H, m), 4.09 
(1 H, m), 2.60 (1 H, ddd, J = 1.6, 4.7, 16.8 Hz), 2.56 (1 H, ddd, J = 1.6, 4.7, 16.8 
Hz), 2.01 (1 H, d, J = 4.6 Hz), 1.47−1.52 (8 H, m), 1.25−1.36 (6 H, m), 0.90 (9 H, 
s), 0.89 (18 H, m), 0.05 (3 H, s), 0.03 (3 H, s) ppm;
 13
C NMR (100 MHz, CDCl3): δ 
146.2 (CH), 145.9 (CH), 135.9 (CH), 134.6 (CH), 132.6 (CH), 108.7 (CH), 85.7 (C), 
81.7 (C), 73.7 (CH), 70.7 (CH), 30.8 (CH2), 29.2 (CH2), 28.9 (CH2), 27.4 (CH2), 
26.0 (CH3), 18.4 (C), 13.8 (CH3), 9.7 (CH2), 9.4 (CH3), −4.4 (CH3), −4.7 (CH3) ppm; 
ATR-FTIR: 3381 (OH) cm
-1
; HRMS (ASAP): [M−18 (H2O)]
+ 
C31H58O2SiSn 




9.4.18  Treatment of the stannane 226 with TBAF 
 
 
TBAF (1 M in tetrahydrofuran, 0.90 mL, 3.44 mmol, 5.0 eq.) was added dropwise to 
the stannane 226 (420 mg, 0.69 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (5 mL) 
at −84 
o
C. The reaction mixture was allowed to warm to room temperature and 
stirred for 12 hours. The mixture was concentrated under reduced pressure and the 
remaining liquid was subjected to column chromatography. The column was 
conditioned with triethylamine (1%). Elution with 40% ethyl acetate/light petroleum 
afforded the stannane 230 as a colourless oil (225 mg, 66%). 
1
H NMR (400 MHz, CDCl3): 6.52 (1 H, dd, J = 9.9, 18.7 Hz), 6.29 (1 H, d, J = 
18.7 Hz), 6.28 (1 H, dd, J = 9.9, 16.2 Hz), 6.10 (1 H, dd, J = 6.2, 16.2 Hz), 5.70 (2 
H, m), 4.33 (1 H, m), 4.08 (1 H, m), 2.63 (1 H, ddd, J = 1.6, 5.3, 16.8 Hz), 2.56 (1 H, 
ddd, J = 1.6, 5.3, 16.8 Hz), 1.98 (1 H, d, J = 4.6 Hz), 1.48−1.53 (7 H, m), 1.25−1.36 
(7 H, m), 0.81−0.97 (18 H, m) ppm; 
13
C NMR (100 MHz, CDCl3): δ 145.9 (CH), 
145.2 (CH), 136.1 (CH), 134.6 (CH), 132.5 (CH), 110.2 (CH), 86.5 (C), 81.2 (C), 
73.8 (CH), 70.7 (CH), 30.0 (CH2), 29.2 (CH2), 28.8 (CH2), 27.4 (CH2), 13.8 (CH3), 

















9.4.19  Stille reaction between the iodide 196 and the stannane 226 
 
 
The iodide 196 (9 mg, 0.03 mmol, 1.0 eq.), Pd(PPh3)4 (3 mg, 2.26 µmol, 7 mol%), 
CuI (1 mg, 3.23 µmol, 10 mol%) and BHT (1 crystal) were added in one portion to 
compound 226 (16 mg, 0.03 mmol, 1.0 eq.) in degassed anhydrous acetonitrile 
(1 mL) and the mixture was stirred for 12 hours at room temperature. After this time, 
another portion of Pd(PPh3)4 (3 mg, 2.26 µmol, 7 mol%) was added and the reaction 
mixture was stirred for an additional 60 hours. The mixture was diluted with ether 
(5 mL) and washed with deionised water (3 x 10 mL). The organic layer was dried 
and the solvent removed under reduced pressure to give a colourless liquid. The 
liquid was subjected to column chromatography and the column was conditioned 
with triethylamine (1%). Elution with 20% ethyl acetate/light petroleum afforded 
compound 227 as a colourless oil (8 mg, 51%). 
1
H NMR (400 MHz, CDCl3): δ 7.87 (1 H, d, J = 7.9 Hz), 7.60 (1 H, d, J = 7.9 Hz), 
7.46 (1 H, dd, J = 7.9, 7.9 Hz), 7.41 (1 H, d, J = 15.4 Hz), 7.29 (1 H, dd, J = 7.9, 
7.9 Hz), 6.70 (1 H, dd, J = 10.4, 15.4 Hz), 6.53 (1 H, dd, J = 10.4, 15.2 Hz), 6.08 (1 
H, dd, J = 5.4, 15.8 Hz), 5.92 (1 H, dd, J = 6.3, 15.2 Hz), 5.64 (1 H, dt, J = 1.6, 15.8 
Hz), 4.40 (1 H, m), 4.37 (2 H, q, J = 7.1 Hz), 4.10 (1 H, m), 2.66 (1 H, ddd, J = 1.6, 
5.3, 16.8 Hz), 2.59 (1 H, ddd, J = 1.6, 5.3, 16.8 Hz), 2.07 (1 H, d, J = 4.6 Hz), 1.51 
(2 H, m), 1.40 (3 H, t, J = 7.1 Hz), 0.90 (9 H, s), 0.87 (3 H, t, J = 7.5 Hz), 0.04 (3 H, 
s), 0.03 (3 H, s) ppm; 
13
C NMR (100 MHz, CDCl3): δ 167.6 (C), 146.2 (CH), 138.7 
(C), 135.2 (CH), 132.0 (CH), 131.9 (CH), 131.9 (CH), 130.8 (CH), 130.6 (CH), 
129.1 (C), 127.3 (CH), 126.9 (CH), 108.7 (CH), 85.5 (C), 81.8 (C), 73.7 (CH), 70.8 









] C28H40O4Si requires 469.2774; found: 469.2786. 
The reaction was repeated in anhydrous dimethylformamide to afford the dimer 228 
in 65% yield.  
 
1
H NMR (400 MHz, CDCl3): δ 6.35 (2 H, dd, J = 9.1, 14.8 Hz), 6.27 (4 H, br. s), 
6.06 (2 H, dd, J = 5.4, 15.8 Hz), 5.79 (2 H, dd, J = 6.3, 14.8 Hz), 5.63 (2 H, dt, J = 
1.6, 15.8 Hz), 4.35 (2 H, m), 4.09 (2 H, m), 2.63 (2 H, ddd, J = 1.6, 5.1, 16.5 Hz), 
2.56 (2 H, ddd, J = 1.6, 5.1, 16.5 Hz), 2.03 (2 H, d, J = 4.9 Hz), 1.48−1.52 (4 H, m), 
0.90 (18 H, s), 0.87 (6 H, t, J = 7.5 Hz), 0.05 (6 H, s), 0.03 (6 H, s) ppm;
 13
C NMR 
(100 MHz, CDCl3): δ 146.2 (CH), 134.4 (CH), 133.5 (CH), 132.5 (CH), 131.5 (CH), 
108.7 (CH), 85.5 (C), 81.8 (C), 73.7 (CH), 70.8 (CH), 30.8 (CH2), 29.0 (CH2), 26.0 
(CH3), 18.4 (C), 9.4 (CH3), −4.4 (CH3), −4.7 (CH3) ppm; HRMS (ESI): Molecular 
ion not found. 
9.4.20  Stille reaction between the iodide 197 and the stannane 230 
 
 
The iodide 197 (43 mg, 0.12 mmol, 1.3 eq.), Pd(PPh3)4 (8 mg, 6.50 µmol, 7 mol%), 
CuI (2 mg, 9.29 µmol, 10 mol%) and BHT (1 crystal) were added to compound 230 
(46 mg, 0.09 mmol, 1.0 eq.) in degassed acetonitrile (1 mL) and the mixture was 




and washed with deionised water (3 x 10 mL). The organic layer was dried and the 
solvent removed under reduced pressure to give a colourless liquid. The liquid was 
subjected to column chromatography and the column was conditioned with 
triethylamine (1%). Elution with 50% ethyl acetate/light petroleum afforded 
compound 231 as a light brown oil (17 mg, 41%, 92% brsm). 
1
H NMR (400 MHz, CDCl3): δ 7.58 (2 H, d, J = 7.4 Hz), 7.43 (1 H, dd, J = 7.4, 
7.4 Hz), 7.30 (1 H, dd, J = 7.4, 7.4 Hz), 7.01 (1 H, d, J = 15.8 Hz), 6.66 (1 H, dd, J 
= 10.5, 15.8 Hz), 6.50 (1 H, dd, J = 10.5, 15.5 Hz), 6.08 (1 H, dd, J = 6.3, 15.9 Hz), 
5.91 (1 H, dd, J = 6.3, 15.5 Hz), 5.64 (1 H, dt, J = 1.4, 15.9 Hz), 5.01 (1 H, sp, J = 
6.3 Hz), 4.39 (1 H, m), 4.09 (1 H, m), 2.95 (2 H, t, J = 7.2 Hz), 2.67 (1 H, ddd, J = 
1.4, 5.3, 16.8 Hz), 2.58 (1 H, ddd, J = 1.4, 5.3, 16.8 Hz), 2.37 (2 H, t, J = 7.2 Hz), 
2.06 (1 H, d, J = 3.2 Hz), 2.03 (2 H, tt, J = 7.2, 7.2 Hz), 1.67 (1 H, d, J = 4.1 Hz), 
1.62 (2 H, m), 1.25 (6 H, d, J = 6.3 Hz), 0.96 (3 H, t, J = 7.5 Hz) ppm; 
13
C NMR 
(100 MHz, CDCl3): δ 204.3 (C), 172.9 (C), 145.3 (CH), 137.7 (C), 136.7 (C), 135.2 
(CH), 131.8 (CH), 131.6 (CH), 131.4 (CH), 131.0 (CH), 128.4 (CH), 127.4 (CH), 
127.3 (CH), 110.1 (CH), 86.3 (C), 81.3 (C), 73.8 (CH), 70.8 (CH), 67.9 (CH), 41.0 
(CH2), 33.9 (CH2), 30.0 (CH2), 28.8 (CH2), 22.0 (CH3), 19.8 (CH2), 9.7 (CH3) ppm; 
HRMS (ESI): [M+23 (Na)]
+
 C27H34O5 requires 461.2304; found: 461.2316.  






 (470 mg, 1.98 mmol, 108.8 eq.) was added in one portion 
to a nitrogen purged solution of the alkyne 231 (8 mg, 0.02 mol, 1.0 eq.) in methanol 
(1 mL) and deionised water (1 mL) at room temperature. The reaction mixture was 
heated at 45 
o
C for 21 hours. The mixture was filtered to remove the Zn(Cu/Ag) 
solid and the filtrate was concentrated under reduced pressure to give a brown liquid. 
The liquid was subjected to column chromatography and the column was 
conditioned with triethylamine (1%). Elution with 70% ethyl acetate/light petroleum 





H NMR (400 MHz, CDCl3): δ 7.57 (2 H, d, J = 7.9 Hz), 7.43 (1 H, dd, J = 7.9, 
7.9 Hz), 7.31 (1 H, dd, J = 7.9, 7.9 Hz), 7.00 (1 H, d, J = 15.4 Hz), 6.65 (1 H, dd, J 
= 10.6, 15.4 Hz), 6.51 (1 H, dd, J = 10.9, 15.2 Hz), 6.45 (1 H, dd, J = 10.6, 
15.3 Hz), 6.17 (1 H, t, J = 10.9 Hz), 5.87 (1 H, dd, J = 6.5, 15.3 Hz), 5.73 (1 H, dd, J 
= 6.6, 15.2 Hz), 5.50 (1 H, dt, J = 7.6, 10.9 Hz), 5.10 (1 H, sp, J = 6.3 Hz), 4.30 (1 
H, m), 4.11 (1 H, m), 2.95 (2 H, t, J = 7.2 Hz), 2.51 (2 H, m), 2.37 (2 H, t, J = 7.2 
Hz), 2.03 (2 H, tt, J = 7.2, 7.2 Hz), 1.68 (2 H, br. s), 1.60 (2 H, m), 1.23 (6 H, d, J = 
6.3 Hz), 0.93 (3 H, t, J = 7.4 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): δ 204.3 (C), 
172.8 (C), 137.8 (C), 137.3 (CH), 136.8 (C), 136.6 (CH), 131.4 (CH), 131.2 (CH), 
131.2 (CH), 131.1 (CH), 131.1 (CH), 128.3 (CH), 127.4 (CH), 127.2 (CH), 126.9 
(CH), 125.7 (CH), 74.2 (CH), 72.1 (CH), 67.9 (CH), 41.1 (CH2), 35.8 (CH2), 33.9 
(CH2), 30.3 (CH2), 22.0 (CH3), 19.8 (CH2), 9.9 (CH3) ppm; HRMS (ESI): 
[M+23 (Na)]
+
 C27H36O5 requires 463.2460; found: 463.2461.  
9.4.22  Reduction of the ketone 232 
 
 
NaBH4 (26 mg, 0.68 mmol, 2.5 eq.) was added in small portions to the ketone 232 
(120 mg, 0.27 mmol, 1.0 eq.) in tetrahydrofuran (3 mL) and methanol (3 mL) at 
−84 
o
C and the reaction mixture was stirred for 3 hours. The reaction was quenched 
with a saturated aqueous solution of NH4Cl (2 mL) and the mixture was stirred for a 
further 30 minutes. The mixture was diluted with ethyl acetate (10 mL) and washed 
with deionised water (2 x 2 mL). The organic layer was dried and the solvent 
removed under reduced pressure to give a yellow liquid. The liquid was subjected to 
column chromatography and the column was conditioned with triethylamine (1%). 
Elution with 50% ethyl acetate/light petroleum afforded compound 233 as a 
colourless oil (98 mg, 81%).  
1
H NMR (400 MHz, CDCl3): δ 7.48 (2 H, m), 7.26 (2 H, m), 6.89 (1 H, d, J = 
15.3 Hz), 6.64 (1 H, dd, J = 10.5, 15.3 Hz), 6.47 (2 H, m), 6.18 (1 H, t, J = 10.9 Hz), 
5.86 (1 H, dd, J = 6.6, 15.2 Hz), 5.74 (1 H, dd, J = 6.7, 15.2 Hz), 5.04 (1 H, dt, J = 




t, J = 7.1 Hz), 1.69−1.81 (7 H, m), 1.59 (2 H, m), 1.17 (6 H, d, J = 6.3 Hz), 0.93 (3 
H, t, J = 7.4 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): δ 173.3 (C), 141.8 (C), 137.3 
(CH), 136.0 (CH), 134.9 (C), 131.2 (CH), 130.7 (CH), 129.6 (CH), 128.0 (CH), 
127.7 (CH), 126.9 (CH), 126.1 (CH), 125.8 (CH), 125.8 (CH), 125.6 (CH), 74.1 
(CH), 72.1 (CH), 70.6 (CH), 67.8 (CH), 37.8 (CH2), 35.9 (CH2), 34.5 (CH2), 30.3 
(CH2), 22.0 (CH3), 21.6 (CH2), 9.9 (CH3) ppm; LRMS (ESI): m/z 465 (M
+
, 100%), 
407 (9), 235 (4), 150 (18), 102 (96); HRMS (ESI): Molecular ion not found. 
9.4.23  Synthesis of benzoresolvin E1 234 
 
LiOH (2 mg, 0.07 mmol, 3.0 eq.) was added in one portion to a solution of 
compound 233 (10 mg, 0.02 mmol, 1.0 eq.) in tetrahydrofuran (0.5 mL), methanol 
(0.2 mL) and deionised water (0.2 mL) and the mixture was stirred at room 
temperature for 3 hours. The reaction mixture was filtered and the filtrate was 
concentrated under reduced pressure to afford the target compound 234 as a light 
brown oil (9 mg, 95%). 
1
H NMR (400 MHz, CD3OD): δ 7.47 (2 H, m), 7.72 (1 H, m), 7.19 (1 H, m), 6.94 (1 
H, d, J = 15.6 Hz), 6.67 (1 H, dd, J = 10.5, 15.6 Hz), 6.53 (1 H, dd, J = 11.0, 
15.2 Hz), 6.45 (1 H, dd, J = 10.5, 15.4 Hz), 6.10 (1 H, t, J = 11.0 Hz), 5.84 (1 H, dd, 
J = 6.2, 15.4 Hz), 5.66 (1 H, dd, J = 6.7, 15.2 Hz), 5.49 (1 H, dt, J = 7.9, 11.0 Hz), 
4.99 (1 H, m), 4.21 (1 H, m), 4.02 (1 H, m), 2.48 (2 H, m), 2.18 (2 H, t, J = 7.9 Hz), 
1.71−1.76 (3 H, m), 1.63 (1 H, m), 1.48−1.56 (2 H, m), 0.91 (3 H, t, J = 7.5 Hz) 
ppm; 
13
C NMR (100 MHz, CD3OD): δ 182.7 (C), 143.7 (C), 137.8 (CH), 137.4 
(CH), 136.1 (C), 132.1 (CH), 131.6 (CH), 131.1 (CH), 130.6 (CH), 128.5 (CH), 
128.1 (CH), 128.1 (CH), 127.0 (CH), 126.7 (CH), 126.6 (CH), 74.7 (CH), 73.1 (CH), 
71.1 (CH), 39.8 (CH2), 38.9 (CH2), 36.8 (CH2), 31.2 (CH2), 24.2 (CH2), 10.2 (CH3) 
ppm; ATR-FTIR: 3411 (3 x OH) and 1655 (C=O) cm
-1
; HRMS (ESI): [M
+
] 
C24H31LiO5 requires 407.2410; found: 407.2422; UV spectrum: λmax (log ε) = 272 




9.5  Chapter 5 experimental procedures 
 





Following the procedure by Li and O'Doherty,
311
 n-BuLi (1.6 M in hexanes, 
61.0 mL, 0.10 mol, 1.0 eq.) was added dropwise to 1-hexyne (8.02 g, 0.10 mol, 
1.0 eq.) in anhydrous tetrahydrofuran (100 mL) at −84 
o
C. The solution was stirred 
for 1 hour at this temperature after which paraformaldehyde (2.93 g, 0.10 mol, 
1.0 eq.) was added in small portions. The reaction mixture was allowed to warm to 
room temperature and stirred for 12 hours. The reaction was quenched with 
deionised water (15 mL) and the mixture was stirred for 30 minutes. The mixture 
was diluted with ether (100 mL) and washed with deionised water (2 x 20 mL). The 
organic layer was dried and concentrated under reduced pressure to give a yellow oil. 
The oil was subjected to column chromatography. Elution with 20% ethyl 
acetate/light petroleum afforded hept-2-yn-1-ol as a yellow oil (9.53 g, 87%). The 
1
H 




H NMR (400 MHz, CDCl3): δ 4.22 (2 H, m), 2.19 (2 H, m), 2.04 (1 H, br. s), 1.47 
(2 H, m), 1.39 (2 H, m), 0.89 (3 H, t, J = 7.3 Hz) ppm. 
9.5.2  Zipper reaction with hept-2-yn-1-ol 
 
 
Adapting the procedure by Matovic et al.,
271
 60% NaH in mineral oil (16.08 g, 
0.40 mol, 5.0 eq.) was added in small portions to anhydrous 1,2-ethylenediamine 
(100 mL) at 0 
o
C over 15 minutes. The mixture was allowed to warm to room 
temperature and stirred for 2 hours. A solution of hept-2-yn-1-ol (9.02 g, 0.08 mol, 
1.0 eq.) in anhydrous 1,2-ethylenediamine (2 mL) was added dropwise to the 
reaction mixture at room temperature and stirred for a further 4 hours. The reaction 
mixture was cooled to 0 
o
C and quenched with 1 M HCl (30 mL). The mixture was 
diluted with ether (150 mL), washed with deionised water (2 x 30 mL), dried and 




subjected to column chromatography. Elution with 20% ethyl acetate/light petroleum 
gave the alcohol 238 as a yellow oil (5.50 g, 61%). The spectroscopic data matched 




H NMR (400 MHz, CDCl3): δ 3.52 (2 H, t, J = 6.5 Hz), 2.82 (1 H, s), 2.15 (2 H, 
ddd, J = 2.7, 7.1, 14.3 Hz), 1.88 (1 H, t, J = 2.7 Hz), 1.46−1.51 (4 H, m), 1.38 (2 H, 
m) ppm. 
9.5.3  Oxidation of the alcohol 238 using Jones reagent  
 
Jones reagent (1.3 M, 79.64 mL, 0.10 mol, 2.1 eq.) was added dropwise to the 
alcohol 238 (5.53 g, 0.05 mol, 1.0 eq.) in acetone (200 mL) and the mixture was 
stirred for 2 hours at 0 
o
C. Methanol (20 mL) was then added dropwise at this 
temperature, resulting in a suspension. The suspension was filtered and the filtrate 
was diluted with ethyl acetate (200 mL) and washed with deionised water (2 x 
30 mL). The organic layer was dried and the solvent removed under reduced 
pressure to afford a brown liquid. The liquid was subjected to column 
chromatography. Elution with 30% ethyl acetate/light petroleum gave compound 239 
as a colourless oil (4.35 g, 70%). The 
1




1H NMR (400 MHz, CDCl3): δ 2.39 (2 H, t, J = 7.3 Hz), 2.23 (2 H, ddd, J = 2.7, 
6.8, 13.9 Hz), 1.96 (1 H, t, J = 2.7 Hz), 1.77 (2 H, m), 1.59 (2 H, m) ppm. 




p-Toluenesulfonic acid (464 mg, 2.70 mmol, 0.1 eq.) was added in one portion to 
compound 239 (3.40 g, 26.95 mmol, 1.0 eq.) in anhydrous isopropyl alcohol 
(100 mL) at room temperature. The reaction mixture was heated at 60 
o
C for 
16 hours. The mixture was diluted with ether (150 mL), washed with a saturated 




The organic layer was dried and concentrated under reduced pressure to give the 
ester 240 as a colourless oil (3.45 g, 76%). The 
1
H NMR spectrum matched that 




H NMR (400 MHz, CDCl3): δ 5.00 (1 H, sp, J = 6.3 Hz), 2.28 (2 H, t, J = 7.3 Hz), 
2.20 (2 H, ddd, J = 2.7, 7.1, 14.1 Hz), 1.94 (1 H, t, J = 2.7 Hz), 1.73 (2 H, m), 1.58 
(2 H, m), 1.22 (6 H, d, J = 6.3 Hz) ppm. 
9.5.5  Propargylic oxidation of the ester 240 
 
 
Adapting the procedure by Li and co-workers,
272
 CuCl2•2 H2O (125 mg, 0.73 mmol, 
4 mol%) was added in one portion to the ester 240 (3.08 g, 18.31 mmol, 1.0 eq.) in t-
butanol (75 mL). The reaction mixture was heated to 70 
o
C and t-butyl 
hydroperoxide (70% in water, 5.04 mL, 0.04 mol, 2.0 eq.) was added in four equal 
portions over 4 hours. After 24 hours, the reaction mixture was cooled to room 
temperature and the solvent removed under reduced pressure. The remaining residue 
was diluted with ether (50 mL), washed with deionised water (2 x 30 mL), dried and 
concentrated under reduced pressure to afford a yellow liquid. The liquid was 
subjected to column chromatography. Elution with 20% ethyl acetate/light petroleum 
gave the ketoester 241 as a colourless oil (1.73 g, 52%). The 
1
H NMR spectrum 




H NMR (400 MHz, CDCl3): δ 5.00 (1 H, sp, J = 6.3 Hz), 3.22 (1 H, s), 2.66 (2 H, t, 
J = 7.3 Hz), 2.31 (2 H, t, J = 7.3 Hz), 1.97 (2 H, tt, J = 7.3, 7.3 Hz), 1.22 (6 H, d, J 
= 6.3 Hz) ppm.  
9.5.6  Asymmetric reduction of the ketoester 241 
 
 
(R)-(+)-2-Methyl-CBS-oxazaborolidine (53 mg, 0.19 mmol, 7 mol%) was added to a 
solution of BH3•DMS (21 mg, 26 µL, 0.27 mmol, 0.1 eq.) in anhydrous 




15 minutes. The mixture was cooled to −45 
o
C and the ketoester 241 (500 mg, 
2.74 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (3 mL) was added in one portion, 
followed by dropwise addition of BH3•DMS (125 mg, 156 µL, 1.65 mmol, 0.6 eq.) 
over 2 hours. The reaction mixture was stirred for another 5 hours at this 
temperature. Methanol (4 mL) and a saturated aqueous solution of NH4Cl (3 mL) 
were then added successively. The mixture was extracted with ethyl acetate (30 mL) 
and washed with deionised water (2 x 10 mL). The organic layer was dried and 
concentrated under reduced pressure to give a colourless liquid. The liquid was 
subjected to column chromatography and the column was conditioned with 
triethylamine (1%). Elution with 20% ethyl acetate/light petroleum afforded the 
alcohol 242 as a colourless oil (359 mg, 71%) in 91% ee. The 
1
H NMR spectrum 




H NMR (400 MHz, CDCl3): δ 5.00 (1 H, sp, J = 6.3 Hz), 4.38 (1 H, br. s), 2.46 (1 
H, d, J = 2.1 Hz), 2.32 (2 H, t, J = 6.6 Hz), 2.10 (1 H, d, J = 4.4 Hz), 1.73−1.78 (4 
H, m), 1.22 (6 H, d, J = 6.3 Hz) ppm; [
23
𝐷




 = +10.30o (c = 2.60, CHCl3) as the (R)-alcohol.
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9.5.7  Bromination of compound 242 
 
 
Silver nitrate (46 mg, 0.27 mmol, 0.2 eq.) was added in one portion to 
compound 242 (247 mg, 1.34 mmol, 1.0 eq.) in acetone (2 mL) and the mixture was 
stirred for 30 minutes at room temperature. N-bromosuccinimide (262 mg, 
1.47 mmol, 1.1 eq.) was then added portionwise and the mixture was stirred for a 
further 12 hours at room temperature. The reaction mixture was filtered and the 
filtrate was diluted with ether (20 mL) and washed with deionised water (2 x 10 mL). 
The organic layer was dried and concentrated under reduced pressure to give a 
brown oil. The oil was subjected to column chromatography. Elution with 20% ethyl 
acetate/light petroleum gave the bromide 236 as a light brown oil (247 mg, 70%). 
1
H NMR (400 MHz, CDCl3): δ 5.00 (1 H, sp, J = 6.3 Hz), 4.41 (1 H, t, J = 6.2 Hz), 




6.3 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): δ 173.1 (C), 80.9 (C), 67.9 (CH), 63.1 
(CH), 45.5 (C), 37.0 (CH2), 34.2 (CH2), 22.0 (CH3), 20.6 (CH2) ppm; ATR-FTIR: 





 = −9.27o (c = 1.00, CHCl3); HRMS (ESI): 
[M+23 (Na)]
+
 C10H15BrO3 requires 285.0102; found: 285.0108. 




The bromide 236 (53 mg, 0.20 mmol, 1.0 eq.), Pd(PPh3)2Cl2 (10 mg, 0.01 mmol, 
7 mol%), CuI (4 mg, 0.02 mmol, 10 mol%) and BHT (1 crystal) were added to the 
stannane 230 (100 mg, 0.20 mmol, 1.0 eq.) in degassed acetonitrile (2 mL) and the 
mixture was stirred for 13 hours at room temperature. The mixture was diluted with 
ethyl acetate (5 mL) and washed with deionised water (2 x 5 mL). The organic layer 
was dried and the solvent removed under reduced pressure to give an orange liquid. 
The liquid was subjected to column chromatography and the column was 
conditioned with triethylamine (1%). Elution with 70% ethyl acetate/light petroleum 
afforded compound 243 as a yellow oil (51 mg, 65%). The spectroscopic data 




H NMR (400 MHz, CD3OD): δ 6.58 (1 H, dd, J = 10.8, 15.5 Hz), 6.35 (1 H, dd, J 
= 10.8, 15.3 Hz), 6.00 (1 H, dd, J = 6.2, 15.9 Hz), 5.89 (1 H, dd, J = 6.1, 15.2 Hz), 
5.67 (2 H, m), 5.00 (1 H, sp, J = 6.3 Hz), 4.45 (1 H, t, J = 6.4 Hz), 4.26 (1 H, q, J = 
6.2 Hz), 3.97 (1 H, q, J = 6.3 Hz), 2.54 (1 H, ddd, J = 2.1, 6.0, 16.7 Hz), 2.50 (1 H, 
ddd, J = 2.1, 6.0, 16.7 Hz), 2.33 (2 H, t, J = 7.3 Hz), 1.75 (4 H, m), 1.51 (2 H, m), 
1.23 (6 H, d, J = 6.3 Hz), 0.91 (3 H, t, J = 7.4 Hz) ppm;
 13
C NMR (100 MHz, 
CD3OD): δ 174.8 (C), 146.1 (CH), 142.3 (CH), 138.6 (CH), 130.9 (CH), 112.1 (CH), 




62.9 (CH), 38.2 (CH2), 35.1 (CH2), 30.9 (CH2), 29.0 (CH2), 22.1 (CH3), 22.0 (CH2), 
10.0 (CH3) ppm. 
9.6  Chapter 6 experimental procedures 
 





Following the procedure by Kuang et al.,
275
 trans-cinnamic acid (2.45 g, 
16.54 mmol, 1.0 eq.) was added in one portion to a mixture of lithium acetate 
(218 mg, 3.31 mmol, 0.2 eq.) and N-bromosuccinimide (3.24 g, 18.19 mmol, 1.1 eq.) 
in acetonitrile (29 mL) and deionised water (1 mL) at room temperature. The 
reaction mixture was stirred for 17 hours at this temperature. The mixture was 
diluted with light petroleum (100 mL) and washed with NaHCO3 (5% aq., 10 mL) 
and deionised water (2 x 10 mL). The organic layer was dried and the solvent 
removed under reduced pressure to give a colourless liquid. The liquid was subjected 
to column chromatography. Elution with 10% ethyl acetate/light petroleum afforded 
the bromide 248 as a colourless oil (2.48 g, 82%). The 
1
H NMR spectrum matched 




H NMR (400 MHz, CDCl3): δ 7.27−7.45 (5 H, m), 7.22 (1 H, d, J = 14.0 Hz), 6.86 











9.6.2 Sonogashira reaction between compound 209 and the bromide 248 
 
 
The bromide 248 (93 mg, 0.51 mmol, 1.0 eq.), Pd(PPh3)4 (41 mg, 0.04 mmol, 
7 mol%), CuI (10 mg, 0.05 mmol, 10 mol%), piperidine (87 mg, 1.02 mmol, 2.0 eq.) 
and BHT (1 crystal) were added in one portion to compound 209 (209 mg, 
0.51 mmol, 1.0 eq.) in degassed toluene (1 mL) and the mixture was stirred for 7 
hours at room temperature. The mixture was diluted with ether (10 mL) and washed 
with deionised water (3 x 10 mL). The organic layer was dried and concentrated 
under reduced pressure to give a yellow liquid. The liquid was subjected to column 
chromatography and the column was conditioned with triethylamine (1%). Elution 
with 10% ethyl acetate/light petroleum afforded the stannane 247 as a colourless oil 
(136 mg, 52%). 
1
H NMR (400 MHz, CDCl3): δ 7.27−7.38 (5 H, m), 6.91 (1 H, d, J = 16.3 Hz), 6.54 
(1 H, dd, J = 10.1, 18.6 Hz), 6.31 (1 H, d, J = 18.6 Hz), 6.28 (1 H, dd, J = 10.1, 
15.5 Hz), 6.15 (1 H, dd, J = 2.2, 16.3 Hz), 5.74 (1 H, dd, J = 6.5, 15.5 Hz), 4.38 (1 
H, m), 2.70 (1 H, ddd, J = 2.2, 5.4, 16.9 Hz), 2.64 (1 H, ddd, J = 2.2, 5.4, 16.9 Hz), 
2.04 (1 H, d, J = 4.6 Hz), 1.47−1.52 (6 H, m), 1.25−1.37 (6 H, m), 0.85−0.95 (15 H, 
m) ppm; 
13
C NMR (100 MHz, CDCl3): δ 145.9 (CH), 141.2 (CH), 136.5 (C), 136.0 
(CH), 134.7 (CH), 132.6 (CH), 128.8 (CH), 128.6 (CH), 126.3 (CH), 108.5 (CH), 
88.1 (C), 82.5 (C), 70.8 (CH), 29.3 (CH2), 29.1 (CH2), 27.4 (CH2), 13.8 (CH3), 9.7 
(CH2) ppm; ATR-FTIR: 3400 (OH) cm
-1
; HRMS (ESI): [M
+
] C28H42OSn requires 






9.6.3 Stille reaction between the iodide 197 and the stannane 247 
 
The iodide 197 (128 mg, 0.35 mmol, 1.3 eq.), Pd(PPh3)4 (22 mg, 0.02 mmol, 
7 mol%), CuI (6 mg, 0.03 mmol, 10 mol%) and BHT (1 crystal) were added to the 
stannane 247 (140 mg, 0.27 mmol, 1.0 eq.) in degassed acetonitrile (2 mL) and the 
reaction mixture was stirred for 3 days at room temperature. The mixture was diluted 
with ether (5 mL) and washed with deionised water (2 x 5 mL). The organic layer 
was dried and the solvent removed under reduced pressure to give a colourless 
liquid. The liquid was subjected to column chromatography and the column was 
conditioned with triethylamine (1%). Elution with 50% ethyl acetate/light petroleum 
afforded compound 249 as a yellow oil (39 mg, 31%, 95% brsm). 
1
H NMR (400 MHz, CDCl3): δ 7.58 (2 H, m), 7.43 (1 H, t, J = 7.4 Hz), 7.34 (2 H, 
m), 7.32 (2 H, m), 7.29 (2 H, m), 7.04 (1 H, d, J = 15.4 Hz), 6.93 (1 H, d, J = 
16.3 Hz), 6.68 (1 H, dd, J = 10.7, 15.4 Hz), 6.52 (1 H, dd, J = 10.7, 15.2 Hz), 6.16 
(1 H, dt, J = 2.2, 16.3 Hz), 5.94 (1 H, dd, J = 6.3, 15.2 Hz), 5.01 (1 H, sp, J = 
6.3 Hz), 4.44 (1 H, m), 2.95 (2 H, t, J = 7.2 Hz), 2.74 (1 H, ddd, J = 2.2, 5.5, 
17.3 Hz), 2.66 (1 H, ddd, J = 2.2, 5.5, 17.3 Hz), 2.37 (2 H, t, J = 7.2 Hz), 2.12 (1 H, 
d, J = 4.6 Hz), 2.03 (2 H, tt, J = 7.2, 7.2 Hz), 1.23 (6 H, d, J = 6.3 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): δ 204.2 (C), 172.8 (C), 141.2 (CH), 137.8 (C), 136.7 
(C), 136.5 (C), 135.3 (CH), 131.8 (CH), 131.6 (CH), 131.4 (CH), 131.1 (CH), 128.8 
(CH), 128.6 (CH), 128.3 (CH), 127.4 (CH), 127.3 (CH), 126.3 (CH), 108.3 (CH), 
88.0 (C), 82.6 (C), 70.8 (CH), 67.9 (CH), 41.0 (CH2), 33.9 (CH2), 29.1 (CH2), 22.0 
(CH3), 19.8 (CH2) ppm; HRMS (ESI): [M+23 (Na)]
+









 (1.56 g, 100.7 eq.) was added in one portion to a nitrogen 
purged solution of compound 249 (30 mg, 0.07 mmol, 1.0 eq.) in methanol (3 mL) 
and deionised water (1 mL) at room temperature. The reaction mixture was heated at 
42 
o
C for 21 hours. The mixture was filtered to remove the Zn(Cu/Ag) solid and the 
filtrate was concentrated under reduced pressure to give a yellow liquid. The liquid 
was subjected to column chromatography and the column was conditioned with 
triethylamine (1%). Elution with 50% ethyl acetate/light petroleum afforded 
compound 250 as a colourless oil (22 mg, 74%).  
1
H NMR (400 MHz, CDCl3): δ 7.56 (2 H, m), 7.41 (3 H, m), 7.31 (3 H, m), 7.22 (1 
H, d, J = 8.6 Hz), 7.06 (1 H, dd, J = 10.9, 15.6 Hz), 7.01 (1 H, d, J = 15.7 Hz), 6.66 
(1 H, dd, J = 10.5, 15.7 Hz), 6.58 (1 H, d, J = 15.6 Hz), 6.48 (1 H, dd, J = 10.5, 15.2 
Hz), 6.34 (1 H, t, J = 10.9 Hz), 5.90 (1 H, dd, J = 6.5, 15.2 Hz), 5.57 (1 H, dt, J = 
7.7, 10.9 Hz), 5.01 (1 H, sp, J = 6.3 Hz), 4.35 (1 H, m), 2.95 (2 H, t, J = 7.2 Hz), 
2.61 (2 H, m), 2.37 (2 H, t, J = 7.2 Hz), 2.03 (2 H, tt, J = 7.2, 7.2 Hz), 1.80 (1 H, d, J 
= 3.8 Hz), 1.23 (6 H, d, J = 6.3 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): δ 204.1 (C), 
172.7 (C), 137.6 (C), 137.3 (C), 136.6 (C), 136.5 (CH), 133.4 (CH), 131.8 (CH), 
131.2 (CH), 131.1 (CH), 131.1 (CH), 131.0 (CH), 128.6 (CH), 128.2 (CH), 127.6 
(CH), 127.2 (CH), 127.1 (CH), 127.0 (CH), 126.5 (CH), 124.0 (CH), 72.0 (CH), 67.7 
(CH), 40.9 (CH2), 35.9 (CH2), 33.7 (CH2), 21.8 (CH3), 19.6 (CH2) ppm; HRMS 
(ESI): [M+23 (Na)]
+









9.6.5  Reduction of the ketone 250 
 
NaBH4 (4 mg, 0.10 mmol, 2.5 eq.) was added in small portions to compound 250 
(18 mg, 0.04 mmol, 1.0 eq.) in tetrahydrofuran (2 mL) and methanol (1 mL) at 
−45 
o
C and the reaction mixture was stirred for 2 hours. The reaction was quenched 
with a saturated aqueous solution of NH4Cl (2 mL) and the mixture was stirred for 
30 minutes. The mixture was diluted with ethyl acetate (30 mL) and washed with 
deionised water (2 x 5 mL). The organic layer was dried and the solvent removed 
under reduced pressure to give a yellow liquid. The liquid was subjected to column 
chromatography and the column was conditioned with triethylamine (1%). Elution 
with 50% ethyl acetate/light petroleum afforded compound 251 as a colourless oil 
(16 mg, 87%).  
1
H NMR (400 MHz, CDCl3): δ 7.40−7.50 (4 H, m), 7.32 (3 H, m), 7.24 (2 H, m), 
7.07 (1 H, dd, J = 11.0, 15.6 Hz), 6.90 (1 H, d, J = 15.2 Hz), 6.57 (1 H, dd, J = 10.4, 
15.2 Hz), 6.59 (1 H, d, J = 15.6 Hz), 6.49 (1 H, dd, J = 10.4, 15.2 Hz), 6.36 (1 H, t, 
J = 11.0 Hz), 5.90 (1 H, dd, J = 6.3, 15.2 Hz), 5.58 (1 H, dt, J = 7.7, 11.0 Hz), 5.02 
(1 H, m), 5.00 (1 H, sp, J = 6.3 Hz), 4.36 (1 H, m), 2.63 (2 H, m), 2.32 (2 H, t, J = 
7.2 Hz), 1.99 (1 H, br. s), 1.68−1.79 (4 H, m), 1.76 (1 H, br. s), 1.22 (6 H, d, J = 
6.3 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): δ 173.3 (C), 141.8 (C), 137.5 (C), 136.1 
(CH), 134.9 (C), 133.6 (CH), 132.0 (CH), 131.2 (CH), 130.7 (CH), 129.7 (CH), 
128.8 (CH), 128.0 (CH), 127.8 (CH), 127.7 (CH), 127.1 (CH), 126.6 (CH), 126.1 
(CH), 125.8 (CH), 124.1 (CH), 72.2 (CH), 70.6 (CH), 67.8 (CH), 37.8 (CH2), 36.2 
(CH2), 34.5 (CH2), 22.0 (CH3), 21.6 (CH2) ppm; HRMS (ESI): [M+23 (Na)]
+
 







9.6.6  Synthesis of the C18-phenyl analogue 244 
 
LiOH (2 mg, 0.07 mmol, 3.0 eq.) was added in one portion to a solution of 
compound 251 (10 mg, 0.02 mmol, 1.0 eq.) in tetrahydrofuran (0.5 mL), methanol 
(0.2 mL) and deionised water (0.2 mL) and the reaction mixture was stirred at room 
temperature for 3 hours. The mixture was filtered and the filtrate was concentrated 
under reduced pressure to afford the target compound 244 as a yellow oil (8 mg, 
92%). 
1
H NMR (400 MHz, CDCl3): δ 7.41−7.49 (4 H, m), 7.29 (2 H, t, J = 7.3 Hz), 7.19 (3 
H, m), 7.16 (1 H, dd, J = 10.9, 15.6 Hz), 6.96 (1 H, d, J = 15.0 Hz), 6.67 (1 H, dd, 
J = 10.6, 15.0 Hz), 6.56 (1 H, d, J = 15.6 Hz), 6.49 (1 H, dd, J = 10.6, 15.2 Hz), 
6.28 (1 H, t, J = 10.9 Hz), 5.89 (1 H, dd, J = 6.5, 15.2 Hz), 5.60 (1 H, dt, J = 7.9, 
10.9 Hz), 5.00 (1 H, m), 4.27 (1 H, m), 2.60 (2 H, m), 2.20 (2 H, m), 1.68−1.75 (3 H, 
m), 1.63 (1 H, m) ppm;
 13
C NMR (100 MHz, CDCl3): δ 182.7 (C), 143.7 (C), 139.0 
(C), 137.5 (CH), 136.1 (C), 133.9 (CH), 132.3 (CH), 132.2 (CH), 131.9 (CH), 131.6 
(CH), 130.7 (CH), 129.7 (CH), 128.9 (CH), 128.5 (CH), 128.0 (CH), 127.4 (CH), 
127.0 (CH), 126.6 (CH), 125.5 (CH), 73.2 (CH), 71.0 (CH), 39.8 (CH2), 38.9 (CH2), 





 C27H29LiO4 requires 425.2304; found: 425.2324; UV 




9.7  Chapter 7 experimental procedures 
 





Following the procedure by Wu and co-workers,
314
 n-BuLi (1.6 M in hexanes, 
32.5 mL, 0.05 mol, 1.0 eq.) was added dropwise to 1-heptyne (5.00 g, 0.05 mol, 
1.0 eq.) in anhydrous tetrahydrofuran (50 mL) at −84 
o
C. The solution was stirred for 
1 hour at this temperature after which small portions of paraformaldehyde (1.56 g, 
0.05 mol, 1.0 eq.) were added. The reaction mixture was allowed to warm to room 
temperature and stirred for 12 hours. The reaction was quenched with deionised 
water (10 mL) and the mixture was stirred for 30 minutes. The mixture was diluted 
with ether (40 mL) and washed with deionised water (2 x 10 mL). The organic layer 
was dried and concentrated under reduced pressure to give a yellow liquid. The 
liquid was subjected to column chromatography. Elution with 20% ethyl 
acetate/light petroleum afforded the alcohol 277 as a yellow oil (5.78 g, 88%). The 
1




H NMR (400 MHz, CDCl3): δ 4.17 (2 H, s), 2.89 (1 H, br. s), 2.13 (2 H, ddd, J = 
2.2, 7.1, 14.3 Hz), 1.44 (2 H, m), 1.26 (4 H, m), 0.83 (3 H, t, J = 7.0 Hz). 
9.7.2  Synthesis of 1-bromo-2-octyne 
 
 
Triphenylphosphine (1.14 g, 4.36 mmol, 1.1 eq.) and N-bromosuccinimide (776 mg, 
4.36 mmol, 1.1 eq.) were added successively to the alcohol 277 (0.50 g, 3.96 mmol, 
1.0 eq.) in anhydrous dichloromethane (25 mL) at −45 
o
C. The mixture was allowed 
to warm to 0 
o
C and was stirred for 2 hours. The reaction mixture was then washed 
with deionised water (3 x 10 mL). The organic layer was dried and concentrated 
under reduced pressure to afford a purple solid. The solid was subjected to column 




colourless oil (577 mg, 77%). The 
1





H NMR (400 MHz, CDCl3): δ 3.92 (2 H, t, J = 2.3 Hz), 2.22 (2 H, ddd, J = 2.3, 
7.1, 14.3 Hz), 1.50 (2 H, m), 1.32 (4 H, m), 0.89 (3 H, t, J = 7.1 Hz) ppm. 
9.7.3  Addition of the Grignard reagent 276 to compound 213 
 
 
The bromide 278 (885 mg, 4.68 mmol, 1.1 eq.) was added in one portion to a 
mixture of magnesium turnings (207 mg, 8.51 mmol, 2.0 eq.), iodine 
(27 mg, 0.21 mmol) and HgCl2 (58 mg, 0.21 mmol) in anhydrous ether (5 mL) at 
0 
o
C. The reaction mixture was stirred for two hours at this temperature then cooled 
to −84 
o
C. Compound 213 (1.58 g, 4.26 mmol, 1.0 eq.) in anhydrous ether (3 mL) 
was added dropwise and the mixture was stirred for two and a half hours. A saturated 
aqueous solution of NH4Cl (5 mL) was then added dropwise. The mixture was 
diluted with ether (30 mL) and washed with deionised water (2 x 10 mL). The 
ethereal layer was dried and concentrated under reduced pressure to afford a yellow 
oil that was a mixture of the stannane 275 (0.82 g, 40%) and the stannane 279 





H NMR (400 MHz, CDCl3): δ 6.52 (1 H, dd, J = 10.1, 18.5 Hz), 6.26 (1 H, d, J = 




H, m), 2.46 (1 H, dddd, J = 2.4, 2.5, 7.0, 16.4 Hz), 2.41 (1 H, dddd, J = 2.4, 2.5, 7.0, 
16.4 Hz), 2.17 (2 H, ddd, J = 2.4, 7.0, 14.2 Hz), 2.04 (1 H, d, J = 4.7 Hz), 1.46−1.51 
(7 H, m), 1.25−1.44 (11 H, m), 0.93−0.97 (18 H, m) ppm; 
13
C NMR (100 MHz, 
CDCl3): δ 146.0 (CH), 135.5 (CH), 134.4 (CH), 132.9 (CH), 83.8 (C), 75.7 (C), 70.8 
(CH), 31.2 (CH2), 29.2 (CH2), 28.8 (CH2), 28.3 (CH2), 27.4 (CH2), 22.4 (CH2), 18.9 
(CH2), 14.2 (CH3), 13.8 (CH3), 9.7 (CH2) ppm; ATR-FTIR: 3375 (OH) cm
-1
; 
HRMS (ESI): [M+23 (Na)]
+
 C25H46OSn requires 481.2643; found: 481.2648. 
Compound 279:  
 
1
H NMR (400 MHz, CDCl3): δ 6.52 (1 H, dd, J = 9.7, 18.6 Hz), 6.29 (1 H, d, J = 
18.6 Hz), 6.16 (1 H, dd, J = 9.7, 15.2 Hz), 5.61 (1 H, dd, J = 7.3, 15.2 Hz), 4.93 (2 
H, m), 4.52 (1 H, m), 1.95 (2 H, m), 1.80 (1 H, d, J = 4.7 Hz), 1.43−1.52 (6 H, m), 
1.26−1.36 (12 H, m), 0.87−0.98 (18 H, m) ppm; 
13
C NMR (100 MHz, CDCl3): δ 
204.2 (C), 146.0 (CH), 135.5 (CH), 134.7 (CH), 132.4 (CH), 107.5 (C), 79.7 (CH2), 
72.6 (CH), 58.6 (CH2), 31.7 (CH2), 29.3 (CH2), 27.4 (CH2), 22.7 (CH2), 18.6 (CH3), 
17.7 (CH2), 13.8 (CH2), 9.7 (CH3) ppm; HRMS (ESI): Molecular ion not found. 
9.7.4  Preparation of trimethylsulfonium methanesulfonate 
 
 
A solution of dimethylsulfoxide (752 mg, 9.63 mmol, 3.0 eq.) and 
dibutylbenzimidazolium bromide 297 (1.00 g, 3.21 mmol, 1.0 eq.) was heated in air 
for 3 days at 130 
o
C. The reaction mixture was cooled to 0 
o
C. Ethanol (4 mL) and 
ether (60 mL) were then added in one portion. The resulting suspension was filtered 




methanesulfonate as white crystals (304 mg, 55%). The 
1
H NMR spectrum matched 




H NMR (400 MHz, D2O): δ 2.94 (9 H, s), 2.84 (3 H, s) ppm. 
9.7.5  Synthesis of the epoxide 286 
 
 
To a solution of trimethylsulfonium methanesulfonate (0.10 g, 0.58 mmol, 1.2 eq.) in 
anhydrous tetrahydrofuran (2 mL) was added 60% NaH in mineral oil (23 mg, 
0.58 mmol, 1.2 eq.) at 0 
o
C. The reaction mixture was stirred for 10 minutes then 
cooled to −45 
o
C and the aldehyde 213 (0.18 g, 0.48 mmol, 1.0 eq.) in anhydrous 
tetrahydrofuran (2 mL) was added dropwise. The reaction mixture was stirred for 
4 hours. The reaction was then quenched with a saturated aqueous solution of NH4Cl 
(3 mL) and the mixture was stirred for 30 minutes. The reaction mixture was diluted 
with light petroleum (40 mL), washed with deionised water (2 x 20 mL), dried and 
concentrated under reduced pressure to give a brown oil. The oil was subjected to 
column chromatography and the column was conditioned with triethylamine (1%). 
Elution with light petroleum afforded the epoxide 286 as a colourless liquid 
(133 mg, 71%). 
1
H NMR (400 MHz, CDCl3): δ 6.53 (1 H, dd, J = 9.9, 18.6 Hz), 6.43 (1 H, dd, J = 
6.5, 14.9 Hz), 6.31 (1 H, d, J = 18.6 Hz), 5.30 (1 H, dd, J = 9.9, 14.9 Hz), 3.36 (1 H, 
m), 2.99 (1 H, dd, J = 4.1, 5.3 Hz), 2.68 (1 H, dd, J = 2.6, 5.3 Hz), 1.47−1.52 (6 H, 
m), 1.25−1.35 (6 H, m), 0.81−0.93 (15 H, m) ppm; 
13
C NMR (100 MHz, CDCl3): δ 
145.4 (CH), 138.0 (CH), 136.4 (CH), 129.1 (CH), 52.4 (CH), 49.4 (CH2), 29.2 






9.7.6  Synthesis of the stannane 289 
 
n-BuLi (1.6 M in hexanes, 58 µL, 0.09 mmol, 1.2 eq.) was added dropwise to 1-
hexyne (7 mg, 0.08 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (2 mL) at −84 
o
C. 
The solution was stirred for 1 hour at this temperature after which the epoxide 286 
(30 mg, 0.08 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (2 mL) was added in one 
portion. The reaction mixture was stirred for 5 minutes followed by the dropwise 
addition of BF3•OEt2 (11 mg, 0.08 mol, 1.0 eq.) at this temperature. After 
30 minutes, the reaction was quenched with a saturated aqueous solution of NH4Cl 
(2 mL) and the mixture was stirred for a further 30 minutes. The reaction mixture 
was diluted with ether (10 mL), washed with deionised water (2 x 5 mL), dried and 
concentrated under reduced pressure to give an orange liquid. The liquid was 
subjected to column chromatography. Elution with 10% ethyl acetate/light petroleum 
afforded the stannane 289 as a colourless oil (20 mg, 52%). 
 
1
H NMR (400 MHz, CDCl3): δ 6.52 (1 H, dd, J = 11.0, 18.6 Hz), 6.17 (1 H, d, J = 
18.6 Hz), 6.16 (1 H, dd, J = 11.0, 15.2 Hz), 5.70 (1 H, dt, J = 7.3, 15.2 Hz), 4.41 (1 
H, m), 2.48 (2 H, t, J = 7.3 Hz), 2.12 (2 H, t, J = 7.1 Hz), 1.80 (1 H, d, J = 5.9 Hz), 
1.47−1.52 (7 H, m), 1.26−1.35 (11 H, m), 0.85−0.96 (18 H, m) ppm;
 13
C NMR 
(100 MHz, CDCl3): δ 146.6 (CH), 137.6 (CH), 133.3 (CH), 127.4 (CH), 86.3 (C), 
80.8 (C), 62.3 (CH), 41.5 (CH2), 31.2 (CH2), 29.3 (CH2), 28.5 (CH2), 27.4 (CH2), 
22.3 (CH2), 18.8 (CH2), 14.1 (CH3), 13.8 (CH3), 9.6 (CH2) ppm; ATR-FTIR: 3320 
(OH) cm
-1
; HRMS (ESI): [M+23 (Na)]
+
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